<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000914</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>434</s160></s100><s200><s210>1</s210><s211>214</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 1Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys    210</s400><s200><s210>2</s210><s211>450</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 2Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val        115                 120                 125Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala    130                 135                 140Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser145                 150                 155                 160Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val                165                 170                 175Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro            180                 185                 190Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys        195                 200                 205Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp    210                 215                 220Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly225                 230                 235                 240Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile                245                 250                 255Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu            260                 265                 270Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His        275                 280                 285Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg    290                 295                 300Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys305                 310                 315                 320Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu                325                 330                 335Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr            340                 345                 350Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu        355                 360                 365Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp    370                 375                 380Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val385                 390                 395                 400Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp                405                 410                 415Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His            420                 425                 430Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro        435                 440                 445Gly Lys    450</s400><s200><s210>3</s210><s211>107</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 3Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>4</s210><s211>120</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 4Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>5</s210><s211>50</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>VARIANT</s221><s222>(1)..(50)</s222><s223>Each copy of Gly Gly Gly Gly Ser at positions 1      to 50 is either present or absent such that the number of copies      of Gly Gly Gly Gly Ser ranges from 1 to 10.</s223></s220></s200><s400> 5Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser    50</s400><s200><s210>6</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 6Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala1               5                   10</s400><s200><s210>7</s210><s211>6</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 7Ser Ala Ser Phe Leu Tyr1               5</s400><s200><s210>8</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 8Gln Gln His Tyr Thr Thr Pro Pro1               5</s400><s200><s210>9</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 9Gly Phe Asn Ile Lys Asp Thr Tyr1               5</s400><s200><s210>10</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 10Ile Tyr Pro Thr Asn Gly Tyr Thr1               5</s400><s200><s210>11</s210><s211>13</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 11Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr1               5                   10</s400><s200><s210>12</s210><s211>242</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 12Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly        115                 120                 125Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser    130                 135                 140Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala145                 150                 155                 160Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly                165                 170                 175Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly            180                 185                 190Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu        195                 200                 205Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln    210                 215                 220Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu225                 230                 235                 240Ile Lys</s400><s200><s210>13</s210><s211>214</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 13Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys    210</s400><s200><s210>14</s210><s211>448</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 14Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr            20                  25                  30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe    50                  55                  60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe        115                 120                 125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu    130                 135                 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145                 150                 155                 160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu                165                 170                 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser            180                 185                 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro        195                 200                 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys    210                 215                 220Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro225                 230                 235                 240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser                245                 250                 255Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp            260                 265                 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn        275                 280                 285Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val    290                 295                 300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu305                 310                 315                 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys                325                 330                 335Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr            340                 345                 350Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr        355                 360                 365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu    370                 375                 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu385                 390                 395                 400Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys                405                 410                 415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu            420                 425                 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly        435                 440                 445</s400><s200><s210>15</s210><s211>107</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 15Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>16</s210><s211>119</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 16Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr            20                  25                  30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe    50                  55                  60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>17</s210><s211>11</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 17Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala1               5                   10</s400><s200><s210>18</s210><s211>6</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 18Ser Ala Ser Tyr Arg Tyr1               5</s400><s200><s210>19</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 19Gln Gln Tyr Tyr Ile Tyr Pro Tyr1               5</s400><s200><s210>20</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 20Gly Phe Thr Phe Thr Asp Tyr Thr Met Asp1               5                   10</s400><s200><s210>21</s210><s211>18</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 21Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe1               5                   10                  15Lys Gly</s400><s200><s210>22</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 22Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr1               5                   10</s400><s200><s210>23</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 23Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn1               5                   10                  15</s400><s200><s210>24</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 24Asp Ala Ser Asn Leu Val Ser1               5</s400><s200><s210>25</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 25Gln Gln Ser Thr Glu Asp Pro Trp Thr1               5</s400><s200><s210>26</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 26Ser Tyr Trp Met Asn1               5</s400><s200><s210>27</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 27Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys1               5                   10                  15Gly</s400><s200><s210>28</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 28Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr1               5                   10                  15</s400><s200><s210>29</s210><s211>249</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 29Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp            20                  25                  30Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro        35                  40                  45Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro    50                  55                  60Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His65                  70                  75                  80Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr                85                  90                  95Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val    130                 135                 140Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr Trp Met145                 150                 155                 160Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Gln                165                 170                 175Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly            180                 185                 190Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln        195                 200                 205Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg    210                 215                 220Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp Tyr Trp225                 230                 235                 240Gly Gln Gly Thr Thr Val Thr Val Ser                245</s400><s200><s210>30</s210><s211>217</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 30Asp Ile Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1               5                   10                  15Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr            20                  25                  30Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu        35                  40                  45Met Ile Tyr Gly Val Asn Asn Arg Pro Ser Gly Val Ser Asn Arg Phe    50                  55                  60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Asp Ile Glu                85                  90                  95Ser Ala Thr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Gly Asp Ser Ser Pro Val145                 150                 155                 160Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Thr Glu Ser Ser    210                 215</s400><s200><s210>31</s210><s211>450</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 31Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1               5                   10                  15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr            20                  25                  30Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met        35                  40                  45Gly Ile Ile Asp Pro Gly Asp Ser Arg Thr Arg Tyr Ser Pro Ser Phe    50                  55                  60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65                  70                  75                  80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys                85                  90                  95Ala Arg Gly Gln Leu Tyr Gly Gly Thr Tyr Met Asp Gly Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val        115                 120                 125Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala    130                 135                 140Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser145                 150                 155                 160Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val                165                 170                 175Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro            180                 185                 190Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys        195                 200                 205Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp    210                 215                 220Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly225                 230                 235                 240Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile                245                 250                 255Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu            260                 265                 270Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His        275                 280                 285Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg    290                 295                 300Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys305                 310                 315                 320Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu                325                 330                 335Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr            340                 345                 350Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu        355                 360                 365Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp    370                 375                 380Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val385                 390                 395                 400Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp                405                 410                 415Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His            420                 425                 430Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro        435                 440                 445Gly Lys    450</s400><s200><s210>32</s210><s211>107</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 32Asp Ile Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1               5                   10                  15Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr            20                  25                  30Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu        35                  40                  45Met Ile Tyr Gly Val Asn Asn Arg Pro Ser Gly Val Ser Asn Arg Phe    50                  55                  60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Asp Ile Glu                85                  90                  95Ser Ala Thr Pro Val Phe Gly Gly Gly Thr Lys            100                 105</s400><s200><s210>33</s210><s211>120</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 33Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu1               5                   10                  15Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr            20                  25                  30Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met        35                  40                  45Gly Ile Ile Asp Pro Gly Asp Ser Arg Thr Arg Tyr Ser Pro Ser Phe    50                  55                  60Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr65                  70                  75                  80Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys                85                  90                  95Ala Arg Gly Gln Leu Tyr Gly Gly Thr Tyr Met Asp Gly Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>34</s210><s211>14</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 34Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Ser Val Ser1               5                   10</s400><s200><s210>35</s210><s211>11</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 35Leu Met Ile Tyr Gly Val Asn Asn Arg Pro Ser1               5                   10</s400><s200><s210>36</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 36Ser Ser Tyr Asp Ile Glu Ser Ala Thr Pro1               5                   10</s400><s200><s210>37</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 37Gly Tyr Ser Phe Thr Ser Tyr Trp Ile Gly1               5                   10</s400><s200><s210>38</s210><s211>16</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 38Trp Met Gly Ile Ile Asp Pro Gly Asp Ser Arg Thr Arg Tyr Ser Pro1               5                   10                  15</s400><s200><s210>39</s210><s211>11</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 39Gly Gln Leu Tyr Gly Gly Thr Tyr Met Asp Gly1               5                   10</s400><s200><s210>40</s210><s211>244</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 40Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Arg Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Gly Arg Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met            100                 105                 110Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser    130                 135                 140Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Ile Ser Cys145                 150                 155                 160Arg Ala Ser Gln Ser Val Ser Ser Asn Phe Ala Trp Tyr Gln Gln Arg                165                 170                 175Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala            180                 185                 190Thr Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe        195                 200                 205Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Ala Tyr Tyr    210                 215                 220Cys His Gln Arg Ser Asn Trp Leu Tyr Thr Phe Gly Gln Gly Thr Lys225                 230                 235                 240Val Asp Ile Lys</s400><s200><s210>41</s210><s211>253</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 41Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Leu Arg Arg Thr Val Val Thr Pro Arg Ala Tyr Tyr Gly            100                 105                 110Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly        115                 120                 125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly    130                 135                 140Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser145                 150                 155                 160Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser                165                 170                 175Asn Ser Leu Asn Trp Tyr Gln Gln Lys Ala Gly Lys Ala Pro Lys Leu            180                 185                 190Leu Ile Tyr Asp Ala Ser Thr Leu Glu Thr Gly Val Pro Ser Arg Phe        195                 200                 205Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Phe Thr Ile Ser Ser Leu    210                 215                 220Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln His Asp Asn Leu225                 230                 235                 240Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys                245                 250</s400><s200><s210>42</s210><s211>217</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 42Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn            20                  25                  30Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu        35                  40                  45Ile Phe Asn Tyr His Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln65                  70                  75                  80Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu                85                  90                  95Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln            100                 105                 110Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu        115                 120                 125Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr    130                 135                 140Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys145                 150                 155                 160Ala Gly Val Glu Thr Thr Thr Pro Asp Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Thr Glu Cys Ser    210                 215</s400><s200><s210>43</s210><s211>453</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 43Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr            20                  25                  30Ala Leu Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Val Ser Arg Ser Lys Ala Tyr Gly Gly Thr Thr Asp Tyr Ala Ala    50                  55                  60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Tyr Cys Ala Ser Ser Gly Tyr Ser Ser Gly Trp Thr Pro Phe Asp Tyr            100                 105                 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>44</s210><s211>111</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 44Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn            20                  25                  30Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu        35                  40                  45Ile Phe Asn Tyr His Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln65                  70                  75                  80Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu                85                  90                  95Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>45</s210><s211>131</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 45Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr            20                  25                  30Ala Leu Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Val Ser Arg Ser Lys Ala Tyr Gly Gly Thr Thr Asp Tyr Ala Ala    50                  55                  60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Tyr Cys Ala Ser Ser Gly Tyr Ser Ser Gly Trp Thr Pro Phe Asp Tyr            100                 105                 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val    130</s400><s200><s210>46</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 46Ser Ser Asn Ile Gly Ser Asn Thr1               5</s400><s200><s210>47</s210><s211>11</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 47Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val1               5                   10</s400><s200><s210>48</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 48Gly Phe Thr Phe Gly Asp Tyr Ala1               5</s400><s200><s210>49</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 49Ser Arg Ser Lys Ala Tyr Gly Gly Thr Thr1               5                   10</s400><s200><s210>50</s210><s211>14</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 50Ala Ser Ser Gly Tyr Ser Ser Gly Trp Thr Pro Phe Asp Tyr1               5                   10</s400><s200><s210>51</s210><s211>249</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 51Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr            20                  25                  30Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Ala Thr Tyr Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe    50                  55                  60Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Gly Ala Ile Tyr Asn Gly Tyr Asp Val Leu Asp Asn Trp Gly            100                 105                 110Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly        115                 120                 125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln    130                 135                 140Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val145                 150                 155                 160Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp                165                 170                 175Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Thr            180                 185                 190Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser        195                 200                 205Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe    210                 215                 220Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Lys Leu Pro Trp Thr Phe Gly225                 230                 235                 240Gln Gly Thr Lys Leu Glu Ile Lys Arg                245</s400><s200><s210>52</s210><s211>249</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 52Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Lys Leu Pro Trp                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Gly            100                 105                 110Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        115                 120                 125Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser    130                 135                 140Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr145                 150                 155                 160Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met                165                 170                 175Gly Ala Thr Tyr Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe            180                 185                 190Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr        195                 200                 205Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys    210                 215                 220Ala Arg Gly Ala Ile Tyr Asn Gly Tyr Asp Val Leu Asp Asn Trp Gly225                 230                 235                 240Gln Gly Thr Leu Val Thr Val Ser Ser                245</s400><s200><s210>53</s210><s211>11</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 53Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn1               5                   10</s400><s200><s210>54</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 54Tyr Thr Ser Asn Leu His Ser1               5</s400><s200><s210>55</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 55Gln Gln Tyr Arg Lys Leu Pro Trp Thr1               5</s400><s200><s210>56</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 56Asn Tyr Trp Met His1               5</s400><s200><s210>57</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 57Ala Thr Tyr Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe Lys1               5                   10                  15Gly</s400><s200><s210>58</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 58Gly Ala Ile Tyr Asn Gly Tyr Asp Val Leu Asp Asn1               5                   10</s400><s200><s210>59</s210><s211>108</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 59Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Lys Leu Pro Trp                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg            100                 105</s400><s200><s210>60</s210><s211>121</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 60Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr            20                  25                  30Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Ala Thr Tyr Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe    50                  55                  60Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Gly Ala Ile Tyr Asp Gly Tyr Asp Val Leu Asp Asn Trp Gly            100                 105                 110Gln Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>61</s210><s211>20</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 61Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro1               5                   10                  15Pro Ala His Gly            20</s400><s200><s210>62</s210><s211>43</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 62Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu1               5                   10                  15Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe            20                  25                  30Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr        35                  40</s400><s200><s210>63</s210><s211>35</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 63Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn1               5                   10                  15Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala            20                  25                  30Ser Arg Tyr        35</s400><s200><s210>64</s210><s211>20</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 64Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln1               5                   10                  15Phe Asn Gln Tyr            20</s400><s200><s210>65</s210><s211>25</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 65Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu1               5                   10                  15Ala Ala Phe Arg Glu Gly Thr Ile Asn            20                  25</s400><s200><s210>66</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 66Arg Tyr Gly Met Ser1               5</s400><s200><s210>67</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 67Thr Ile Ser Gly Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>68</s210><s211>13</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 68Asp Asn Tyr Gly Arg Asn Tyr Asp Tyr Gly Met Asp Tyr1               5                   10</s400><s200><s210>69</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 69Ser Ala Thr Ser Ser Val Ser Tyr Ile His1               5                   10</s400><s200><s210>70</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 70Ser Thr Ser Asn Leu Ala Ser1               5</s400><s200><s210>71</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 71Gln Gln Arg Ser Ser Ser Pro Phe Thr1               5</s400><s200><s210>72</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 72Gly Tyr Ala Met Ser1               5</s400><s200><s210>73</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 73Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>74</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 74Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val1               5                   10</s400><s200><s210>75</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 75Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His1               5                   10                  15</s400><s200><s210>76</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 76Leu Ala Ser Asn Leu Glu Ser1               5</s400><s200><s210>77</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 77Gln His Ser Arg Glu Leu Pro Phe Thr1               5</s400><s200><s210>78</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 78Asp Tyr Ala Met Asn1               5</s400><s200><s210>79</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 79Val Ile Ser Thr Phe Ser Gly Asn Ile Asn Phe Asn Gln Lys Phe Lys1               5                   10                  15Gly</s400><s200><s210>80</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 80Ser Asp Tyr Tyr Gly Pro Tyr Phe Asp Tyr1               5                   10</s400><s200><s210>81</s210><s211>16</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 81Arg Ser Ser Gln Thr Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu1               5                   10                  15</s400><s200><s210>82</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 82Lys Val Ser Asn Arg Phe Ser1               5</s400><s200><s210>83</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 83Phe Gln Gly Ser His Val Pro Phe Thr1               5</s400><s200><s210>84</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 84Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr1               5</s400><s200><s210>85</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 85Thr Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His1               5                   10                  15</s400><s200><s210>86</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 86Leu Val Ser Asn Leu Glu Ser1               5</s400><s200><s210>87</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 87Gln His Ile Arg Glu Leu Thr Arg Ser Glu1               5                   10</s400><s200><s210>88</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 88Gly Phe Thr Phe Ser Asn Tyr Tyr1               5</s400><s200><s210>89</s210><s211>8</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 89Ile Ser Gly Arg Gly Ser Thr Ile1               5</s400><s200><s210>90</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 90Val Lys Asp Arg Gly Gly Tyr Ser Pro Tyr1               5                   10</s400><s200><s210>91</s210><s211>6</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 91Gln Ser Ile Ser Thr Tyr1               5</s400><s200><s210>92</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 92Gln Gln Ser Tyr Ser Thr Pro Pro Ile Thr1               5                   10</s400><s200><s210>93</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 93Asp Lys Thr His Thr1               5</s400><s200><s210>94</s210><s211>4</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 94Cys Pro Pro Cys1</s400><s200><s210>95</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 95Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg1               5                   10                  15</s400><s200><s210>96</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 96Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr1               5                   10</s400><s200><s210>97</s210><s211>10</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 97Lys Ser Cys Asp Lys Thr His Thr Cys Pro1               5                   10</s400><s200><s210>98</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 98Lys Cys Cys Val Asp Cys Pro1               5</s400><s200><s210>99</s210><s211>7</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 99Lys Tyr Gly Pro Pro Cys Pro1               5</s400><s200><s210>100</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 100Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro1               5                   10                  15</s400><s200><s210>101</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 101Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro1               5                   10</s400><s200><s210>102</s210><s211>17</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 102Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys1               5                   10                  15Pro</s400><s200><s210>103</s210><s211>12</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 103Ser Pro Asn Met Val Pro His Ala His His Ala Gln1               5                   10</s400><s200><s210>104</s210><s211>45</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 104Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala1               5                   10                  15Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly            20                  25                  30Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp        35                  40                  45</s400><s200><s210>105</s210><s211>24</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 105Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu1               5                   10                  15Ser Leu Val Ile Thr Leu Tyr Cys            20</s400><s200><s210>106</s210><s211>23</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 106Leu Gly Leu Leu Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly1               5                   10                  15Val Ala Ile His Leu Cys Cys            20</s400><s200><s210>107</s210><s211>25</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 107Ala Leu Ile Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe Ile Gly1               5                   10                  15Leu Gly Ile Phe Phe Cys Val Arg Cys            20                  25</s400><s200><s210>108</s210><s211>23</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 108Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu1               5                   10                  15Thr Ala Leu Phe Leu Arg Val            20</s400><s200><s210>109</s210><s211>26</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 109Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu1               5                   10                  15Val Thr Val Ala Phe Ile Ile Phe Trp Val            20                  25</s400><s200><s210>110</s210><s211>26</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 110Val Ala Ala Ile Leu Gly Leu Gly Leu Val Leu Gly Leu Leu Gly Pro1               5                   10                  15Leu Ala Ile Leu Leu Ala Leu Tyr Leu Leu            20                  25</s400><s200><s210>111</s210><s211>24</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 111Ala Leu Pro Ala Ala Leu Ala Val Ile Ser Phe Leu Leu Gly Leu Gly1               5                   10                  15Leu Gly Val Ala Cys Val Leu Ala            20</s400><s200><s210>112</s210><s211>42</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 112Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met1               5                   10                  15Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe            20                  25                  30Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu        35                  40</s400><s200><s210>113</s210><s211>44</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 113Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met1               5                   10                  15Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro            20                  25                  30Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser        35                  40</s400><s200><s210>114</s210><s211>35</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 114Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn Gly Glu Tyr1               5                   10                  15Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg Leu Thr Asp            20                  25                  30Val Thr Leu        35</s400><s200><s210>115</s210><s211>37</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 115Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly1               5                   10                  15Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser            20                  25                  30Thr Leu Ala Lys Ile        35</s400><s200><s210>116</s210><s211>114</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 116Cys Cys Leu Arg Arg His Gln Gly Lys Gln Asn Glu Leu Ser Asp Thr1               5                   10                  15Ala Gly Arg Glu Ile Asn Leu Val Asp Ala His Leu Lys Ser Glu Gln            20                  25                  30Thr Glu Ala Ser Thr Arg Gln Asn Ser Gln Val Leu Leu Ser Glu Thr        35                  40                  45Gly Ile Tyr Asp Asn Asp Pro Asp Leu Cys Phe Arg Met Gln Glu Gly    50                  55                  60Ser Glu Val Tyr Ser Asn Pro Cys Leu Glu Glu Asn Lys Pro Gly Ile65                  70                  75                  80Val Tyr Ala Ser Leu Asn His Ser Val Ile Gly Pro Asn Ser Arg Leu                85                  90                  95Ala Arg Asn Val Lys Glu Ala Pro Thr Glu Tyr Ala Ser Ile Cys Val            100                 105                 110Arg Ser</s400><s200><s210>117</s210><s211>49</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 117His Gln Arg Arg Lys Tyr Arg Ser Asn Lys Gly Glu Ser Pro Val Glu1               5                   10                  15Pro Ala Glu Pro Cys Arg Tyr Ser Cys Pro Arg Glu Glu Glu Gly Ser            20                  25                  30Thr Ile Pro Ile Gln Glu Asp Tyr Arg Lys Pro Glu Pro Ala Cys Ser        35                  40                  45Pro</s400><s200><s210>118</s210><s211>187</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 118Arg Arg Ala Cys Arg Lys Arg Ile Arg Gln Lys Leu His Leu Cys Tyr1               5                   10                  15Pro Val Gln Thr Ser Gln Pro Lys Leu Glu Leu Val Asp Ser Arg Pro            20                  25                  30Arg Arg Ser Ser Thr Gln Leu Arg Ser Gly Ala Ser Val Thr Glu Pro        35                  40                  45Val Ala Glu Glu Arg Gly Leu Met Ser Gln Pro Leu Met Glu Thr Cys    50                  55                  60His Ser Val Gly Ala Ala Tyr Leu Glu Ser Leu Pro Leu Gln Asp Ala65                  70                  75                  80Ser Pro Ala Gly Gly Pro Ser Ser Pro Arg Asp Leu Pro Glu Pro Arg                85                  90                  95Val Ser Thr Glu His Thr Asn Asn Lys Ile Glu Lys Ile Tyr Ile Met            100                 105                 110Lys Ala Asp Thr Val Ile Val Gly Thr Val Lys Ala Glu Leu Pro Glu        115                 120                 125Gly Arg Gly Leu Ala Gly Pro Ala Glu Pro Glu Leu Glu Glu Glu Leu    130                 135                 140Glu Ala Asp His Thr Pro His Tyr Pro Glu Gln Glu Thr Glu Pro Pro145                 150                 155                 160Leu Gly Ser Cys Ser Asp Val Met Leu Ser Val Glu Glu Glu Gly Lys                165                 170                 175Glu Asp Pro Leu Pro Thr Ala Ala Ser Gly Lys            180                 185</s400><s200><s210>119</s210><s211>54</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 119His Ile Trp Gln Leu Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln1               5                   10                  15Leu Leu Leu Glu Val Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln            20                  25                  30Phe Pro Glu Glu Glu Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg        35                  40                  45Leu Gly Asp Leu Trp Val    50</s400><s200><s210>120</s210><s211>60</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 120Cys Val Lys Arg Arg Lys Pro Arg Gly Asp Val Val Lys Val Ile Val1               5                   10                  15Ser Val Gln Arg Lys Arg Gln Glu Ala Glu Gly Glu Ala Thr Val Ile            20                  25                  30Glu Ala Leu Gln Ala Pro Pro Asp Val Thr Thr Val Ala Val Glu Glu        35                  40                  45Thr Ile Pro Ser Phe Thr Gly Arg Ser Pro Asn His    50                  55                  60</s400><s200><s210>121</s210><s211>4</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(2)..(3)</s222><s223>The amino acids at positions 2 and 3 are      independently any amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(4)..(4)</s222><s223>The amino acid at position 4 may also be Ile</s223></s220></s200><s400> 121Tyr Xaa Xaa Leu1</s400><s200><s210>122</s210><s211>16</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(2)..(3)</s222><s223>The amino acids at positions 2 and 3 are      independently any amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(4)..(4)</s222><s223>The amino acid at position 4 may also be Ile</s223></s220><s220><s221>VARIANT</s221><s222>(5)..(12)</s222><s223>Where Xaa is independently any amino acid and      each copy of Xaa at positions 5 to 12 is either present or absent      such that the number of Xaa ranges from 6 to 8.</s223></s220><s220><s221>VARIANT</s221><s222>(14)..(15)</s222><s223>The amino acids at positions 14 and 15 are      independently any amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>The amino acid at position 16 may also be Ile</s223></s220></s200><s400> 122Tyr Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Leu1               5                   10                  15</s400><s200><s210>123</s210><s211>561</s211><s212>PRT</s212><s213>Cytomegalovirus</s213></s200><s400> 123Met Glu Ser Arg Gly Arg Arg Cys Pro Glu Met Ile Ser Val Leu Gly1               5                   10                  15Pro Ile Ser Gly His Val Leu Lys Ala Val Phe Ser Arg Gly Asp Thr            20                  25                  30Pro Val Leu Pro His Glu Thr Arg Leu Leu Gln Thr Gly Ile His Val        35                  40                  45Arg Val Ser Gln Pro Ser Leu Ile Leu Val Ser Gln Tyr Thr Pro Asp    50                  55                  60Ser Thr Pro Cys His Arg Gly Asp Asn Gln Leu Gln Val Gln His Thr65                  70                  75                  80Tyr Phe Thr Gly Ser Glu Val Glu Asn Val Ser Val Asn Val His Asn                85                  90                  95Pro Thr Gly Arg Ser Ile Cys Pro Ser Gln Glu Pro Met Ser Ile Tyr            100                 105                 110Val Tyr Ala Leu Pro Leu Lys Met Leu Asn Ile Pro Ser Ile Asn Val        115                 120                 125His His Tyr Pro Ser Ala Ala Glu Arg Lys His Arg His Leu Pro Val    130                 135                 140Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala Arg145                 150                 155                 160Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp Lys                165                 170                 175Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys Asp            180                 185                 190Val Ala Leu Arg His Val Val Cys Ala His Glu Leu Val Cys Ser Met        195                 200                 205Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr Val    210                 215                 220Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys Leu225                 230                 235                 240Phe Met His Val Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr Met                245                 250                 255Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly Phe            260                 265                 270Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile Ser        275                 280                 285His Ile Met Leu Asp Val Ala Phe Thr Ser His Glu His Phe Gly Leu    290                 295                 300Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu Leu305                 310                 315                 320Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu Thr                325                 330                 335Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe Asp            340                 345                 350Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro Thr        355                 360                 365Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His Thr    370                 375                 380Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val Trp385                 390                 395                 400Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg Lys                405                 410                 415Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr Ser            420                 425                 430Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr Ser        435                 440                 445Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala Pro    450                 455                 460Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro Ala465                 470                 475                 480Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn Leu                485                 490                 495Val Pro Met Val Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln Glu            500                 505                 510Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu Glu        515                 520                 525Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg Gln    530                 535                 540Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg545                 550                 555                 560Gly</s400><s200><s210>124</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 124Lys Leu Pro Gln Leu Cys Thr Glu Leu1               5</s400><s200><s210>125</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 125Leu Gln Thr Thr Ile His Asp Ile Ile1               5</s400><s200><s210>126</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 126Val Tyr Asp Phe Ala Phe Arg Asp Leu1               5</s400><s200><s210>127</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 127Phe Ala Phe Arg Asp Leu Cys Ile Val1               5</s400><s200><s210>128</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 128Lys Phe Tyr Ser Lys Ile Ser Glu Tyr1               5</s400><s200><s210>129</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 129Ile Ser Glu Tyr Arg His Tyr Cys Tyr1               5</s400><s200><s210>130</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 130Thr Leu His Glu Tyr Met Leu Asp Leu1               5</s400><s200><s210>131</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 131Tyr Met Leu Asp Leu Gln Pro Glu Thr1               5</s400><s200><s210>132</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 132Gln Ala Glu Pro Asp Arg Ala His Tyr1               5</s400><s200><s210>133</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 133Arg Ala His Tyr Asn Ile Val Thr Phe1               5</s400><s200><s210>134</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 134Cys Asp Ser Thr Leu Arg Leu Cys Val1               5</s400><s200><s210>135</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 135Leu Cys Val Gln Ser Thr His Val Asp Ile1               5                   10</s400><s200><s210>136</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 136Leu Leu Met Gly Thr Leu Gly Ile Val1               5</s400><s200><s210>137</s210><s211>8</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 137Thr Leu Gly Ile Val Cys Pro Ile1               5</s400><s200><s210>138</s210><s211>12</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 138Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile1               5                   10</s400><s200><s210>139</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 139Cys Tyr Ser Leu Tyr Gly Thr Thr Leu1               5</s400><s200><s210>140</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 140Glu Tyr Arg His Tyr Cys Tyr Ser Leu1               5</s400><s200><s210>141</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 141Asp Pro Gln Glu Arg Pro Arg Lys Leu1               5</s400><s200><s210>142</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 142His Tyr Cys Tyr Ser Leu Tyr Gly Thr1               5</s400><s200><s210>143</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 143Asp Phe Ala Phe Arg Asp Leu Cys Ile1               5</s400><s200><s210>144</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 144Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr1               5                   10</s400><s200><s210>145</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 145His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr1               5                   10</s400><s200><s210>146</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 146Glu Val Tyr Asp Phe Ala Phe Arg Asp Leu1               5                   10</s400><s200><s210>147</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 147Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr1               5                   10</s400><s200><s210>148</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 148Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys1               5                   10</s400><s200><s210>149</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 149Tyr Cys Tyr Ser Ile Tyr Gly Thr Thr Leu1               5                   10</s400><s200><s210>150</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 150Val Tyr Cys Lys Thr Val Leu Glu Leu1               5</s400><s200><s210>151</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 151Val Tyr Gly Asp Thr Leu Glu Lys Leu1               5</s400><s200><s210>152</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 152Leu Thr Asn Thr Gly Leu Tyr Asn Leu Leu1               5                   10</s400><s200><s210>153</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 153Asp Leu Gln Pro Glu Thr Thr Asp Leu1               5</s400><s200><s210>154</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 154Thr Pro Thr Leu His Glu Tyr Met Leu1               5</s400><s200><s210>155</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 155Gly Thr Leu Gly Ile Val Cys Pro Ile1               5</s400><s200><s210>156</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 156Glu Pro Asp Arg Ala His Tyr Asn Ile1               5</s400><s200><s210>157</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 157Gln Leu Phe Leu Asn Thr Leu Ser Phe1               5</s400><s200><s210>158</s210><s211>9</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 158Phe Gln Gln Leu Phe Leu Asn Thr Leu1               5</s400><s200><s210>159</s210><s211>10</s211><s212>PRT</s212><s213>human papillomavirus</s213></s200><s400> 159Ala Phe Gln Gln Leu Phe Leu Asn Thr Leu1               5                   10</s400><s200><s210>160</s210><s211>9</s211><s212>PRT</s212><s213>influenza virus</s213></s200><s400> 160Gly Ile Leu Gly Phe Val Phe Thr Leu1               5</s400><s200><s210>161</s210><s211>14</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 161Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Phe Glu1               5                   10</s400><s200><s210>162</s210><s211>14</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 162Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu1               5                   10</s400><s200><s210>163</s210><s211>15</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 163Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile1               5                   10                  15</s400><s200><s210>164</s210><s211>7</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 164Val Asn Asn Glu Ser Ser Glu1               5</s400><s200><s210>165</s210><s211>17</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 165Pro Gly Ile Asn Gly Lys Ala Ile His Leu Val Asn Asn Glu Ser Ser1               5                   10                  15Glu</s400><s200><s210>166</s210><s211>6</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 166Pro Asn Arg Asp Ile Leu1               5</s400><s200><s210>167</s210><s211>7</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 167Phe Ile Gly Ile Thr Glu Leu1               5</s400><s200><s210>168</s210><s211>6</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 168Ser Tyr Phe Pro Ser Val1               5</s400><s200><s210>169</s210><s211>20</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 169Asn Ser Val Asp Asp Ala Leu Ile Asn Ser Thr Lys Ile Tyr Ser Tyr1               5                   10                  15Phe Pro Ser Val            20</s400><s200><s210>170</s210><s211>20</s211><s212>PRT</s212><s213>Clostridium tetani</s213></s200><s400> 170Ile Asp Lys Ile Ser Asp Val Ser Thr Ile Val Pro Tyr Ile Gly Pro1               5                   10                  15Ala Leu Asn Ile            20</s400><s200><s210>171</s210><s211>9</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 171Asn Leu Met Pro Met Val Ala Thr Val1               5</s400><s200><s210>172</s210><s211>9</s211><s212>PRT</s212><s213>Cytomegalovirus</s213></s200><s400> 172Asn Leu Val Pro Met Val Ala Thr Val1               5</s400><s200><s210>173</s210><s211>906</s211><s212>PRT</s212><s213>Cytomegalovirus</s213></s200><s400> 173Met Glu Ser Arg Ile Trp Cys Leu Val Val Cys Val Asn Leu Cys Ile1               5                   10                  15Val Cys Leu Gly Ala Ala Val Ser Ser Ser Ser Thr Ser His Ala Thr            20                  25                  30Ser Ser Thr His Asn Gly Ser His Thr Ser Arg Thr Thr Ser Ala Gln        35                  40                  45Thr Arg Ser Val Tyr Ser Gln His Val Thr Ser Ser Glu Ala Val Ser    50                  55                  60His Arg Ala Asn Glu Thr Ile Tyr Asn Thr Thr Leu Lys Tyr Gly Asp65                  70                  75                  80Val Val Gly Val Asn Thr Thr Lys Tyr Pro Tyr Arg Val Cys Ser Met                85                  90                  95Ala Gln Gly Thr Asp Leu Ile Arg Phe Glu Arg Asn Ile Ile Cys Thr            100                 105                 110Ser Met Lys Pro Ile Asn Glu Asp Leu Asp Glu Gly Ile Met Val Val        115                 120                 125Tyr Lys Arg Asn Ile Val Ala His Thr Phe Lys Val Arg Val Tyr Gln    130                 135                 140Lys Val Leu Thr Phe Arg Arg Ser Tyr Ala Tyr Ile Tyr Thr Thr Tyr145                 150                 155                 160Leu Leu Gly Ser Asn Thr Glu Tyr Val Ala Pro Pro Met Trp Glu Ile                165                 170                 175His His Ile Asn Lys Phe Ala Gln Cys Tyr Ser Ser Tyr Ser Arg Val            180                 185                 190Ile Gly Gly Thr Val Phe Val Ala Tyr His Arg Asp Ser Tyr Glu Asn        195                 200                 205Lys Thr Met Gln Leu Ile Pro Asp Asp Tyr Ser Asn Thr His Ser Thr    210                 215                 220Arg Tyr Val Thr Val Lys Asp Gln Trp His Ser Arg Gly Ser Thr Trp225                 230                 235                 240Leu Tyr Arg Glu Thr Cys Asn Leu Asn Cys Met Leu Thr Ile Thr Thr                245                 250                 255Ala Arg Ser Lys Tyr Pro Tyr His Phe Phe Ala Thr Ser Thr Gly Asp            260                 265                 270Val Val Tyr Ile Ser Pro Phe Tyr Asn Gly Thr Asn Arg Asn Ala Ser        275                 280                 285Tyr Phe Gly Glu Asn Ala Asp Lys Phe Phe Ile Phe Pro Asn Tyr Thr    290                 295                 300Ile Val Ser Asp Phe Gly Arg Pro Asn Ala Ala Pro Glu Thr His Arg305                 310                 315                 320Leu Val Ala Phe Leu Glu Arg Ala Asp Ser Val Ile Ser Trp Asp Ile                325                 330                 335Gln Asp Glu Lys Asn Val Thr Cys Gln Leu Thr Phe Trp Glu Ala Ser            340                 345                 350Glu Arg Thr Ile Arg Ser Glu Ala Glu Asp Ser Tyr His Phe Ser Ser        355                 360                 365Ala Lys Met Thr Ala Thr Phe Leu Ser Lys Lys Gln Glu Val Asn Met    370                 375                 380Ser Asp Ser Ala Leu Asp Cys Val Arg Asp Glu Ala Ile Asn Lys Leu385                 390                 395                 400Gln Gln Ile Phe Asn Thr Ser Tyr Asn Gln Thr Tyr Glu Lys Tyr Gly                405                 410                 415Asn Val Ser Val Phe Glu Thr Ser Gly Gly Leu Val Val Phe Trp Gln            420                 425                 430Gly Ile Lys Gln Lys Ser Leu Val Glu Leu Glu Arg Leu Ala Asn Arg        435                 440                 445Ser Ser Leu Asn Ile Thr His Arg Thr Arg Arg Ser Thr Ser Asp Asn    450                 455                 460Asn Thr Thr His Leu Ser Ser Met Glu Ser Val His Asn Leu Val Tyr465                 470                 475                 480Ala Gln Leu Gln Phe Thr Tyr Asp Thr Leu Arg Gly Tyr Ile Asn Arg                485                 490                 495Ala Leu Ala Gln Ile Ala Glu Ala Trp Cys Val Asp Gln Arg Arg Thr            500                 505                 510Leu Glu Val Phe Lys Glu Leu Ser Lys Ile Asn Pro Ser Ala Ile Leu        515                 520                 525Ser Ala Ile Tyr Asn Lys Pro Ile Ala Ala Arg Phe Met Gly Asp Val    530                 535                 540Leu Gly Leu Ala Ser Cys Val Thr Ile Asn Gln Thr Ser Val Lys Val545                 550                 555                 560Leu Arg Asp Met Asn Val Lys Glu Ser Pro Gly Arg Cys Tyr Ser Arg                565                 570                 575Pro Val Val Ile Phe Asn Phe Ala Asn Ser Ser Tyr Val Gln Tyr Gly            580                 585                 590Gln Leu Gly Glu Asp Asn Glu Ile Leu Leu Gly Asn His Arg Thr Glu        595                 600                 605Glu Cys Gln Leu Pro Ser Leu Lys Ile Phe Ile Ala Gly Asn Ser Ala    610                 615                 620Tyr Glu Tyr Val Asp Tyr Leu Phe Lys Arg Met Ile Asp Leu Ser Ser625                 630                 635                 640Ile Ser Thr Val Asp Ser Met Ile Ala Leu Asp Ile Asp Pro Leu Glu                645                 650                 655Asn Thr Asp Phe Arg Val Leu Glu Leu Tyr Ser Gln Lys Glu Leu Arg            660                 665                 670Ser Ser Asn Val Phe Asp Leu Glu Glu Ile Met Arg Glu Phe Asn Ser        675                 680                 685Tyr Lys Gln Arg Val Lys Tyr Val Glu Asp Lys Val Val Asp Pro Leu    690                 695                 700Pro Pro Tyr Leu Lys Gly Leu Asp Asp Leu Met Ser Gly Leu Gly Ala705                 710                 715                 720Ala Gly Lys Ala Val Gly Val Ala Ile Gly Ala Val Gly Gly Ala Val                725                 730                 735Ala Ser Val Val Glu Gly Val Ala Thr Phe Leu Lys Asn Pro Phe Gly            740                 745                 750Ala Phe Thr Ile Ile Leu Val Ala Ile Ala Val Val Ile Ile Thr Tyr        755                 760                 765Leu Ile Tyr Thr Arg Gln Arg Arg Leu Cys Thr Gln Pro Leu Gln Asn    770                 775                 780Leu Phe Pro Tyr Leu Val Ser Ala Asp Gly Thr Thr Val Thr Ser Gly785                 790                 795                 800Ser Thr Lys Asp Thr Ser Leu Gln Ala Pro Pro Ser Tyr Glu Glu Ser                805                 810                 815Val Tyr Asn Ser Gly Arg Lys Gly Pro Gly Pro Pro Ser Ser Asp Ala            820                 825                 830Ser Thr Ala Ala Pro Pro Tyr Thr Asn Glu Gln Ala Tyr Gln Met Leu        835                 840                 845Leu Ala Leu Ala Arg Leu Asp Ala Glu Gln Arg Ala Gln Gln Asn Gly    850                 855                 860Thr Asp Ser Leu Asp Gly Gln Thr Gly Thr Gln Asp Lys Gly Gln Lys865                 870                 875                 880Pro Asn Leu Leu Asp Arg Leu Arg His Arg Lys Asn Gly Tyr Arg His                885                 890                 895Leu Lys Asp Ser Asp Glu Glu Glu Asn Val            900                 905</s400><s200><s210>174</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 174Gly Thr Leu Arg Gly1               5</s400><s200><s210>175</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 175Tyr Asn Gln Ser Glu1               5</s400><s200><s210>176</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 176Thr Ala Ala Asp Met1               5</s400><s200><s210>177</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 177Ala Gln Thr Thr Lys1               5</s400><s200><s210>178</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 178Val Glu Thr Arg Pro1               5</s400><s200><s210>179</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 179Gly Asp Gly Thr Phe1               5</s400><s200><s210>180</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 180Arg Asn Leu Arg Gly1               5</s400><s200><s210>181</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 181Thr Ala Ala Asp Thr1               5</s400><s200><s210>182</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 182Ala Gln Ile Thr Gln1               5</s400><s200><s210>183</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 183Gly Asp Arg Thr Phe1               5</s400><s200><s210>184</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(9)..(9)</s222><s223>Xaa is Phe, Tyr, Ser, or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(44)..(44)</s222><s223>Xaa is Lys or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(62)..(62)</s222><s223>Xaa is Gln, Gly, Glu, or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(63)..(63)</s222><s223>Xaa is Asn or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(65)..(65)</s222><s223>Xaa is Arg or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is Asn or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(67)..(67)</s222><s223>Xaa is Met or Val</s223></s220><s220><s221>VARIANT</s221><s222>(70)..(70)</s222><s223>Xaa is His or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(73)..(73)</s222><s223>Xaa is His or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(74)..(74)</s222><s223>Xaa is Asp or His</s223></s220><s220><s221>VARIANT</s221><s222>(76)..(76)</s222><s223>Xaa is Ala, Val, or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(77)..(77)</s222><s223>Xaa is Asn or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(79)..(79)</s222><s223>Xaa is Gly or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(80)..(80)</s222><s223>Xaa is Thr or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(81)..(81)</s222><s223>Xaa is Leu or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(82)..(82)</s222><s223>Xaa is Arg or Leu</s223></s220><s220><s221>VARIANT</s221><s222>(83)..(83)</s222><s223>Xaa is Gly or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(90)..(90)</s222><s223>Xaa is Ala or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(95)..(95)</s222><s223>Xaa is Ile, Leu, or Val</s223></s220><s220><s221>VARIANT</s221><s222>(97)..(97)</s222><s223>Xaa is Ile, Arg or Met</s223></s220><s220><s221>VARIANT</s221><s222>(99)..(99)</s222><s223>Xaa is Phe or Tyr</s223></s220><s220><s221>VARIANT</s221><s222>(105)..(105)</s222><s223>Xaa is Ser or Pro</s223></s220><s220><s221>VARIANT</s221><s222>(107)..(107)</s222><s223>Xaa is Try or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(114)..(114)</s222><s223>Xaa is Arg, His, or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(116)..(116)</s222><s223>Xaa is Asp or Tyr</s223></s220><s220><s221>VARIANT</s221><s222>(127)..(127)</s222><s223>Xaa is Asn or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(142)..(142)</s222><s223>Xaa is Thr or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(144)..(144)</s222><s223>Xaa is Lys or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(145)..(145)</s222><s223>Xaa is Arg or His</s223></s220><s220><s221>VARIANT</s221><s222>(149)..(149)</s222><s223>Xaa is Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(150)..(150)</s222><s223>Xaa is Ala or Val</s223></s220><s220><s221>VARIANT</s221><s222>(151)..(151)</s222><s223>Xaa is His or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(156)..(156)</s222><s223>Xaa is Arg, Leu, Gln, or Try</s223></s220><s220><s221>VARIANT</s221><s222>(158)..(158)</s222><s223>Xaa is Val or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(161)..(161)</s222><s223>Xaa is Asp or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(163)..(163)</s222><s223>Xaa is Arg or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(166)..(166)</s222><s223>Xaa is Asp or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(167)..(167)</s222><s223>Xaa is Try or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(184)..(184)</s222><s223>Xaa is Pro or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(193)..(193)</s222><s223>Xaa is Pro or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(194)..(194)</s222><s223>Xaa is Pro or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(207)..(207)</s222><s223>Xaa is Ser or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(246)..(246)</s222><s223>Xaa is Ala or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(253)..(253)</s222><s223>Xaa is Gln or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(276)..(276)</s222><s223>Xaa is Pro or Leu</s223></s220></s200><s400> 184Gly Ser His Ser Met Arg Tyr Phe Xaa Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Xaa Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Xaa Xaa Thr    50                  55                  60Xaa Xaa Xaa Lys Ala Xaa Ser Gln Xaa Xaa Arg Xaa Xaa Leu Xaa Xaa65                  70                  75                  80Xaa Xaa Xaa Tyr Tyr Asn Gln Ser Glu Xaa Gly Ser His Thr Xaa Gln                85                  90                  95Xaa Met Xaa Gly Cys Asp Val Gly Xaa Asp Xaa Arg Phe Leu Arg Gly            100                 105                 110Tyr Xaa Gln Xaa Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Xaa Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Xaa Thr Xaa    130                 135                 140Xaa Lys Trp Glu Xaa Xaa Xaa Glu Ala Glu Gln Xaa Arg Xaa Tyr Leu145                 150                 155                 160Xaa Gly Xaa Cys Val Xaa Xaa Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Xaa Pro Lys Thr His Met Thr His His            180                 185                 190Xaa Xaa Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Xaa Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Xaa Val Val Val Pro Ser Gly Xaa Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Xaa        275</s400><s200><s210>185</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 185Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>186</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 186Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>187</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 187Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Ala Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>188</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 188Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Ala Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>189</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 189Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Cys Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Cys Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>190</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 190Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Ala Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>191</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 191Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Ala Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Ala Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>192</s210><s211>341</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 192Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu Thr    50                  55                  60Gly Lys Val Lys Ala His Ser Gln Thr Asp Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Val Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro Ser Ser Gln Pro Thr Val Pro Ile Val Gly Ile Ile        275                 280                 285Ala Gly Leu Val Leu Leu Gly Ala Val Ile Thr Gly Ala Val Val Ala    290                 295                 300Ala Val Met Trp Arg Arg Asn Ser Ser Asp Arg Lys Gly Gly Ser Tyr305                 310                 315                 320Ser Gln Ala Ala Ser Ser Asp Ser Ala Gln Gly Ser Asp Val Ser Leu                325                 330                 335Thr Ala Cys Lys Val            340</s400><s200><s210>193</s210><s211>341</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 193Gly Ser His Ser Met Arg Tyr Phe Thr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Arg Asn Val Lys Ala His Ser Gln Ile Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln                85                  90                  95Met Met Tyr Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Gln Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ser Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro Ser Ser Gln Pro Thr Ile Pro Ile Val Gly Ile Ile        275                 280                 285Ala Gly Leu Val Leu Phe Gly Ala Val Phe Ala Gly Ala Val Val Ala    290                 295                 300Ala Val Arg Trp Arg Arg Lys Ser Ser Asp Arg Lys Gly Gly Ser Tyr305                 310                 315                 320Ser Gln Ala Ala Ser Ser Asp Ser Ala Gln Gly Ser Asp Met Ser Leu                325                 330                 335Thr Ala Cys Lys Val            340</s400><s200><s210>194</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(9)..(9)</s222><s223>Xaa is His, Tyr or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(11)..(11)</s222><s223>Xaa is Ala or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(12)..(12)</s222><s223>Xaa is Met or Val</s223></s220><s220><s221>VARIANT</s221><s222>(24)..(24)</s222><s223>Xaa is Ala, Ser, or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(32)..(32)</s222><s223>Xaa is Gln or Leu</s223></s220><s220><s221>VARIANT</s221><s222>(41)..(41)</s222><s223>Xaa is Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is Glu, Met, Lys, or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(46)..(46)</s222><s223>Xaa is Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(63)..(63)</s222><s223>Xaa is Glu or Asn</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is Ile or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(67)..(67)</s222><s223>Xaa is Tyr, Phe, Ser, or Cys</s223></s220><s220><s221>VARIANT</s221><s222>(70)..(70)</s222><s223>Xaa is Asn or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(71)..(71)</s222><s223>Xaa is Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(74)..(74)</s222><s223>Xaa is Asp or Tyr</s223></s220><s220><s221>VARIANT</s221><s222>(76)..(76)</s222><s223>Xaa is Glu or Val</s223></s220><s220><s221>VARIANT</s221><s222>(77)..(77)</s222><s223>Xaa is Ser or Asn</s223></s220><s220><s221>VARIANT</s221><s222>(80)..(80)</s222><s223>Xaa is Thr, Asn or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(81)..(81)</s222><s223>Xaa is Ala or Leu</s223></s220><s220><s221>VARIANT</s221><s222>(82)..(82)</s222><s223>Xaa is Leu or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(83)..(83)</s222><s223>Xaa is Arg or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(94)..(94)</s222><s223>Xaa is Thr or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(95)..(95)</s222><s223>Xaa is Leu or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(97)..(97)</s222><s223>Xaa is Arg or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(131)..(131)</s222><s223>Xaa is Arg or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(143)..(143)</s222><s223>Xaa is Ser or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(147)..(147)</s222><s223>Xaa is Leu or Try</s223></s220><s220><s221>VARIANT</s221><s222>(152)..(152)</s222><s223>Xaa is Glu or Val</s223></s220><s220><s221>VARIANT</s221><s222>(156)..(156)</s222><s223>Xaa is Arg, Asp, Leu or Try</s223></s220><s220><s221>VARIANT</s221><s222>(158)..(158)</s222><s223>Xaa is Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(163)..(163)</s222><s223>Xaa is Leu, Glu or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(177)..(177)</s222><s223>Xaa is Glu or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(178)..(178)</s222><s223>Xaa is Lys or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(180)..(180)</s222><s223>Xaa is Glu or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(194)..(194)</s222><s223>Xaa is Ile or Val</s223></s220></s200><s400> 194Gly Ser His Ser Met Arg Tyr Phe Xaa Thr Xaa Xaa Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Xaa Val Gly Tyr Val Asp Asp Thr Xaa            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Xaa Ser Pro Arg Xaa Xaa Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Xaa Thr    50                  55                  60Gln Xaa Xaa Lys Thr Xaa Xaa Thr Gln Xaa Tyr Xaa Xaa Asn Leu Xaa65                  70                  75                  80Xaa Xaa Xaa Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Xaa Xaa Gln                85                  90                  95Xaa Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Xaa Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Xaa Gln    130                 135                 140Arg Lys Xaa Glu Ala Ala Arg Xaa Ala Glu Gln Xaa Arg Xaa Tyr Leu145                 150                 155                 160Glu Gly Xaa Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Xaa Xaa Leu Xaa Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Xaa Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>195</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 195Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Tyr Lys Ala Gln Ala Gln Thr Asp Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>196</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 196Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Tyr Lys Ala Gln Ala Gln Thr Asp Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Ala Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>197</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 197Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Tyr Lys Ala Gln Ala Gln Thr Asp Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Cys Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Cys Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>198</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(1)..(1)</s222><s223>Xaa is Cys or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(6)..(6)</s222><s223>Xaa is Arg or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(9)..(9)</s222><s223>Xaa is Phe, Tyr, Ser, or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(14)..(14)</s222><s223>Xaa is Arg or Try</s223></s220><s220><s221>VARIANT</s221><s222>(21)..(21)</s222><s223>Xaa is His or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(24)..(24)</s222><s223>Xaa is Ala or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(35)..(35)</s222><s223>Xaa is Gln or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(49)..(49)</s222><s223>Xaa is Ala or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is Asn or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(73)..(73)</s222><s223>Xaa is Thr or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(77)..(77)</s222><s223>Xaa is Ser or Asn</s223></s220><s220><s221>VARIANT</s221><s222>(80)..(80)</s222><s223>Xaa is Asn or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(90)..(90)</s222><s223>Xaa is Ala or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is Gly or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(94)..(94)</s222><s223>Xaa is Thr or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(95)..(95)</s222><s223>Xaa is Leu or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(97)..(97)</s222><s223>Xaa is Try or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(99)..(99)</s222><s223>Xaa is Cys, Tyr, Phe, or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(103)..(103)</s222><s223>Xaa is Leu or Val</s223></s220><s220><s221>VARIANT</s221><s222>(113)..(113)</s222><s223>Xaa is Tyr or His</s223></s220><s220><s221>VARIANT</s221><s222>(114)..(114)</s222><s223>Xaa is Asp or Asn</s223></s220><s220><s221>VARIANT</s221><s222>(116)..(116)</s222><s223>Xaa is Tyr, Phe, Ser, or Leu</s223></s220><s220><s221>VARIANT</s221><s222>(147)..(147)</s222><s223>Xaa is Leu or Try</s223></s220><s220><s221>VARIANT</s221><s222>(152)..(152)</s222><s223>Xaa is Glu, Ala or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(156)..(156)</s222><s223>Xaa is Arg, Leu or Try</s223></s220><s220><s221>VARIANT</s221><s222>(163)..(163)</s222><s223>Xaa is Leu or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(173)..(173)</s222><s223>Xaa is Glu or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(177)..(177)</s222><s223>Xaa is Glu or Lys</s223></s220><s220><s221>VARIANT</s221><s222>(184)..(184)</s222><s223>Xaa is His or Pro</s223></s220><s220><s221>VARIANT</s221><s222>(194)..(194)</s222><s223>Xaa is Arg or Val</s223></s220><s220><s221>VARIANT</s221><s222>(219)..(219)</s222><s223>Xaa is Try or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(248)..(248)</s222><s223>Xaa is Val or Met</s223></s220><s220><s221>VARIANT</s221><s222>(253)..(253)</s222><s223>Xaa is Glu or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(261)..(261)</s222><s223>Xaa is Met or Val</s223></s220><s220><s221>VARIANT</s221><s222>(267)..(267)</s222><s223>Xaa is Pro or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(273)..(273)</s222><s223>Xaa is Arg or Ser</s223></s220><s220><s221>VARIANT</s221><s222>(275)..(275)</s222><s223>Xaa is Pro or Gly</s223></s220></s200><s400> 198Xaa Ser His Ser Met Xaa Tyr Phe Xaa Thr Ala Val Ser Xaa Pro Gly1               5                   10                  15Arg Gly Glu Pro Xaa Phe Ile Xaa Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Xaa Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Xaa Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Xaa Tyr Lys Arg Gln Ala Gln Xaa Asp Arg Val Xaa Leu Arg Xaa65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Xaa Xaa Ser His Xaa Xaa Gln                85                  90                  95Xaa Met Xaa Gly Cys Asp Xaa Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Xaa Xaa Gln Xaa Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Xaa Glu Ala Ala Arg Xaa Ala Glu Gln Xaa Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Xaa Cys Val Glu Trp Leu Arg Arg Tyr Leu Xaa Asn Gly Lys                165                 170                 175Xaa Thr Leu Gln Arg Ala Glu Xaa Pro Lys Thr His Val Thr His His            180                 185                 190Pro Xaa Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Xaa Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Xaa Val Pro Ser Gly Xaa Glu Gln Arg                245                 250                 255Tyr Thr Cys His Xaa Gln His Glu Gly Leu Xaa Glu Pro Leu Thr Leu            260                 265                 270Xaa Trp Xaa Pro        275</s400><s200><s210>199</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 199Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Asn Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Leu Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Met Gln His Glu Gly Leu Gln Glu Pro Leu Thr Leu            260                 265                 270Ser Trp Glu Pro        275</s400><s200><s210>200</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 200Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Asn Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Ala Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Leu Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Met Gln His Glu Gly Leu Gln Glu Pro Leu Thr Leu            260                 265                 270Ser Trp Glu Pro        275</s400><s200><s210>201</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 201Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Asn Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Cys Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Cys Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Leu Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Met Gln His Glu Gly Leu Gln Glu Pro Leu Thr Leu            260                 265                 270Ser Trp Glu Pro        275</s400><s200><s210>202</s210><s211>99</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 202Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Cys His Pro Ala Glu1               5                   10                  15Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser Gly Phe His Pro            20                  25                  30Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys        35                  40                  45Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp Ser Phe Tyr Leu    50                  55                  60Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp Glu Tyr Ala Cys65                  70                  75                  80Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile Val Lys Trp Asp                85                  90                  95Arg Asp Met</s400><s200><s210>203</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(79)..(83)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(85)..(88)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(89)..(93)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 89 to 93 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220><s220><s221>VARIANT</s221><s222>(95)..(99)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 95 to 99 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220><s220><s221>VARIANT</s221><s222>(134)..(138)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(140)..(143)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(144)..(148)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 144 to 148 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220><s220><s221>VARIANT</s221><s222>(150)..(154)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 150 to 154 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220><s220><s221>VARIANT</s221><s222>(231)..(235)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 231 to 235 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220><s220><s221>VARIANT</s221><s222>(237)..(241)</s222><s223>Where Xaa is independently any naturally      occurring amino acid except proline or glycine and each copy of      Xaa at positions 237 to 241 is either present or absent such that      the number of Xaa ranges from 1 to 5.</s223></s220></s200><s400> 203Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Xaa Xaa65                  70                  75                  80Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Xaa Xaa Xaa Xaa Xaa Ile Xaa Xaa Xaa Xaa225                 230                 235                 240Xaa Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>204</s210><s211>99</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 204Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg His Pro Ala Glu1               5                   10                  15Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser Gly Phe His Pro            20                  25                  30Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys        35                  40                  45Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp Ser Phe Tyr Leu    50                  55                  60Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp Glu Tyr Ala Cys65                  70                  75                  80Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile Val Lys Trp Asp                85                  90                  95Arg Asp Met</s400><s200><s210>205</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 205Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>206</s210><s211>55</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(6)..(55)</s222><s223>Each copy of Gly Gly Gly Gly Ser at positions 6      to 55 is either present or absent such that the number of copies      of Gly Gly Gly Gly Ser ranges from 1 to 10.</s223></s220></s200><s400> 206Gly Cys Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser    50                  55</s400><s200><s210>207</s210><s211>20</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 207Gly Cys Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser            20</s400><s200><s210>208</s210><s211>15</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 208Gly Cys Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>209</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(19)..(19)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220></s200><s400> 209Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Xaa Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>210</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(63)..(63)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220></s200><s400> 210Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Xaa Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>211</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(67)..(67)</s222><s223>Xaa is any amino acid other than Ile. In some      cases, Xaa is Ala</s223></s220></s200><s400> 211Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Xaa Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>212</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(86)..(86)</s222><s223>Xaa is any amino acid other than Lys. In some      cases, Xaa is Ala</s223></s220></s200><s400> 212Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Xaa Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>213</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(157)..(157)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 213Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Xaa Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>214</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(158)..(158)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 214Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Xaa Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>215</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(25)..(25)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 215Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Xaa Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>216</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(31)..(31)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 216Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Xaa Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>217</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(33)..(33)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 217Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Xaa Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>218</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(38)..(38)</s222><s223>Xaa is any amino acid other than Met. In some      cases, Xaa is Ala</s223></s220></s200><s400> 218Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Xaa Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>219</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(39)..(39)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 219Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Xaa Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>220</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(49)..(49)</s222><s223>Xaa is any amino acid other than Ile. In some      cases, Xaa is Ala</s223></s220></s200><s400> 220Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Xaa Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>221</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(53)..(53)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 221Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Xaa Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>222</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(60)..(60)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 222Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Xaa Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>223</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(108)..(108)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 223Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Xaa Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>224</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(156)..(156)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 224Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Xaa Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>225</s210><s211>208</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(111)..(111)</s222><s223>Xaa is any amino acid other than Pro. In some      cases, Xaa is Ala</s223></s220></s200><s400> 225Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys1               5                   10                  15Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp            20                  25                  30Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn        35                  40                  45Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn    50                  55                  60Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr65                  70                  75                  80Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His                85                  90                  95Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Xaa Ser            100                 105                 110Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys        115                 120                 125Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn    130                 135                 140Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu145                 150                 155                 160Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr                165                 170                 175Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn            180                 185                 190Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn        195                 200                 205</s400><s200><s210>226</s210><s211>224</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 226Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>227</s210><s211>110</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 227Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>228</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220></s200><s400> 228Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>229</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 229Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>230</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(70)..(70)</s222><s223>Xaa is any amino acid other than Trp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 230Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Xaa Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>231</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 231Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>232</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>where Xaa is any amino acid other than Asn. In      some cases, Xaa is Ala</s223></s220></s200><s400> 232Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>233</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 233Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>234</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(70)..(70)</s222><s223>Xaa is any amino acid other than Trp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 234Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Xaa Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>235</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 235Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>236</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(41)..(41)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 236Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Xaa Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>237</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(41)..(41)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 237Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Xaa Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>238</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(35)..(35)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 238Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Xaa Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>239</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(35)..(35)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 239Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Xaa Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>240</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(33)..(33)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 240Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Xaa Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>241</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(33)..(33)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 241Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Xaa Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>242</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(72)..(72)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 242Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Xaa Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>243</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(72)..(72)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 243Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Xaa Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>244</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(59)..(59)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 244Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Xaa Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>245</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(59)..(59)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 245Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Xaa Met Asn Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>246</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>Xaa is any amino acid other than Asn, In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His, In some      cases, Xaa is Ala</s223></s220></s200><s400> 246Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>247</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala.</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala.</s223></s220></s200><s400> 247Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>248</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala.</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala.</s223></s220></s200><s400> 248Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>249</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 249Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Asn Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>250</s210><s211>224</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala.</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala.</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala.</s223></s220></s200><s400> 250Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn            100                 105                 110Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val        115                 120                 125Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys    130                 135                 140Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp145                 150                 155                 160Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val                165                 170                 175Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr            180                 185                 190Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro        195                 200                 205Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro    210                 215                 220</s400><s200><s210>251</s210><s211>110</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(61)..(61)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(91)..(91)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 251Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro1               5                   10                  15Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val            20                  25                  30Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly        35                  40                  45Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Xaa Arg Thr Ser    50                  55                  60Phe Xaa Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys65                  70                  75                  80Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Xaa Lys Lys Pro Thr Gly                85                  90                  95Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu            100                 105                 110</s400><s200><s210>252</s210><s211>254</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 252Met Glu Tyr Ala Ser Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro1               5                   10                  15Pro Ala Pro Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu Val            20                  25                  30Ala Gly Leu Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys Ala Val Phe        35                  40                  45Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser    50                  55                  60Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp65                  70                  75                  80Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val                85                  90                  95Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            100                 105                 110Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        115                 120                 125Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    130                 135                 140Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser145                 150                 155                 160Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                165                 170                 175Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            180                 185                 190Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        195                 200                 205Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    210                 215                 220Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val225                 230                 235                 240Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                245                 250</s400><s200><s210>253</s210><s211>174</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 253Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>254</s210><s211>175</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 254Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu1               5                   10                  15Val Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser            20                  25                  30Asp Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys        35                  40                  45Glu Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val    50                  55                  60Phe Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly65                  70                  75                  80Ser Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly                85                  90                  95Ala Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu            100                 105                 110Ala Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser        115                 120                 125Ala Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg    130                 135                 140His Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg145                 150                 155                 160Val Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170                 175</s400><s200><s210>255</s210><s211>167</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 255Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu1               5                   10                  15Val Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser            20                  25                  30Asp Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys        35                  40                  45Glu Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val    50                  55                  60Phe Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly65                  70                  75                  80Ser Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly                85                  90                  95Ala Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu            100                 105                 110Ala Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser        115                 120                 125Ala Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg    130                 135                 140His Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg145                 150                 155                 160Val Thr Pro Glu Ile Pro Ala                165</s400><s200><s210>256</s210><s211>174</s211><s212>PRT</s212><s213>Homo sapiens</s213><s220><s221>VARIANT</s221><s222>(47)..(47)</s222><s223>Xaa is any amino acid other than Lys. In some      cases, Xaa is Ala</s223></s220></s200><s400> 256Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Xaa Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>257</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(147)..(147)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 257Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Xaa Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>258</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(11)..(11)</s222><s223>Xaa is any amino acid other than Met. In some      cases, Xaa is Ala</s223></s220></s200><s400> 258Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Xaa Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>259</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(12)..(12)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 259Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Xaa Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>260</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(14)..(14)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 260Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Xaa Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>261</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(15)..(15)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 261Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Xaa Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>262</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 262Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Xaa1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>263</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(18)..(18)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 263Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Xaa Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>264</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(19)..(19)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220></s200><s400> 264Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Xaa Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>265</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 265Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Xaa Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>266</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(21)..(21)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 266Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Xaa Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>267</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(22)..(22)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 267Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Xaa Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>268</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(23)..(23)</s222><s223>Xaa is any amino acid other than Ile. In some      cases, Xaa is Ala</s223></s220></s200><s400> 268Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Xaa Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>269</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(24)..(24)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 269Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Xaa Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>270</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(25)..(25)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 270Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Xaa Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>271</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(26)..(26)</s222><s223>Xaa is any amino acid other than Pro. In some      cases, Xaa is Ala</s223></s220></s200><s400> 271Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Xaa Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>272</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(27)..(27)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 272Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Xaa Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>273</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(28)..(28)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 273Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Xaa Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>274</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(29)..(29)</s222><s223>Xaa is any amino acid other than Trp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 274Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Xaa Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>275</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(30)..(30)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 275Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Xaa Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>276</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(31)..(31)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 276Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Xaa Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>277</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(32)..(32)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 277Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Xaa            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>278</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(33)..(33)</s222><s223>Xaa is any amino acid other than Pro. In some      cases, Xaa is Ala</s223></s220></s200><s400> 278Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Xaa Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>279</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(34)..(34)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 279Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Xaa Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>280</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(35)..(35)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 280Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Xaa Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>281</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(37)..(37)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 281Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Xaa Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>282</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(38)..(38)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 282Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Xaa Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>283</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(39)..(39)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 283Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Xaa Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>284</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(40)..(40)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 284Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Xaa Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>285</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(41)..(41)</s222><s223>Xaa is any amino acid other than Thr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 285Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Xaa Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>286</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 286Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Xaa Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>287</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(43)..(43)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 287Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Xaa Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>288</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(44)..(44)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 288Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Xaa Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>289</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 289Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Xaa Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>290</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(46)..(46)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 290Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Xaa Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>291</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(48)..(48)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 291Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Xaa        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>292</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(49)..(49)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 292Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Xaa Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>293</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(50)..(50)</s222><s223>Xaa is any amino acid other than Thr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 293Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Xaa Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>294</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(51)..(51)</s222><s223>Xaa is any amino acid other than Lys. In some      cases, Xaa is Ala</s223></s220></s200><s400> 294Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Xaa Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>295</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(52)..(52)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 295Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Xaa Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>296</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(64)..(64)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 296Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Xaa    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>297</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(65)..(65)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 297Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Xaa Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>298</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(66)..(66)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 298Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Xaa Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>299</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(67)..(67)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 299Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Xaa Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>300</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(68)..(68)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 300Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Xaa Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>301</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(69)..(69)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 301Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Xaa Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>302</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(70)..(70)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 302Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Xaa Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>303</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(71)..(71)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 303Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Xaa Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>304</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(72)..(72)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 304Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Xaa Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>305</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(73)..(73)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 305Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Xaa Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>306</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(75)..(75)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 306Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Xaa Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>307</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(76)..(76)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 307Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Xaa Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>308</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(77)..(77)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 308Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Xaa Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>309</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(78)..(78)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 309Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Xaa Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>310</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(104)..(104)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 310Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Xaa Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>311</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(105)..(105)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 311Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Xaa Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>312</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(106)..(106)</s222><s223>Xaa is any amino acid other than Pro. In some      cases, Xaa is Ala</s223></s220></s200><s400> 312Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Xaa Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>313</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(109)..(109)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 313Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Xaa Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>314</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(110)..(110)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 314Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Xaa Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>315</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(111)..(111)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 315Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Xaa Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>316</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(113)..(113)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 316Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Xaa Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>317</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(114)..(114)</s222><s223>Xaa is any amino acid other than Asn. In some      cases, Xaa is Ala</s223></s220></s200><s400> 317Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Xaa Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>318</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(115)..(115)</s222><s223>Xaa is any amino acid other than Ser. In some      cases, Xaa is Ala</s223></s220></s200><s400> 318Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Xaa Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>319</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(117)..(117)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 319Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Xaa Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>320</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(130)..(130)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 320Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Xaa Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>321</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(131)..(131)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 321Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Xaa Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>322</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(132)..(132)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 322Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Xaa Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>323</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(133)..(133)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 323Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Xaa Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>324</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(134)..(134)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 324Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Xaa His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>325</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(135)..(135)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 325Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val Xaa Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>326</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(136)..(136)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 326Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Xaa His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>327</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(137)..(137)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 327Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu Xaa Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>328</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(138)..(138)</s222><s223>Xaa is any amino acid other than Thr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 328Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Xaa Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>329</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(139)..(139)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 329Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Xaa Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>330</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(141)..(141)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 330Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Xaa Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>331</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(143)..(143)</s222><s223>Xaa is any amino acid other than Arg. In some      cases, Xaa is Ala</s223></s220></s200><s400> 331Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Xaa His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>332</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(144)..(144)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220></s200><s400> 332Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg Xaa    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>333</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(146)..(146)</s222><s223>Xaa is any amino acid other than Trp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 333Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Xaa Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>334</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(148)..(148)</s222><s223>Xaa is any amino acid other than Leu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 334Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Xaa Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>335</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(149)..(149)</s222><s223>Xaa is any amino acid other than Thr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 335Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Xaa Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>336</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(150)..(150)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 336Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Xaa Gly Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>337</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(151)..(151)</s222><s223>Xaa is any amino acid other than Gly. In some      cases, Xaa is Ala</s223></s220></s200><s400> 337Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Xaa Ala Thr Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>338</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(153)..(153)</s222><s223>Xaa is any amino acid other than Thr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 338Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Xaa Val Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>339</s210><s211>174</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(154)..(154)</s222><s223>Xaa is any amino acid other than Val. In some      cases, Xaa is Ala</s223></s220></s200><s400> 339Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val1               5                   10                  15Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp            20                  25                  30Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu        35                  40                  45Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe    50                  55                  60Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser65                  70                  75                  80Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala                85                  90                  95Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala            100                 105                 110Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala        115                 120                 125Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His    130                 135                 140Ala Trp Gln Leu Thr Gln Gly Ala Thr Xaa Leu Gly Leu Phe Arg Val145                 150                 155                 160Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu                165                 170</s400><s200><s210>340</s210><s211>133</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 340Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>341</s210><s211>251</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 341Glu Leu Cys Asp Asp Asp Pro Pro Glu Ile Pro His Ala Thr Phe Lys1               5                   10                  15Ala Met Ala Tyr Lys Glu Gly Thr Met Leu Asn Cys Glu Cys Lys Arg            20                  25                  30Gly Phe Arg Arg Ile Lys Ser Gly Ser Leu Tyr Met Leu Cys Thr Gly        35                  40                  45Asn Ser Ser His Ser Ser Trp Asp Asn Gln Cys Gln Cys Thr Ser Ser    50                  55                  60Ala Thr Arg Asn Thr Thr Lys Gln Val Thr Pro Gln Pro Glu Glu Gln65                  70                  75                  80Lys Glu Arg Lys Thr Thr Glu Met Gln Ser Pro Met Gln Pro Val Asp                85                  90                  95Gln Ala Ser Leu Pro Gly His Cys Arg Glu Pro Pro Pro Trp Glu Asn            100                 105                 110Glu Ala Thr Glu Arg Ile Tyr His Phe Val Val Gly Gln Met Val Tyr        115                 120                 125Tyr Gln Cys Val Gln Gly Tyr Arg Ala Leu His Arg Gly Pro Ala Glu    130                 135                 140Ser Val Cys Lys Met Thr His Gly Lys Thr Arg Trp Thr Gln Pro Gln145                 150                 155                 160Leu Ile Cys Thr Gly Glu Met Glu Thr Ser Gln Phe Pro Gly Glu Glu                165                 170                 175Lys Pro Gln Ala Ser Pro Glu Gly Arg Pro Glu Ser Glu Thr Ser Cys            180                 185                 190Leu Val Thr Thr Thr Asp Phe Gln Ile Gln Thr Glu Met Ala Ala Thr        195                 200                 205Met Glu Thr Ser Ile Phe Thr Thr Glu Tyr Gln Val Ala Val Ala Gly    210                 215                 220Cys Val Phe Leu Leu Ile Ser Val Leu Leu Leu Ser Gly Leu Thr Trp225                 230                 235                 240Gln Arg Arg Gln Arg Lys Ser Arg Arg Thr Ile                245                 250</s400><s200><s210>342</s210><s211>524</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 342Val Asn Gly Thr Ser Gln Phe Thr Cys Phe Tyr Asn Ser Arg Ala Asn1               5                   10                  15Ile Ser Cys Val Trp Ser Gln Asp Gly Ala Leu Gln Asp Thr Ser Cys            20                  25                  30Gln Val His Ala Trp Pro Asp Arg Arg Arg Trp Asn Gln Thr Cys Glu        35                  40                  45Leu Leu Pro Val Ser Gln Ala Ser Trp Ala Cys Asn Leu Ile Leu Gly    50                  55                  60Ala Pro Asp Ser Gln Lys Leu Thr Thr Val Asp Ile Val Thr Leu Arg65                  70                  75                  80Val Leu Cys Arg Glu Gly Val Arg Trp Arg Val Met Ala Ile Gln Asp                85                  90                  95Phe Lys Pro Phe Glu Asn Leu Arg Leu Met Ala Pro Ile Ser Leu Gln            100                 105                 110Val Val His Val Glu Thr His Arg Cys Asn Ile Ser Trp Glu Ile Ser        115                 120                 125Gln Ala Ser His Tyr Phe Glu Arg His Leu Glu Phe Glu Ala Arg Thr    130                 135                 140Leu Ser Pro Gly His Thr Trp Glu Glu Ala Pro Leu Leu Thr Leu Lys145                 150                 155                 160Gln Lys Gln Glu Trp Ile Cys Leu Glu Thr Leu Thr Pro Asp Thr Gln                165                 170                 175Tyr Glu Phe Gln Val Arg Val Lys Pro Leu Gln Gly Glu Phe Thr Thr            180                 185                 190Trp Ser Pro Trp Ser Gln Pro Leu Ala Phe Arg Thr Lys Pro Ala Ala        195                 200                 205Leu Gly Lys Asp Thr Ile Pro Trp Leu Gly His Leu Leu Val Gly Leu    210                 215                 220Ser Gly Ala Phe Gly Phe Ile Ile Leu Val Tyr Leu Leu Ile Asn Cys225                 230                 235                 240Arg Asn Thr Gly Pro Trp Leu Lys Lys Val Leu Lys Cys Asn Thr Pro                245                 250                 255Asp Pro Ser Lys Phe Phe Ser Gln Leu Ser Ser Glu His Gly Gly Asp            260                 265                 270Val Gln Lys Trp Leu Ser Ser Pro Phe Pro Ser Ser Ser Phe Ser Pro        275                 280                 285Gly Gly Leu Ala Pro Glu Ile Ser Pro Leu Glu Val Leu Glu Arg Asp    290                 295                 300Lys Val Thr Gln Leu Leu Leu Gln Gln Asp Lys Val Pro Glu Pro Ala305                 310                 315                 320Ser Leu Ser Ser Asn His Ser Leu Thr Ser Cys Phe Thr Asn Gln Gly                325                 330                 335Tyr Phe Phe Phe His Leu Pro Asp Ala Leu Glu Ile Glu Ala Cys Gln            340                 345                 350Val Tyr Phe Thr Tyr Asp Pro Tyr Ser Glu Glu Asp Pro Asp Glu Gly        355                 360                 365Val Ala Gly Ala Pro Thr Gly Ser Ser Pro Gln Pro Leu Gln Pro Leu    370                 375                 380Ser Gly Glu Asp Asp Ala Tyr Cys Thr Phe Pro Ser Arg Asp Asp Leu385                 390                 395                 400Leu Leu Phe Ser Pro Ser Leu Leu Gly Gly Pro Ser Pro Pro Ser Thr                405                 410                 415Ala Pro Gly Gly Ser Gly Ala Gly Glu Glu Arg Met Pro Pro Ser Leu            420                 425                 430Gln Glu Arg Val Pro Arg Asp Trp Asp Pro Gln Pro Leu Gly Pro Pro        435                 440                 445Thr Pro Gly Val Pro Asp Leu Val Asp Phe Gln Pro Pro Pro Glu Leu    450                 455                 460Val Leu Arg Glu Ala Gly Glu Glu Val Pro Asp Ala Gly Pro Arg Glu465                 470                 475                 480Gly Val Ser Phe Pro Trp Ser Arg Pro Pro Gly Gln Gly Glu Phe Arg                485                 490                 495Ala Leu Asn Ala Arg Leu Pro Leu Asn Thr Asp Ala Tyr Leu Ser Leu            500                 505                 510Gln Glu Leu Gln Gly Gln Asp Pro Thr His Leu Val        515                 520</s400><s200><s210>343</s210><s211>347</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 343Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly Asn Glu Asp Thr Thr Ala1               5                   10                  15Asp Phe Phe Leu Thr Thr Met Pro Thr Asp Ser Leu Ser Val Ser Thr            20                  25                  30Leu Pro Leu Pro Glu Val Gln Cys Phe Val Phe Asn Val Glu Tyr Met        35                  40                  45Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro Gln Pro Thr Asn Leu Thr    50                  55                  60Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn Asp Lys Val Gln Lys Cys65                  70                  75                  80Ser His Tyr Leu Phe Ser Glu Glu Ile Thr Ser Gly Cys Gln Leu Gln                85                  90                  95Lys Lys Glu Ile His Leu Tyr Gln Thr Phe Val Val Gln Leu Gln Asp            100                 105                 110Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln Met Leu Lys Leu Gln Asn        115                 120                 125Leu Val Ile Pro Trp Ala Pro Glu Asn Leu Thr Leu His Lys Leu Ser    130                 135                 140Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn Arg Phe Leu Asn His Cys145                 150                 155                 160Leu Glu His Leu Val Gln Tyr Arg Thr Asp Trp Asp His Ser Trp Thr                165                 170                 175Glu Gln Ser Val Asp Tyr Arg His Lys Phe Ser Leu Pro Ser Val Asp            180                 185                 190Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg Ser Arg Phe Asn Pro Leu        195                 200                 205Cys Gly Ser Ala Gln His Trp Ser Glu Trp Ser His Pro Ile His Trp    210                 215                 220Gly Ser Asn Thr Ser Lys Glu Asn Pro Phe Leu Phe Ala Leu Glu Ala225                 230                 235                 240Val Val Ile Ser Val Gly Ser Met Gly Leu Ile Ile Ser Leu Leu Cys                245                 250                 255Val Tyr Phe Trp Leu Glu Arg Thr Met Pro Arg Ile Pro Thr Leu Lys            260                 265                 270Asn Leu Glu Asp Leu Val Thr Glu Tyr His Gly Asn Phe Ser Ala Trp        275                 280                 285Ser Gly Val Ser Lys Gly Leu Ala Glu Ser Leu Gln Pro Asp Tyr Ser    290                 295                 300Glu Arg Leu Cys Leu Val Ser Glu Ile Pro Pro Lys Gly Gly Ala Leu305                 310                 315                 320Gly Glu Gly Pro Gly Ala Ser Pro Cys Asn Gln His Ser Pro Tyr Trp                325                 330                 335Ala Pro Pro Cys Tyr Thr Leu Lys Pro Glu Thr            340                 345</s400><s200><s210>344</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala, Met, Pro, Ser, Thr, Trp, Tyr, Val or His.</s223></s220></s200><s400> 344Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>345</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220></s200><s400> 345Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>346</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(15)..(15)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220></s200><s400> 346Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Xaa His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>347</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala. In some cases, Xaa is Thr. In some cases, Xaa      is Asn. In some cases, Xaa is Cys. In some cases, Xaa is Gln. In      some cases, Xaa is Met. In some cases, Xaa is Val. In some cases,      Xaa is Trp</s223></s220></s200><s400> 347Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>348</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala. In some cases, Xaa is Arg. In some cases, Xaa      is Asn. In some cases, Xaa is Asp. In some cases, Xaa is Cys. In      some cases, Xaa is Glu, Gln, Gly, Ile, Lys, Met, Phe, Pro, Ser,      Thr, Tyr, Trp or</s223></s220></s200><s400> 348Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>349</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 349Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Xaa Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>350</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(126)..(126)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 350Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Xaa Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>351</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala. In some cases, Xaa is Thr.</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 351Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>352</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala.</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala.</s223></s220></s200><s400> 352Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>353</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(15)..(15)</s222><s223>Xaa is any amino acid other than Glu. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 353Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Xaa His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>354</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220></s200><s400> 354Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>355</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(126)..(126)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 355Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Xaa Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>356</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 356Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Xaa Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>357</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220></s200><s400> 357Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Xaa Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>358</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(126)..(126)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 358Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Xaa Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Xaa Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>359</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(20)..(20)</s222><s223>Xaa is any amino acid other than Asp. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(45)..(45)</s222><s223>Xaa is any amino acid other than Tyr. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(126)..(126)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 359Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Xaa Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Xaa Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Xaa Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>360</s210><s211>133</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(16)..(16)</s222><s223>Xaa is any amino acid other than His. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(42)..(42)</s222><s223>Xaa is any amino acid other than Phe. In some      cases, Xaa is Ala</s223></s220><s220><s221>VARIANT</s221><s222>(126)..(126)</s222><s223>Xaa is any amino acid other than Gln. In some      cases, Xaa is Ala</s223></s220></s200><s400> 360Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Xaa1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Xaa Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Xaa Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>361</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(4)..(4)</s222><s223>Xaa is any amino acid other than Pro</s223></s220></s200><s400> 361Val Pro Gly Xaa Gly1               5</s400><s200><s210>362</s210><s211>223</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 362Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser1               5                   10                  15Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg            20                  25                  30Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro        35                  40                  45Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala    50                  55                  60Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val65                  70                  75                  80Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr                85                  90                  95Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr            100                 105                 110Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu        115                 120                 125Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys    130                 135                 140Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser145                 150                 155                 160Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp                165                 170                 175Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser            180                 185                 190Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala        195                 200                 205Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly    210                 215                 220</s400><s200><s210>363</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 363Gly Ser Gly Gly Ser1               5</s400><s200><s210>364</s210><s211>4</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 364Gly Gly Gly Ser1</s400><s200><s210>365</s210><s211>4</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 365Gly Gly Ser Gly1</s400><s200><s210>366</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 366Gly Gly Ser Gly Gly1               5</s400><s200><s210>367</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 367Gly Ser Gly Ser Gly1               5</s400><s200><s210>368</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 368Gly Ser Gly Gly Gly1               5</s400><s200><s210>369</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 369Gly Gly Gly Ser Gly1               5</s400><s200><s210>370</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 370Gly Ser Ser Ser Gly1               5</s400><s200><s210>371</s210><s211>50</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(1)..(50)</s222><s223>Each copy of Ser Gly Gly Gly Gly at positions 1      to 50 is either present or absent such that the number of copies      of Ser Gly Gly Gly Gly ranges from 1 to 10.</s223></s220></s200><s400> 371Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly1               5                   10                  15Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser            20                  25                  30Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser Ser        35                  40                  45Ser Ser    50</s400><s200><s210>372</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 372Ala Ala Ala Gly Gly1               5</s400><s200><s210>373</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 373Gly Cys Gly Gly Ser1               5</s400><s200><s210>374</s210><s211>5</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 374Cys Gly Gly Gly Ser1               5</s400><s200><s210>375</s210><s211>55</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(6)..(55)</s222><s223>Each copy of Gly Gly Gly Gly Ser at positions 6      to 55 is either present or absent such that the number of copies      of Gly Gly Gly Gly Ser ranges from 1 to 10.</s223></s220></s200><s400> 375Cys Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser    50                  55</s400><s200><s210>376</s210><s211>227</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 376Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1               5                   10                  15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            20                  25                  30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        35                  40                  45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    50                  55                  60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr65                  70                  75                  80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                85                  90                  95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile            100                 105                 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        115                 120                 125Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser    130                 135                 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145                 150                 155                 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                165                 170                 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            180                 185                 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        195                 200                 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    210                 215                 220Pro Gly Lys225</s400><s200><s210>377</s210><s211>325</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 377Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser1               5                   10                  15Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe            20                  25                  30Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly        35                  40                  45Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu    50                  55                  60Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr65                  70                  75                  80Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr                85                  90                  95Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro            100                 105                 110Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr        115                 120                 125Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val    130                 135                 140Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val145                 150                 155                 160Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser                165                 170                 175Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu            180                 185                 190Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala        195                 200                 205Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro    210                 215                 220Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln225                 230                 235                 240Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala                245                 250                 255Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr            260                 265                 270Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu        275                 280                 285Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser    290                 295                 300Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser305                 310                 315                 320Leu Ser Pro Gly Lys                325</s400><s200><s210>378</s210><s211>246</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 378His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Leu Lys Thr1               5                   10                  15Pro Leu Gly Asp Thr Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            20                  25                  30Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        35                  40                  45Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    50                  55                  60Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly65                  70                  75                  80Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn                85                  90                  95Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            100                 105                 110Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro        115                 120                 125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    130                 135                 140Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn145                 150                 155                 160Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile                165                 170                 175Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            180                 185                 190Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys        195                 200                 205Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    210                 215                 220Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu225                 230                 235                 240Ser Leu Ser Pro Gly Lys                245</s400><s200><s210>379</s210><s211>383</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 379Pro Thr Lys Ala Pro Asp Val Phe Pro Ile Ile Ser Gly Cys Arg His1               5                   10                  15Pro Lys Asp Asn Ser Pro Val Val Leu Ala Cys Leu Ile Thr Gly Tyr            20                  25                  30His Pro Thr Ser Val Thr Val Thr Trp Tyr Met Gly Thr Gln Ser Gln        35                  40                  45Pro Gln Arg Thr Phe Pro Glu Ile Gln Arg Arg Asp Ser Tyr Tyr Met    50                  55                  60Thr Ser Ser Gln Leu Ser Thr Pro Leu Gln Gln Trp Arg Gln Gly Glu65                  70                  75                  80Tyr Lys Cys Val Val Gln His Thr Ala Ser Lys Ser Lys Lys Glu Ile                85                  90                  95Phe Arg Trp Pro Glu Ser Pro Lys Ala Gln Ala Ser Ser Val Pro Thr            100                 105                 110Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro        115                 120                 125Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu    130                 135                 140Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys145                 150                 155                 160Pro Ser His Thr Gln Pro Leu Gly Val Tyr Leu Leu Thr Pro Ala Val                165                 170                 175Gln Asp Leu Trp Leu Arg Asp Lys Ala Thr Phe Thr Cys Phe Val Val            180                 185                 190Gly Ser Asp Leu Lys Asp Ala His Leu Thr Trp Glu Val Ala Gly Lys        195                 200                 205Val Pro Thr Gly Gly Val Glu Glu Gly Leu Leu Glu Arg His Ser Asn    210                 215                 220Gly Ser Gln Ser Gln His Ser Arg Leu Thr Leu Pro Arg Ser Leu Trp225                 230                 235                 240Asn Ala Gly Thr Ser Val Thr Cys Thr Leu Asn His Pro Ser Leu Pro                245                 250                 255Pro Gln Arg Leu Met Ala Leu Arg Glu Pro Ala Ala Gln Ala Pro Val            260                 265                 270Lys Leu Ser Leu Asn Leu Leu Ala Ser Ser Asp Pro Pro Glu Ala Ala        275                 280                 285Ser Trp Leu Leu Cys Glu Val Ser Gly Phe Ser Pro Pro Asn Ile Leu    290                 295                 300Leu Met Trp Leu Glu Asp Gln Arg Glu Val Asn Thr Ser Gly Phe Ala305                 310                 315                 320Pro Ala Arg Pro Pro Pro Gln Pro Arg Ser Thr Thr Phe Trp Ala Trp                325                 330                 335Ser Val Leu Arg Val Pro Ala Pro Pro Ser Pro Gln Pro Ala Thr Tyr            340                 345                 350Thr Cys Val Val Ser His Glu Asp Ser Arg Thr Leu Leu Asn Ala Ser        355                 360                 365Arg Ser Leu Glu Val Ser Tyr Val Thr Asp His Gly Pro Met Lys    370                 375                 380</s400><s200><s210>380</s210><s211>276</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 380Val Thr Ser Thr Leu Thr Ile Lys Glx Ser Asp Trp Leu Gly Glu Ser1               5                   10                  15Met Phe Thr Cys Arg Val Asp His Arg Gly Leu Thr Phe Gln Gln Asn            20                  25                  30Ala Ser Ser Met Cys Val Pro Asp Gln Asp Thr Ala Ile Arg Val Phe        35                  40                  45Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys    50                  55                  60Leu Thr Cys Leu Val Thr Asp Leu Thr Thr Tyr Asx Ser Val Thr Ile65                  70                  75                  80Ser Trp Thr Arg Glu Glu Asn Gly Ala Val Lys Thr His Thr Asn Ile                85                  90                  95Ser Glu Ser His Pro Asn Ala Thr Phe Ser Ala Val Gly Glu Ala Ser            100                 105                 110Ile Cys Glu Asp Asx Asp Trp Ser Gly Glu Arg Phe Thr Cys Thr Val        115                 120                 125Thr His Thr Asp Leu Pro Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro    130                 135                 140Lys Gly Val Ala Leu His Arg Pro Asx Val Tyr Leu Leu Pro Pro Ala145                 150                 155                 160Arg Glx Glx Leu Asn Leu Arg Glu Ser Ala Thr Ile Thr Cys Leu Val                165                 170                 175Thr Gly Phe Ser Pro Ala Asp Val Phe Val Glu Trp Met Gln Arg Gly            180                 185                 190Glu Pro Leu Ser Pro Gln Lys Tyr Val Thr Ser Ala Pro Met Pro Glu        195                 200                 205Pro Gln Ala Pro Gly Arg Tyr Phe Ala His Ser Ile Leu Thr Val Ser    210                 215                 220Glu Glu Glu Trp Asn Thr Gly Gly Thr Tyr Thr Cys Val Val Ala His225                 230                 235                 240Glu Ala Leu Pro Asn Arg Val Thr Glu Arg Thr Val Asp Lys Ser Thr                245                 250                 255Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val Met Ser Asp Thr Ala            260                 265                 270Gly Thr Cys Tyr        275</s400><s200><s210>381</s210><s211>353</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 381Ala Ser Pro Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Cys Ser Thr1               5                   10                  15Gln Pro Asp Gly Asn Val Val Ile Ala Cys Leu Val Gln Gly Phe Phe            20                  25                  30Pro Gln Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gln Gly Val        35                  40                  45Thr Ala Arg Asn Phe Pro Pro Ser Gln Asp Ala Ser Gly Asp Leu Tyr    50                  55                  60Thr Thr Ser Ser Gln Leu Thr Leu Pro Ala Thr Gln Cys Leu Ala Gly65                  70                  75                  80Lys Ser Val Thr Cys His Val Lys His Tyr Thr Asn Pro Ser Gln Asp                85                  90                  95Val Thr Val Pro Cys Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro            100                 105                 110Ser Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser        115                 120                 125Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn    130                 135                 140Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe145                 150                 155                 160Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro Glu                165                 170                 175Arg Asp Leu Cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys            180                 185                 190Ala Glu Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr        195                 200                 205Pro Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn    210                 215                 220Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu225                 230                 235                 240Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser                245                 250                 255Pro Lys Asp Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro            260                 265                 270Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly        275                 280                 285Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp    290                 295                 300Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu305                 310                 315                 320Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro                325                 330                 335Thr His Val Asn Val Ser Val Val Met Ala Glu Val Asp Gly Thr Cys            340                 345                 350Tyr</s400><s200><s210>382</s210><s211>222</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 382Ala Asp Pro Cys Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser1               5                   10                  15Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr            20                  25                  30Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr        35                  40                  45Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu    50                  55                  60Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val65                  70                  75                  80Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr                85                  90                  95His Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser            100                 105                 110Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp        115                 120                 125Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe    130                 135                 140Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu145                 150                 155                 160Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser                165                 170                 175Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu            180                 185                 190Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro        195                 200                 205Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys    210                 215                 220</s400><s200><s210>383</s210><s211>327</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 383Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg1               5                   10                  15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr            20                  25                  30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser        35                  40                  45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser    50                  55                  60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr65                  70                  75                  80Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys                85                  90                  95Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro            100                 105                 110Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys        115                 120                 125Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val    130                 135                 140Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp145                 150                 155                 160Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe                165                 170                 175Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp            180                 185                 190Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu        195                 200                 205Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg    210                 215                 220Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys225                 230                 235                 240Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp                245                 250                 255Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys            260                 265                 270Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser        275                 280                 285Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser    290                 295                 300Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser305                 310                 315                 320Leu Ser Leu Ser Leu Gly Lys                325</s400><s200><s210>384</s210><s211>227</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 384Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1               5                   10                  15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            20                  25                  30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        35                  40                  45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    50                  55                  60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr65                  70                  75                  80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                85                  90                  95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile            100                 105                 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        115                 120                 125Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser    130                 135                 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145                 150                 155                 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                165                 170                 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            180                 185                 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        195                 200                 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    210                 215                 220Pro Gly Lys225</s400><s200><s210>385</s210><s211>227</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 385Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly1               5                   10                  15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            20                  25                  30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        35                  40                  45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    50                  55                  60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr65                  70                  75                  80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                85                  90                  95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Ser Ile            100                 105                 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        115                 120                 125Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser    130                 135                 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145                 150                 155                 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                165                 170                 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            180                 185                 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        195                 200                 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    210                 215                 220Pro Gly Lys225</s400><s200><s210>386</s210><s211>227</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 386Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1               5                   10                  15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            20                  25                  30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        35                  40                  45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    50                  55                  60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr65                  70                  75                  80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                85                  90                  95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile            100                 105                 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        115                 120                 125Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser    130                 135                 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145                 150                 155                 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                165                 170                 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            180                 185                 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        195                 200                 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    210                 215                 220Pro Gly Lys225</s400><s200><s210>387</s210><s211>227</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 387Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly1               5                   10                  15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            20                  25                  30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        35                  40                  45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    50                  55                  60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr65                  70                  75                  80Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                85                  90                  95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile            100                 105                 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        115                 120                 125Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser    130                 135                 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145                 150                 155                 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                165                 170                 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            180                 185                 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        195                 200                 205His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    210                 215                 220Pro Gly Lys225</s400><s200><s210>388</s210><s211>119</s211><s212>PRT</s212><s213>Unknown</s213><s220><s223>Originating from from either Homo sapiens or      Pan troglodytes.</s223></s220></s200><s400> 388Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser1               5                   10                  15Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg            20                  25                  30His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser        35                  40                  45Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu    50                  55                  60Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp65                  70                  75                  80Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp                85                  90                  95Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile            100                 105                 110Val Lys Trp Asp Arg Asp Met        115</s400><s200><s210>389</s210><s211>119</s211><s212>PRT</s212><s213>Macaca mulatta</s213></s200><s400> 389Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser1               5                   10                  15Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg            20                  25                  30His Pro Pro Glu Asn Gly Lys Pro Asn Phe Leu Asn Cys Tyr Val Ser        35                  40                  45Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu    50                  55                  60Lys Met Gly Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp65                  70                  75                  80Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Asn Glu Lys Asp                85                  90                  95Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gly Pro Arg Thr            100                 105                 110Val Lys Trp Asp Arg Asp Met        115</s400><s200><s210>390</s210><s211>118</s211><s212>PRT</s212><s213>Bos taurus</s213></s200><s400> 390Met Ala Arg Phe Val Ala Leu Val Leu Leu Gly Leu Leu Ser Leu Ser1               5                   10                  15Gly Leu Asp Ala Ile Gln Arg Pro Pro Lys Ile Gln Val Tyr Ser Arg            20                  25                  30His Pro Pro Glu Asp Gly Lys Pro Asn Tyr Leu Asn Cys Tyr Val Tyr        35                  40                  45Gly Phe His Pro Pro Gln Ile Glu Ile Asp Leu Leu Lys Asn Gly Glu    50                  55                  60Lys Ile Lys Ser Glu Gln Ser Asp Leu Ser Phe Ser Lys Asp Trp Ser65                  70                  75                  80Phe Tyr Leu Leu Ser His Ala Glu Phe Thr Pro Asn Ser Lys Asp Gln                85                  90                  95Tyr Ser Cys Arg Val Lys His Val Thr Leu Glu Gln Pro Arg Ile Val            100                 105                 110Lys Trp Asp Arg Asp Leu        115</s400><s200><s210>391</s210><s211>119</s211><s212>PRT</s212><s213>Mus musculus</s213></s200><s400> 391Met Ala Arg Ser Val Thr Leu Val Phe Leu Val Leu Val Ser Leu Thr1               5                   10                  15Gly Leu Tyr Ala Ile Gln Lys Thr Pro Gln Ile Gln Val Tyr Ser Arg            20                  25                  30His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys Tyr Val Thr        35                  40                  45Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys Asn Gly Lys    50                  55                  60Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser Lys Asp Trp65                  70                  75                  80Ser Phe Tyr Ile Leu Ala His Thr Glu Phe Thr Pro Thr Glu Thr Asp                85                  90                  95Thr Tyr Ala Cys Arg Val Lys His Ala Ser Met Ala Glu Pro Lys Thr            100                 105                 110Val Tyr Trp Asp Arg Asp Met        115</s400><s200><s210>392</s210><s211>365</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 392Met Ala Val Met Ala Pro Arg Thr Leu Leu Leu Leu Leu Ser Gly Ala1               5                   10                  15Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe            20                  25                  30Phe Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Gln Lys Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Gln Glu Thr Arg Asn Met Lys Ala His Ser Gln                85                  90                  95Thr Asp Arg Ala Asn Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser            100                 105                 110Glu Asp Gly Ser His Thr Ile Gln Ile Met Tyr Gly Cys Asp Val Gly        115                 120                 125Pro Asp Gly Arg Phe Leu Arg Gly Tyr Arg Gln Asp Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Met Ala Ala Gln Ile Thr Lys Arg Lys Trp Glu Ala Val His Ala                165                 170                 175Ala Glu Gln Arg Arg Val Tyr Leu Glu Gly Arg Cys Val Asp Gly Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Pro        195                 200                 205Pro Lys Thr His Met Thr His His Pro Ile Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val            260                 265                 270Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu        275                 280                 285Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Leu Ser Ser Gln Pro    290                 295                 300Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Ala305                 310                 315                 320Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser                325                 330                 335Ser Asp Arg Lys Gly Gly Ser Tyr Thr Gln Ala Ala Ser Ser Asp Ser            340                 345                 350Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val        355                 360                 365</s400><s200><s210>393</s210><s211>365</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 393Met Ala Val Met Ala Pro Arg Thr Leu Leu Leu Leu Leu Ser Gly Ala1               5                   10                  15Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe            20                  25                  30Tyr Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Gln Glu Thr Arg Asn Val Lys Ala Gln Ser Gln                85                  90                  95Thr Asp Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser            100                 105                 110Glu Asp Gly Ser His Thr Ile Gln Ile Met Tyr Gly Cys Asp Val Gly        115                 120                 125Pro Asp Gly Arg Phe Leu Arg Gly Tyr Arg Gln Asp Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Met Ala Ala Gln Ile Thr Lys Arg Lys Trp Glu Ala Ala His Ala                165                 170                 175Ala Glu Gln Gln Arg Ala Tyr Leu Glu Gly Arg Cys Val Glu Trp Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Pro        195                 200                 205Pro Lys Thr His Met Thr His His Pro Ile Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val            260                 265                 270Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu        275                 280                 285Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Leu Ser Ser Gln Pro    290                 295                 300Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Ala305                 310                 315                 320Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser                325                 330                 335Ser Asp Arg Lys Gly Gly Ser Tyr Thr Gln Ala Ala Ser Ser Asp Ser            340                 345                 350Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val        355                 360                 365</s400><s200><s210>394</s210><s211>365</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 394Met Ala Val Met Ala Pro Arg Thr Leu Val Leu Leu Leu Ser Gly Ala1               5                   10                  15Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe            20                  25                  30Ser Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Glu Glu Thr Gly Lys Val Lys Ala His Ser Gln                85                  90                  95Thr Asp Arg Glu Asn Leu Arg Ile Ala Leu Arg Tyr Tyr Asn Gln Ser            100                 105                 110Glu Ala Gly Ser His Thr Leu Gln Met Met Phe Gly Cys Asp Val Gly        115                 120                 125Ser Asp Gly Arg Phe Leu Arg Gly Tyr His Gln Tyr Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Lys Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Met Ala Ala Gln Ile Thr Lys Arg Lys Trp Glu Ala Ala His Val                165                 170                 175Ala Glu Gln Gln Arg Ala Tyr Leu Glu Gly Thr Cys Val Asp Gly Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Pro        195                 200                 205Pro Lys Thr His Met Thr His His Pro Ile Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val            260                 265                 270Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu        275                 280                 285Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Pro    290                 295                 300Thr Val Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Leu Gly Ala305                 310                 315                 320Val Ile Thr Gly Ala Val Val Ala Ala Val Met Trp Arg Arg Asn Ser                325                 330                 335Ser Asp Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser            340                 345                 350Ala Gln Gly Ser Asp Val Ser Leu Thr Ala Cys Lys Val        355                 360                 365</s400><s200><s210>395</s210><s211>365</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 395Met Ala Val Met Ala Pro Arg Thr Leu Leu Leu Leu Leu Leu Gly Ala1               5                   10                  15Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe            20                  25                  30Thr Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Arg Asn Thr Arg Asn Val Lys Ala His Ser Gln                85                  90                  95Ile Asp Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser            100                 105                 110Glu Ala Gly Ser His Thr Ile Gln Met Met Tyr Gly Cys Asp Val Gly        115                 120                 125Ser Asp Gly Arg Phe Leu Arg Gly Tyr Gln Gln Asp Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Met Ala Ala Gln Ile Thr Gln Arg Lys Trp Glu Ala Ala Arg Val                165                 170                 175Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Pro        195                 200                 205Pro Lys Thr His Met Thr His His Ala Val Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Ser Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val            260                 265                 270Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu        275                 280                 285Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Pro    290                 295                 300Thr Ile Pro Ile Val Gly Ile Ile Ala Gly Leu Val Leu Phe Gly Ala305                 310                 315                 320Val Phe Ala Gly Ala Val Val Ala Ala Val Arg Trp Arg Arg Lys Ser                325                 330                 335Ser Asp Arg Lys Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser            340                 345                 350Ala Gln Gly Ser Asp Met Ser Leu Thr Ala Cys Lys Val        355                 360                 365</s400><s200><s210>396</s210><s211>362</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 396Met Leu Val Met Ala Pro Arg Thr Val Leu Leu Leu Leu Ser Ala Ala1               5                   10                  15Leu Ala Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe            20                  25                  30Tyr Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ser        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Pro Arg Glu Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Arg Asn Thr Gln Ile Tyr Lys Ala Gln Ala Gln                85                  90                  95Thr Asp Arg Glu Ser Leu Arg Asn Leu Arg Gly Tyr Tyr Asn Gln Ser            100                 105                 110Glu Ala Gly Ser His Thr Leu Gln Ser Met Tyr Gly Cys Asp Val Gly        115                 120                 125Pro Asp Gly Arg Leu Leu Arg Gly His Asp Gln Tyr Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Trp Glu Ala Ala Arg Glu                165                 170                 175Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Glu Cys Val Glu Trp Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Asp Lys Leu Glu Arg Ala Asp Pro        195                 200                 205Pro Lys Thr His Val Thr His His Pro Ile Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Arg Thr Phe Gln Lys Trp Ala Ala Val Val            260                 265                 270Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu        275                 280                 285Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Ser Ser Gln Ser    290                 295                 300Thr Val Pro Ile Val Gly Ile Val Ala Gly Leu Ala Val Leu Ala Val305                 310                 315                 320Val Val Ile Gly Ala Val Val Ala Ala Val Met Cys Arg Arg Lys Ser                325                 330                 335Ser Gly Gly Lys Gly Gly Ser Tyr Ser Gln Ala Ala Cys Ser Asp Ser            340                 345                 350Ala Gln Gly Ser Asp Val Ser Leu Thr Ala        355                 360</s400><s200><s210>397</s210><s211>366</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 397Met Arg Val Met Ala Pro Arg Ala Leu Leu Leu Leu Leu Ser Gly Gly1               5                   10                  15Leu Ala Leu Thr Glu Thr Trp Ala Cys Ser His Ser Met Arg Tyr Phe            20                  25                  30Asp Thr Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ser        35                  40                  45Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala    50                  55                  60Ala Ser Pro Arg Gly Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly65                  70                  75                  80Pro Glu Tyr Trp Asp Arg Glu Thr Gln Asn Tyr Lys Arg Gln Ala Gln                85                  90                  95Ala Asp Arg Val Ser Leu Arg Asn Leu Arg Gly Tyr Tyr Asn Gln Ser            100                 105                 110Glu Asp Gly Ser His Thr Leu Gln Arg Met Tyr Gly Cys Asp Leu Gly        115                 120                 125Pro Asp Gly Arg Leu Leu Arg Gly Tyr Asp Gln Ser Ala Tyr Asp Gly    130                 135                 140Lys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala145                 150                 155                 160Asp Thr Ala Ala Gln Ile Thr Gln Arg Lys Leu Glu Ala Ala Arg Ala                165                 170                 175Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu            180                 185                 190Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Ala Glu Pro        195                 200                 205Pro Lys Thr His Val Thr His His Pro Leu Ser Asp His Glu Ala Thr    210                 215                 220Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Thr Leu Thr225                 230                 235                 240Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu                245                 250                 255Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val            260                 265                 270Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Met Gln His Glu        275                 280                 285Gly Leu Gln Glu Pro Leu Thr Leu Ser Trp Glu Pro Ser Ser Gln Pro    290                 295                 300Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Ala Val Leu Val Val305                 310                 315                 320Leu Ala Val Leu Gly Ala Val Val Thr Ala Met Met Cys Arg Arg Lys                325                 330                 335Ser Ser Gly Gly Lys Gly Gly Ser Cys Ser Gln Ala Ala Cys Ser Asn            340                 345                 350Ser Ala Gln Gly Ser Asp Glu Ser Leu Ile Thr Cys Lys Ala        355                 360                 365</s400><s200><s210>398</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 398Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Lys Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Met Lys Ala His Ser Gln Thr Asp Arg Ala Asn Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Val His Ala Ala Glu Gln Arg Arg Val Tyr Leu145                 150                 155                 160Glu Gly Arg Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>399</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 399Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Tyr Lys Ala Gln Ala Gln Thr Asp Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>400</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 400Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Asn Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Leu Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Met Gln His Glu Gly Leu Gln Glu Pro Leu Thr Leu            260                 265                 270Ser Trp Glu        275</s400><s200><s210>401</s210><s211>274</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 401Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Leu Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Asp Asn Pro Arg Phe Glu Pro Arg        35                  40                  45Ala Pro Trp Met Glu Gln Glu Gly Pro Glu Tyr Trp Glu Glu Gln Thr    50                  55                  60Gln Arg Ala Lys Ser Asp Glu Gln Trp Phe Arg Val Ser Leu Arg Thr65                  70                  75                  80Ala Gln Arg Tyr Tyr Asn Gln Ser Lys Gly Gly Ser His Thr Phe Gln                85                  90                  95Arg Met Phe Gly Cys Asp Val Gly Ser Asp Trp Arg Leu Leu Arg Gly            100                 105                 110Tyr Gln Gln Phe Ala Tyr Asp Gly Arg Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Lys Thr Trp Thr Ala Ala Asp Thr Ala Ala Leu Ile Thr Arg    130                 135                 140Arg Lys Trp Glu Gln Ala Gly Asp Ala Glu Tyr Tyr Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Leu Gly Asn                165                 170                 175Glu Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala His Val Thr Tyr His            180                 185                 190Pro Arg Ser Gln Val Asp Val Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu Asn Gly Glu Asp Leu    210                 215                 220Thr Gln Asp Met Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Leu Gly Lys Glu Gln Asn                245                 250                 255Tyr Thr Cys His Val His His Lys Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp</s400><s200><s210>402</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 402Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gly Glu Thr    50                  55                  60Arg Lys Val Lys Ala His Ser Gln Thr His Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Cys Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Val Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Ser Asp Trp Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Cys Ala Gln Thr Thr Lys    130                 135                 140His Lys Trp Glu Ala Ala His Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Cys Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu        275</s400><s200><s210>403</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 403Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Ala Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Arg Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Leu        275</s400><s200><s210>404</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 404Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu Thr    50                  55                  60Gly Lys Val Lys Ala His Ser Gln Thr Asp Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Val Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>405</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 405Gly Ser His Ser Met Arg Tyr Phe Thr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Arg Asn Val Lys Ala His Ser Gln Ile Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln                85                  90                  95Met Met Tyr Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Gln Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ser Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>406</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 406Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Lys Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Met Lys Ala His Ser Gln Thr Asp Arg Ala Asn Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Val His Ala Ala Glu Gln Arg Arg Val Tyr Leu145                 150                 155                 160Glu Gly Arg Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Leu        275</s400><s200><s210>407</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 407Gly Ser His Ser Met Arg Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr His    130                 135                 140His Lys Trp Glu Ala Ala His Glu Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Asp Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Leu        275</s400><s200><s210>408</s210><s211>311</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 408Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Gln Glu Thr    50                  55                  60Arg Asn Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Ile Gln                85                  90                  95Ile Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Arg Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Ala Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Arg Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Leu Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu        275                 280                 285Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro    290                 295                 300Leu Thr Leu Arg Trp Glu Pro305                 310</s400><s200><s210>409</s210><s211>381</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 409Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu Thr    50                  55                  60Gly Lys Val Lys Ala His Ser Gln Thr Asp Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu        275                 280                 285Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro    290                 295                 300Leu Thr Leu Arg Trp Glu Pro Gln Lys Trp Ala Ser Val Val Val Pro305                 310                 315                 320Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu                325                 330                 335Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro Gln Lys Trp Ala Ser Val            340                 345                 350Val Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His        355                 360                 365Glu Gly Leu Pro Lys Pro Leu Thr Leu Arg Trp Glu Pro    370                 375                 380</s400><s200><s210>410</s210><s211>241</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 410Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu Thr    50                  55                  60Gly Lys Val Lys Ala His Ser Gln Thr Asp Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Val Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe</s400><s200><s210>411</s210><s211>241</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 411Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Glu Glu Thr    50                  55                  60Gly Lys Val Lys Ala Gln Ser Gln Thr Asp Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Met Met Phe Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr His Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Lys Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Lys    130                 135                 140Arg Lys Trp Glu Ala Ala His Val Ala Glu Gln Gln Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Asp Gly Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe</s400><s200><s210>412</s210><s211>241</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 412Gly Ser His Ser Met Arg Tyr Phe Thr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Arg Asn Val Lys Ala His Ser Gln Ile Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln                85                  90                  95Met Met Tyr Gly Cys Asp Val Gly Ser Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Gln Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Pro Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe</s400><s200><s210>413</s210><s211>241</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 413Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Gln Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Arg Lys Val Lys Ala Gln Ser Gln Thr Asp Arg Val Asp Leu Gly Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Phe Leu Arg Gly            100                 105                 110Tyr Gln Gln Asp Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Met Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Thr Ala His Glu Ala Glu Gln Trp Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Thr Asp Ala Pro Lys Thr His Met Thr His His            180                 185                 190Ala Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Ser Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe</s400><s200><s210>414</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 414Gly Ser His Ser Met Arg Tyr Phe Asp Thr Ala Met Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Phe Lys Thr Asn Thr Gln Thr Asp Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asn Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Asp Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Thr Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>415</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 415Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Met Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Met Ala Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Ser Lys Thr Asn Thr Gln Thr Tyr Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Ile Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Ser Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Leu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>416</s210><s211>275</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 416Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Val Asp Asp Thr Gln Phe            20                  25                  30Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg Ala        35                  40                  45Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr Gln    50                  55                  60Ile Cys Lys Thr Asn Thr Gln Thr Tyr Arg Glu Asn Leu Arg Thr Ala65                  70                  75                  80Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln Arg                85                  90                  95Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly His            100                 105                 110Asn Gln Phe Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu Asp        115                 120                 125Leu Ser Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln Arg    130                 135                 140Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Thr Tyr Leu Glu145                 150                 155                 160Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys Glu                165                 170                 175Thr Leu Gln Arg Ala Asp Pro Pro Lys Thr His Val Thr His His Pro            180                 185                 190Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr        195                 200                 205Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln Thr    210                 215                 220Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr Phe225                 230                 235                 240Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg Tyr                245                 250                 255Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu Arg            260                 265                 270Trp Glu Pro        275</s400><s200><s210>417</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 417Gly Ser His Ser Met Arg Tyr Phe His Thr Ala Met Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Thr Val Gly Tyr Val Asp Asp Thr Leu            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Thr Ser Pro Arg Lys Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Ile Ser Lys Thr Asn Thr Gln Thr Tyr Arg Glu Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asn Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Ser Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>418</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 418Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Met Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Met Ala Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Ser Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Trp Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Leu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>419</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 419Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Met Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Thr Glu Pro Arg        35                  40                  45Ala Pro Trp Ile Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr    50                  55                  60Gln Ile Phe Lys Thr Asn Thr Gln Thr Tyr Arg Glu Asn Leu Arg Ile65                  70                  75                  80Ala Leu Arg Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Ile Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Ser Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Val Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Leu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Lys Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>420</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 420Cys Ser His Ser Met Lys Tyr Phe Phe Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Trp Met Cys Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Trp Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Met Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>421</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 421Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro His Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Arg Ser His Ile Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Leu Cys Val Glu Trp Leu Arg Arg Tyr Leu Lys Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Trp Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>422</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 422Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro His Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Ile Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Leu Cys Val Glu Trp Leu Arg Arg Tyr Leu Lys Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Trp Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>423</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 423Gly Ser His Ser Met Arg Tyr Phe Ser Thr Ser Val Ser Trp Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Glu Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Asn Leu Arg Lys65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Phe Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asn Gln Phe Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Trp Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Lys Pro        275</s400><s200><s210>424</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 424Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Asn Leu Arg Lys65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Trp Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Trp Arg Ala Tyr Leu145                 150                 155                 160Glu Cys Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Cys Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>425</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 425Cys Ser His Ser Met Arg Tyr Phe Asp Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Ala Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Asp Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Ser Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asp Gln Ser Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Leu Glu Ala Ala Arg Ala Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Leu Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Gln Glu Gln Arg                245                 250                 255Tyr Thr Cys His Met Gln His Glu Gly Leu Gln Glu Pro Leu Thr Leu            260                 265                 270Ser Trp Glu Pro        275</s400><s200><s210>426</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 426Cys Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Gln Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Lys Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Ser Leu Arg Asn65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr Asn Gln Phe Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Thr Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Lys Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Gly Pro        275</s400><s200><s210>427</s210><s211>276</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220></s200><s400> 427Cys Ser His Ser Met Arg Tyr Phe Tyr Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro His Phe Ile Ala Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Gly Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Gln Glu Gly Pro Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Gln Asn Tyr Lys Arg Gln Ala Gln Thr Asp Arg Val Asn Leu Arg Lys65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Ile Ile Gln                85                  90                  95Arg Met Tyr Gly Cys Asp Leu Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110His Asp Gln Leu Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln    130                 135                 140Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Leu Arg Ala Tyr Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Glu His Pro Lys Thr His Val Thr His His            180                 185                 190Pro Val Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Thr Leu            260                 265                 270Arg Trp Glu Pro        275</s400><s200><s210>428</s210><s211>286</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(89)..(89)</s222><s223>Xaa is Lys or Glu</s223></s220><s220><s221>VARIANT</s221><s222>(108)..(108)</s222><s223>Xaa is Arg or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(158)..(158)</s222><s223>Xaa is Arg or Gly</s223></s220><s220><s221>VARIANT</s221><s222>(159)..(159)</s222><s223>Xaa is Ala or Val</s223></s220><s220><s221>VARIANT</s221><s222>(256)..(256)</s222><s223>Xaa is Gln or Pro</s223></s220><s220><s221>VARIANT</s221><s222>(269)..(269)</s222><s223>Xaa is Pro or Ser</s223></s220></s200><s400> 428Gly Ser His Ser Leu Lys Tyr Phe His Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Asn Asp Ala Ala Ser Pro Arg Met Val Pro Arg        35                  40                  45Ala Pro Trp Met Glu Gln Glu Gly Ser Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Arg Ser Ala Arg Asp Thr Ala Gln Ile Phe Arg Val Asn Leu Arg Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Xaa Leu Ala Gly Ser His Thr Leu                85                  90                  95Gln Trp Met His Gly Cys Glu Leu Gly Pro Asp Xaa Arg Phe Leu Arg            100                 105                 110Gly Tyr Glu Gln Phe Ala Tyr Asp Gly Lys Asp Tyr Leu Thr Leu Asn        115                 120                 125Glu Asp Leu Arg Ser Trp Thr Ala Val Asp Thr Ala Ala Gln Ile Ser    130                 135                 140Glu Gln Lys Ser Asn Asp Ala Ser Glu Ala Glu His Gln Xaa Xaa Tyr145                 150                 155                 160Leu Glu Asp Thr Cys Val Glu Trp Leu His Lys Tyr Leu Glu Lys Gly                165                 170                 175Lys Glu Thr Leu Leu His Leu Glu Pro Pro Lys Thr His Val Thr His            180                 185                 190His Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly        195                 200                 205Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Gln Asp Gly Glu Gly    210                 215                 220His Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly225                 230                 235                 240Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Xaa                245                 250                 255Ser Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Xaa Glu Pro Val            260                 265                 270Thr Leu Arg Trp Lys Pro Ala Ser Gln Pro Thr Ile Pro Ile        275                 280                 285</s400><s200><s210>429</s210><s211>285</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(7)..(7)</s222><s223>Xaa is Tyr or Phe</s223></s220><s220><s221>VARIANT</s221><s222>(51)..(51)</s222><s223>Xaa is Pro or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(252)..(252)</s222><s223>Xaa is Ser or Pro</s223></s220><s220><s221>VARIANT</s221><s222>(279)..(279)</s222><s223>Xaa is Pro or Leu</s223></s220></s200><s400> 429Gly Ser His Ser Leu Arg Xaa Leu Phe Ser Thr Ala Val Ser Arg Pro1               5                   10                  15Gly Arg Gly Glu Pro Arg Tyr Ile Ala Val Glu Tyr Val Asp Asp Thr            20                  25                  30Gln Phe Leu Arg Phe Asp Ser Asp Ala Ala Ile Pro Arg Met Glu Pro        35                  40                  45Arg Glu Xaa Trp Val Glu Gln Glu Gly Pro Gln Tyr Trp Glu Trp Thr    50                  55                  60Thr Gly Tyr Ala Lys Ala Asn Ala Gln Thr Asp Arg Val Ala Leu Arg65                  70                  75                  80Asn Leu Leu Arg Arg Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu                85                  90                  95Gln Gly Met Asn Gly Cys Asp Met Gly Pro Asp Gly Arg Leu Leu Arg            100                 105                 110Gly Tyr His Gln His Ala Tyr Asp Gly Lys Asp Tyr Ile Ser Leu Asn        115                 120                 125Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Val Ala Gln Ile Thr    130                 135                 140Gln Arg Phe Tyr Glu Ala Glu Glu Tyr Ala Glu Glu Phe Arg Thr Tyr145                 150                 155                 160Leu Glu Gly Glu Cys Leu Glu Leu Leu Arg Arg Tyr Leu Glu Asn Gly                165                 170                 175Lys Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Ala His Val Ala His            180                 185                 190His Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly        195                 200                 205Phe Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Glu    210                 215                 220Gln Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly225                 230                 235                 240Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Xaa Gly Glu Glu Gln                245                 250                 255Arg Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Gln Pro Leu Ile            260                 265                 270Leu Arg Trp Glu Gln Ser Xaa Gln Pro Thr Ile Pro Ile        275                 280                 285</s400><s200><s210>430</s210><s211>286</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(13)..(13)</s222><s223>Xaa is Ser or Phe</s223></s220><s220><s221>VARIANT</s221><s222>(27)..(27)</s222><s223>Xaa is Tyr or His</s223></s220><s220><s221>VARIANT</s221><s222>(31)..(31)</s222><s223>Xaa is Thr, Ser or Met</s223></s220><s220><s221>VARIANT</s221><s222>(34)..(34)</s222><s223>Xaa is Leu or Val</s223></s220><s220><s221>VARIANT</s221><s222>(54)..(54)</s222><s223>Xaa is Gln or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(82)..(82)</s222><s223>Xaa is Pro or Leu</s223></s220><s220><s221>VARIANT</s221><s222>(101)..(101)</s222><s223>Xaa is Gly or Asp</s223></s220><s220><s221>VARIANT</s221><s222>(105)..(105)</s222><s223>Xaa is Gly or Val</s223></s220><s220><s221>VARIANT</s221><s222>(106)..(106)</s222><s223>Xaa is Ser or Cys</s223></s220><s220><s221>VARIANT</s221><s222>(111)..(111)</s222><s223>Xaa is Leu or Ile</s223></s220><s220><s221>VARIANT</s221><s222>(160)..(160)</s222><s223>Xaa is Tyr or His</s223></s220><s220><s221>VARIANT</s221><s222>(170)..(170)</s222><s223>Xaa is His or Arg</s223></s220><s220><s221>VARIANT</s221><s222>(172)..(172)</s222><s223>Xaa is Tyr or His</s223></s220><s220><s221>VARIANT</s221><s222>(179)..(179)</s222><s223>Xaa is Met or Thr</s223></s220><s220><s221>VARIANT</s221><s222>(186)..(186)</s222><s223>Xaa is Pro or Ala</s223></s220><s220><s221>VARIANT</s221><s222>(221)..(221)</s222><s223>Xaa is Arg, Try or Gln</s223></s220><s220><s221>VARIANT</s221><s222>(260)..(260)</s222><s223>Xaa is Thr or Met</s223></s220><s220><s221>VARIANT</s221><s222>(277)..(277)</s222><s223>Xaa is Lys or Glu</s223></s220></s200><s400> 430Gly Ser His Ser Met Arg Tyr Phe Ser Ala Ala Val Xaa Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Met Gly Xaa Val Asp Asp Xaa Gln            20                  25                  30Phe Xaa Arg Phe Asp Ser Asp Ser Ala Cys Pro Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Xaa Ser Glu Gly Pro Glu Tyr Trp Glu Glu Glu    50                  55                  60Thr Arg Asn Thr Lys Ala His Ala Gln Thr Asp Arg Met Asn Leu Gln65                  70                  75                  80Thr Xaa Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Ser Ser His Thr Leu                85                  90                  95Gln Trp Met Ile Xaa Cys Asp Leu Xaa Xaa Asp Gly Arg Leu Xaa Arg            100                 105                 110Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Leu Ala Leu Asn        115                 120                 125Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Ser    130                 135                 140Lys Arg Lys Cys Glu Ala Ala Asn Val Ala Glu Gln Arg Arg Ala Xaa145                 150                 155                 160Leu Glu Gly Thr Cys Val Glu Trp Leu Xaa Arg Xaa Leu Glu Asn Gly                165                 170                 175Lys Glu Xaa Leu Gln Arg Ala Asp Pro Xaa Ser Lys Thr His Val Thr            180                 185                 190His His Pro Val Phe Asp Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu        195                 200                 205Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr Trp Gln Xaa Asp Gly Glu    210                 215                 220Asp Gln Thr Gln Asp Val Glu Leu Val Glu Thr Arg Pro Ala Gly Asp225                 230                 235                 240Gly Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu                245                 250                 255Gln Arg Tyr Xaa Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu            260                 265                 270Met Leu Arg Trp Xaa Gln Ser Ser Leu Pro Thr Ile Pro Ile        275                 280                 285</s400><s200><s210>431</s210><s211>284</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(89)..(89)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(107)..(107)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(157)..(158)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(255)..(255)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(267)..(267)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 431Gly Ser His Ser Leu Lys Tyr Phe His Thr Ser Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Val Arg Phe Asp Asn Asp Ala Ala Ser Pro Arg Met Val Pro Arg        35                  40                  45Ala Pro Trp Met Glu Gln Glu Gly Ser Glu Tyr Trp Asp Arg Glu Thr    50                  55                  60Arg Ser Ala Arg Asp Thr Ala Gln Ile Phe Arg Val Asn Leu Arg Thr65                  70                  75                  80Leu Arg Gly Tyr Tyr Asn Gln Ser Xaa Ala Gly Ser His Thr Leu Gln                85                  90                  95Trp Met His Gly Cys Glu Leu Gly Pro Asp Xaa Arg Phe Leu Arg Gly            100                 105                 110Tyr Glu Gln Phe Ala Tyr Asp Gly Lys Asp Tyr Leu Thr Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Val Asp Thr Ala Ala Gln Ile Ser Glu    130                 135                 140Gln Lys Ser Asn Asp Ala Ser Glu Ala Glu His Gln Xaa Xaa Tyr Leu145                 150                 155                 160Glu Asp Thr Cys Val Glu Trp Leu His Lys Tyr Leu Glu Lys Gly Lys                165                 170                 175Glu Thr Leu Leu His Leu Glu Pro Pro Lys Thr His Val Thr His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Gln Asp Gly Glu Gly His    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Xaa Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Xaa Glu Pro Val Thr Leu            260                 265                 270Arg Trp Lys Pro Ala Ser Gln Pro Thr Ile Pro Ile        275                 280</s400><s200><s210>432</s210><s211>284</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(7)..(7)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(50)..(50)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(251)..(251)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(278)..(278)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 432Gly Ser His Ser Leu Arg Xaa Phe Ser Thr Ala Val Ser Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Tyr Ile Ala Val Glu Tyr Val Asp Asp Thr Gln            20                  25                  30Phe Leu Arg Phe Asp Ser Asp Ala Ala Ile Pro Arg Met Glu Pro Arg        35                  40                  45Glu Xaa Trp Val Glu Gln Glu Gly Pro Gln Tyr Trp Glu Trp Thr Thr    50                  55                  60Gly Tyr Ala Lys Ala Asn Ala Gln Thr Asp Arg Val Ala Leu Arg Asn65                  70                  75                  80Leu Leu Arg Arg Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln                85                  90                  95Gly Met Asn Gly Cys Asp Met Gly Pro Asp Gly Arg Leu Leu Arg Gly            100                 105                 110Tyr His Gln His Ala Tyr Asp Gly Lys Asp Tyr Ile Ser Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Val Ala Gln Ile Thr Gln    130                 135                 140Arg Phe Tyr Glu Ala Glu Glu Tyr Ala Glu Glu Phe Arg Thr Tyr Leu145                 150                 155                 160Glu Gly Glu Cys Leu Glu Leu Leu Arg Arg Tyr Leu Glu Asn Gly Lys                165                 170                 175Glu Thr Leu Gln Arg Ala Asp Pro Pro Lys Ala His Val Ala His His            180                 185                 190Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Glu Gln    210                 215                 220Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Xaa Gly Glu Glu Gln Arg                245                 250                 255Tyr Thr Cys His Val Gln His Glu Gly Leu Pro Gln Pro Leu Ile Leu            260                 265                 270Arg Trp Glu Gln Ser Xaa Gln Pro Thr Ile Pro Ile        275                 280</s400><s200><s210>433</s210><s211>284</s211><s212>PRT</s212><s213>Artificial sequence</s213><s220><s223>synthetic sequence</s223></s220><s220><s221>VARIANT</s221><s222>(13)..(13)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(27)..(27)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(31)..(31)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(34)..(34)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(54)..(54)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(81)..(81)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(100)..(100)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(104)..(105)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(110)..(110)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(159)..(159)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(169)..(169)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(171)..(171)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(178)..(178)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(185)..(185)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(219)..(219)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(258)..(258)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220><s220><s221>VARIANT</s221><s222>(275)..(275)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 433Gly Ser His Ser Met Arg Tyr Phe Ser Ala Ala Val Xaa Arg Pro Gly1               5                   10                  15Arg Gly Glu Pro Arg Phe Ile Ala Met Gly Xaa Val Asp Asp Xaa Gln            20                  25                  30Phe Xaa Arg Phe Asp Ser Asp Ser Ala Cys Pro Arg Met Glu Pro Arg        35                  40                  45Ala Pro Trp Val Glu Xaa Glu Gly Pro Glu Tyr Trp Glu Glu Glu Thr    50                  55                  60Arg Asn Thr Lys Ala His Ala Gln Thr Asp Arg Met Asn Leu Gln Thr65                  70                  75                  80Xaa Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Ser Ser His Thr Leu Gln                85                  90                  95Trp Met Ile Xaa Cys Asp Leu Xaa Xaa Asp Gly Arg Leu Xaa Arg Gly            100                 105                 110Tyr Glu Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Leu Ala Leu Asn Glu        115                 120                 125Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Ser Lys    130                 135                 140Arg Lys Cys Glu Ala Ala Asn Val Ala Glu Gln Arg Arg Ala Xaa Leu145                 150                 155                 160Glu Gly Thr Cys Val Glu Trp Leu Xaa Arg Xaa Leu Glu Asn Gly Lys                165                 170                 175Glu Xaa Leu Gln Arg Ala Asp Pro Xaa Lys Thr His Val Thr His His            180                 185                 190Pro Val Phe Asp Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe        195                 200                 205Tyr Pro Ala Glu Ile Ile Leu Thr Trp Gln Xaa Asp Gly Glu Asp Gln    210                 215                 220Thr Gln Asp Val Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr225                 230                 235                 240Phe Gln Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg                245                 250                 255Tyr Xaa Cys His Val Gln His Glu Gly Leu Pro Glu Pro Leu Met Leu            260                 265                 270Arg Trp Xaa Gln Ser Ser Leu Pro Thr Ile Pro Ile        275                 280</s400><s200><s210>434</s210><s211>255</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 434Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu1               5                   10                  15Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro            20                  25                  30Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys        35                  40                  45Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile    50                  55                  60Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser65                  70                  75                  80Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly                85                  90                  95Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu            100                 105                 110Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln        115                 120                 125Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys    130                 135                 140Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro145                 150                 155                 160Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala                165                 170                 175Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe Leu            180                 185                 190Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe Leu Thr Leu        195                 200                 205Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe    210                 215                 220Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly225                 230                 235                 240Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu                245                 250                 255</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000915A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000915</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17778611</doc-number><date>20201124</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>JP</country><doc-number>2019-212718</doc-number><date>20191125</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0783</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>62</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>725</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>705</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0636</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>625</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>7051</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>70517</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2740</main-group><subgroup>10043</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2506</main-group><subgroup>45</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2501</main-group><subgroup>998</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2500</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2500</main-group><subgroup>44</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2500</main-group><subgroup>24</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2501</main-group><subgroup>26</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2501</main-group><subgroup>2307</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">T-CELL MASTER CELL BANK</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Kyoto University</orgname><address><city>Sakyo-ku, Kyoto-shi, Kyoto</city><country>JP</country></address></addressbook><residence><country>JP</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Takeda Pharmaceutical Company Limited</orgname><address><city>Chuo-ku, Osaka-shi, Osaka</city><country>JP</country></address></addressbook><residence><country>JP</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>KANEKO</last-name><first-name>Shin</first-name><address><city>Kyoto</city><country>JP</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>ARIMA</last-name><first-name>Suguru</first-name><address><city>Kanagawa</city><country>JP</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>TAKIGUCHI</last-name><first-name>Maiko</first-name><address><city>Kanagawa</city><country>JP</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>KASSAI</last-name><first-name>Yoshiaki</first-name><address><city>Kanagawa</city><country>JP</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>HAYASHI</last-name><first-name>Akira</first-name><address><city>Kanagawa</city><country>JP</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Kyoto University</orgname><role>03</role><address><city>Sakyo-ku, Kyoto-shi, Kyoto</city><country>JP</country></address></addressbook></assignee><assignee><addressbook><orgname>Takeda Pharmaceutical Company Limited</orgname><role>03</role><address><city>Chuo-ku, Osaka-shi, Osaka</city><country>JP</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/JP2020/043573</doc-number><date>20201124</date></document-id><us-371c12-date><date>20220520</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="112.10mm" wi="158.75mm" file="US20230000915A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="214.63mm" wi="147.32mm" orientation="landscape" file="US20230000915A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="184.07mm" wi="139.11mm" orientation="landscape" file="US20230000915A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="226.65mm" wi="139.87mm" file="US20230000915A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="193.80mm" wi="151.98mm" file="US20230000915A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="233.85mm" wi="86.28mm" file="US20230000915A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="234.44mm" wi="100.16mm" file="US20230000915A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="220.98mm" wi="105.58mm" file="US20230000915A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="219.54mm" wi="105.07mm" file="US20230000915A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="87.63mm" wi="108.80mm" file="US20230000915A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="234.44mm" wi="143.00mm" orientation="landscape" file="US20230000915A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="238.84mm" wi="139.95mm" orientation="landscape" file="US20230000915A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD OF THE INVENTION</heading><p id="p-0002" num="0001">The present invention relates to a master cell bank of T cell, a working cell bank of T cell, and a system and the like for providing a T cell product, including the bank.</p><heading id="h-0002" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0003" num="0002">In recent years, immune cell therapy has been attracting attention as a treatment method for cancer. Immune cell therapy is a therapeutic method including proliferating and activating immune cells outside the patient's body and administering the immune cells to the patient to allow the immune cells to attack the cancer cells. Immune cell therapy is advantageous in that it causes almost no side effects compared to the conventional three major therapies of surgical treatment, radiation therapy, and chemotherapy. There are various kinds of treatment methods for immune cell therapy. Among them, off-the-shelf allogeneic T cell products are highly expected.</p><p id="p-0004" num="0003">As a system for providing the above-mentioned allogeneic T cell products, a system has been reported in which an iPS cell prepared by introducing a CAR gene into an iPS cell in advance using an iPS cell banking technique (e.g., patent document 1 and the like) or a technique for introducing a CAR gene into an iPS cell (e.g., patent document 2 and the like) is expansion cultured, the cells are stocked to construct a master cell bank of iPS cells having the CAR gene, and T cells obtained by differentiating the iPS cells derived from the cell bank into T cells are used as an allogeneic T cell product (e.g., non-patent document 1).</p><p id="p-0005" num="0004">In the above-mentioned system, a process of introducing an exogenous gene such as a CAR gene or the like into a pluripotent stem cell such as an iPS cell and differentiating the cell into a T cell is required. Therefore, it is necessary to maintain, differentiate, and culture cells (e.g., iPS cell, T cell, CAR-T cell) at each stage of the process while satisfying GMP (Good Manufacturing Practice) standards set by the authorities of each country. For example, since a master cell bank of iPS cells is used, preparation of T cell products requires differentiation of iPS cells into T cells. Due to the multipotency of iPS cells, however, high level of process and quality management is always required to induce uniform differentiated cells from each lot, and human, time and financial costs are extremely high. Such costs have a great influence on the stable provision of T cell products. Particularly, when plural kinds of T cell products are provided, the cost and time of each of them are accumulated and the influence thereof becomes more serious. Therefore, a system for supplying a product with a low cost while satisfying the GMP standard, and further, a system capable of providing a high-quality product with a low cost even when plural kinds of T cell products are used, have been desired.</p><heading id="h-0003" level="1">DOCUMENT LIST</heading><heading id="h-0004" level="1">Patent Documents</heading><p id="p-0006" num="0000"><ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0005">Patent document 1: US-A-2009-0299763</li>    <li id="ul0001-0002" num="0006">Patent document 2: WO 2017/088012</li></ul></p><heading id="h-0005" level="1">Non-Patent Document</heading><p id="p-0007" num="0000"><ul id="ul0002" list-style="none">    <li id="ul0002-0001" num="0007">Non-patent document 1: Bob Valamehr (Vice President of Fate Therapeutics) &#x201c;Generation of off-the-shelf TCR-less CAR T cells from renewable pluripotent cells&#x201d;, Apr. 14-18, 2018 (AACR Annual Meeting 2018 Press Program)</li></ul></p><heading id="h-0006" level="1">SUMMARY OF THE INVENTION</heading><heading id="h-0007" level="1">Problems to be Solved by the Invention</heading><p id="p-0008" num="0008">Accordingly, the present invention aims to provide a system for providing a high quality, off-the-shelf allogenic T cell product, that can reduce human, time and financial costs and minimize difference between lots. The present invention also aims to provide a master cell bank of T cell, a working cell bank of T cell, and the collection of these that can be used for the provision of the aforementioned system.</p><heading id="h-0008" level="1">Means of Solving the Problems</heading><p id="p-0009" num="0009">The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and assumed that the conventional techniques described in non-patent document 1 and the like exclusively focus on the construction method of a master cell bank of iPS cell because iPS cells are superior to T cells in the proliferative capacity. Thus, they considered that a T cell or T cells sufficiently proliferated by expansion culture can be used as a master cell bank. That is, the present inventors conceived an idea that a high-quality T cell product can be rapidly provided from a master cell bank of T cell containing an exogenous gene such as CAR gene and the like, rather than a master cell bank of iPS cell having the exogenous gene. As far as the present inventors knew, the idea of constructing a master cell bank of T cell was a completely unknown and completely new idea. The present inventors have further studied based on these findings and completed the present invention.</p><p id="p-0010" num="0010">Therefore, the present invention provides the following.</p><p id="p-0011" num="0000">[1] A system for providing a T cell product, comprising a master cell bank of T cell and/or a working cell bank of T cell.<br/>[2] The system of [1], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell derived from an induced pluripotent stem cell.<br/>[3] The system of [1] or [2], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell with suppressed expression of at least one kind of HLA gene.<br/>[3a] The system of any one of [1] to [3], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell into which an exogenous gene has been introduced.<br/>[3b] The system of any one of [1] to [3a], further comprising a step of constructing a master cell bank collection of T cell and/or a working cell bank collection of T cell comprising two or more kinds of master cell banks of T cell and/or working cell banks of T cell by collecting the master cell banks of T cell and/or the working cell banks of T cell.<br/>[3c] The system of any one of [1] to [3b], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) two or more kinds thereof.<br/>[3d] The system of any one of [1] to [3c], further comprising a step of selecting a master cell bank of T cell and/or working cell bank of T cell.<br/>[4] The system of any one of [1] to [3d], further comprising a step of introducing a nucleic acid comprising the exogenous gene into a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.<br/>[5] The system of [4], wherein the exogenous gene is a CAR gene or an exogenous TCR gene.<br/>[6] The system of any one of [1] to [5], wherein the T cell product comprises two or more kinds thereof.<br/>[6a] The system of any one of [1] to [6], further comprising a step of selecting the T cell product.<br/>[7] The system of any one of [1] to [6a], further comprising a step of expansion culturing a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.<br/>[8] The system of [7], wherein the step of expansion culturing the T cell comprises a process of stimulating the cell with a CD30 agonist.<br/>[8a] The system of [7], wherein the step of expansion culturing the T cell comprises a process of culturing the cell in the presence of a CD30 agonist.<br/>[9] The system of any one of [7] to [Ba], further comprising a step of producing a frozen T cell product comprising the expansion cultured T cell.<br/>[10] The system of any one of [6] to [9], further comprising a step of constructing a T cell product collection comprising two or more kinds of T cell products by collecting T cell products.<br/>[10a] The system of any one of [1] to [10], further comprising a step of obtaining information of a test subject.<br/>[10b] The system of [10a], further comprising a step of selecting an appropriate master cell bank of T cell and/or an appropriate working cell bank of T cell based on the information of the test subject.<br/>[10c] The system of [10a], further comprising a step of selecting an appropriate T cell product based on the information of the test subject.<br/>[11] The system of any one of [1] to [10c], further comprising a step of identifying a tumor-specific antigen or a tumor-associated antigen expressed in a tumor of the test subject.<br/>[12] The system of [11], further comprising a step of selecting a T cell product expressing a CAR or an exogenous TCR that recognizes and binds to the identified antigen from a T cell product collection comprising two or more kinds of T cell products.<br/>[13] A method for producing a T cell product, comprising a process of constructing a master cell bank of T cell and/or a working cell bank of T cell.<br/>[14] The method for producing a T cell product of [13], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell derived from an induced pluripotent stem cell.<br/>[15] The method for producing a T cell product of [13] or [14], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell with suppressed expression of at least one kind of HLA gene.<br/>[15a] The method for producing a T cell product of any one of [13] to [15], wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell into which an exogenous gene has been introduced.<br/>[16] The method for producing a T cell product of any one of [13] to [15a], further comprising a process of introducing a nucleic acid comprising the exogenous gene into a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.<br/>[17] The method for producing a T cell product of [16], wherein the exogenous gene is a CAR gene or an exogenous TCR gene.<br/>[18] The method for producing a T cell product of any one of [13] to [17], further comprising a process of expansion culturing a T cell.<br/>[19] The method for producing a T cell product of [18], wherein the process of expansion culturing the T cell comprises a process of stimulating the cell with a CD30 agonist.<br/>[19a] The method for producing a T cell product of [18], wherein the process of expansion culturing the T cell comprises a process of culturing the cell in the presence of a CD30 agonist.<br/>[20] A master cell bank of T cell and/or a working cell bank of T cell.<br/>[21] The master cell bank of T cell and/or working cell bank of T cell of [20], comprising a T cell derived from an induced pluripotent stem cell.<br/>[22] The master cell bank of T cell and/or working cell bank of T cell of [20] or [21], comprising a T cell with suppressed expression of at least one kind of HLA gene.<br/>[22a] The master cell bank of T cell and/or working cell bank of T cell of any one of [20] to [22], comprising a T cell into which an exogenous gene has been introduced.<br/>[23] A master cell bank collection of T cell and/or a working cell bank collection of T cell comprising two or more kinds of the master cell banks of T cell and/or working cell banks of T cell of any one of [20] to [22a].<br/>[24] A method for constructing a master cell bank of T cell and/or a working cell bank of T cell, comprising the following processes:</p><p id="p-0012" num="0011">(I) a process of differentiating an induced pluripotent stem cell free of a chimeric antigen receptor (CAR) gene into a T cell for CAR-T therapy,</p><p id="p-0013" num="0012">(II) a process of stocking the differentiated T cell, and</p><p id="p-0014" num="0013">(III) a process of Characterisation of the differentiated T cell.</p><p id="p-0015" num="0000">[25] A method for constructing a master cell bank of T cell and/or a working cell bank of T cell, comprising the following processes:</p><p id="p-0016" num="0014">(i) a process of differentiating an induced pluripotent stem cell free of an exogenous T cell receptor (TCR) gene into a T cell for TCR-T therapy,</p><p id="p-0017" num="0015">(ii) a process of stocking the differentiated T cell, and</p><p id="p-0018" num="0016">(iii) a process of Characterisation of the differentiated T cell.</p><p id="p-0019" num="0000">[25a] The method of [24] or [25], wherein the induced pluripotent stem cell has an exogenous gene.<br/>[26] The method of [24] or [25a], wherein the induced pluripotent stem cell has an exogenous T cell receptor (TCR) gene.<br/>[27] The method of any one of [24] to [26], wherein at least one kind of HLA gene is deleted in the induced pluripotent stem cell.<br/>[27a] The method of any one of [24] to [26], wherein the induced pluripotent stem cell is suppressed in expression of at least one kind of HLA gene.<br/>[28] The method of any one of [24] to [27a], wherein the T cell expresses CD8&#x3b1;&#x3b2;.<br/>[29] A master cell bank of T cell and/or a working cell bank of T cell constructed by the method of any one of [24] to [28].<br/>[30] A method for producing a T cell product expressing a CAR or an exogenous TCR, comprising the following processes:</p><p id="p-0020" num="0017">(A) a process of preparing a T cell from the master cell bank of T cell and/or the working cell bank of T cell of [29],</p><p id="p-0021" num="0018">(B) a process of introducing a CAR gene or an exogenous TCR gene into the prepared T cell, and</p><p id="p-0022" num="0019">(C) a process of expansion culturing the T cell into which the CAR gene or exogenous TCR gene has been introduced.</p><p id="p-0023" num="0000">[30a] The method of [30], further comprising (D) a process of freezing the expansion cultured T cell.<br/>[31] The method of [30] or [30a], wherein the CAR or exogenous TCR recognizes and binds to a tumor-specific antigen or a tumor-associated antigen.<br/>[32] The method of any one of [30] to [31], wherein the process (C) comprises a process of stimulating the T cell with a CD30 agonist.<br/>[32a] The method of any one of [30] to [31], wherein the process (C) comprises a process of culturing the cells in the presence of a CD30 agonist.<br/>[33] A T cell product produced by the method of any one of [30] to [32a].<br/>[34] A method for constructing a T cell product collection comprising two or more kinds of T cell products, comprising a process of collecting the T cell product of [33].<br/>[35] A T cell product collection constructed by the method of [34].<br/>[36] A method for providing a T cell product suitable for a test subject, comprising the following processes:</p><p id="p-0024" num="0020">(x) a process of identifying a tumor-specific antigen or a tumor-associated antigen expressed in the tumor of a test subject, and</p><p id="p-0025" num="0021">(y) a process of selecting a T cell product that expresses a CAR or an exogenous TCR that recognizes and binds to the identified antigen from the T cell product collection of [35].</p><p id="p-0026" num="0000">[37] A method for providing a T cell product suitable for a test subject, comprising the following processes:</p><p id="p-0027" num="0022">(p) a process of obtaining information of a test subject, and</p><p id="p-0028" num="0023">(q) a process of selecting an appropriate master cell bank of T cell and/or an appropriate working cell bank of T cell based on the obtained information of the test subject.</p><heading id="h-0009" level="1">Effect of the Invention</heading><p id="p-0029" num="0024">According to the present invention, a system for providing a high quality, off-the-shelf allogenic T cell product, that can reduce human, time and financial costs and minimize difference between lots, and a method for providing same are provided. Such system and method for provision are particularly superior when plural kinds of T cell products are provided. The present invention also provides a master cell bank of T cell, a working cell bank of T cell, and the collection of these that can be used for the provision of the aforementioned system or method are also provided.</p><p id="p-0030" num="0025">Various cells used in the present specification are sometimes indicated as follows. The outline of each cell is also described.</p><p id="p-0031" num="0000">&#x3c;Induced Pluripotent Stem Cell (iPSC)&#x3e;</p><p id="p-0032" num="0026">&#x3b1;&#x3b2;-iPSC: iPS cell into which TCR-&#x3b1; chain gene (TRA gene) and TCR-&#x3b2; chain gene (TRB gene) have been introduced</p><p id="p-0033" num="0027">V&#x3b3;9V&#x3b2;2-iPSC: iPS cell into which TCR-&#x3b3; chain gene (TRG gene) and TCR-&#x3b4; chain gene (TRD gene) encoding V&#x3b3;9V&#x3b2;2TCR G115 have been introduced</p><heading id="h-0010" level="2">&#x3c;Hematopoietic Progenitor Cell (HPC)&#x3e;</heading><p id="p-0034" num="0028">V&#x3b3;9V&#x3b2;2-iHPC: HPC into which TCR-&#x3b3; chain gene (TRG gene) and TCR-&#x3b4; chain gene (TRD gene) encoding V&#x3b3;9V&#x3b4;2TCR G115 have been introduced</p><heading id="h-0011" level="2">&#x3c;T Cell&#x3e;</heading><p id="p-0035" num="0029">i&#x3b3;&#x3b4;TC: T cell differentiated from iPS cell free of introduction of exogenous TCR</p><p id="p-0036" num="0030">i&#x3b1;&#x3b2;TC: T cell differentiated from &#x3b1;&#x3b2;-iPSC</p><p id="p-0037" num="0031">V&#x3b3;9V&#x3b4;2-iTC: T cell differentiated from V&#x3b3;9V&#x3b4;2-iPSC</p><p id="p-0038" num="0032">V&#x3b3;9V&#x3b4;2-iHTC: T cell differentiated from V&#x3b3;9V&#x3b4;2-iHPC</p><p id="p-0039" num="0000">&#x3c;T Cell into which CAR Gene has been Introduced&#x3e;</p><p id="p-0040" num="0033">CD19i&#x3b1;&#x3b2;CARTC: T cell produced by introducing gene encoding anti-CD19-CAR into i&#x3b1;&#x3b2;TC</p><p id="p-0041" num="0034">BCMAi&#x3b1;&#x3b2;CARTC: T cell produced by introducing gene encoding anti-BCMA-CAR into i&#x3b1;&#x3b2;TC</p><p id="p-0042" num="0035">CD19-CD30-i&#x3b1;&#x3b2;CARTC: T cell produced by introducing gene encoding anti-CD19-CAR containing CD30-derived intracellular domain into i&#x3b1;&#x3b2;TC</p><p id="p-0043" num="0000">&#x3c;T Cell into which CAR Gene and IL-15R&#x3b1;/IL-15 Gene have been Introduced&#x3e;</p><p id="p-0044" num="0036">CD19/IL15i&#x3b1;&#x3b2;CARTC: T cell produced by introducing gene encoding anti-CD19-CAR and gene encoding IL-15R&#x3b1;/IL-15 chimeric protein into i&#x3b1;&#x3b2;TC</p><p id="p-0045" num="0037">CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC: T cell produced by introducing gene encoding anti-CD19-CAR and gene encoding IL-15R&#x3b1;/IL-15 chimeric protein into V&#x3b3;9V&#x3b4;2-iTC</p><p id="p-0046" num="0038">CD19/IL15i&#x3b3;&#x3b4;CARTC: T cell produced by introducing gene encoding anti-CD19-CAR and gene encoding IL-15R&#x3b1;/IL-15 chimeric protein into i&#x3b3;&#x3b4;TC</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0012" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0047" num="0039"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows one embodiment of a T cell product providing system including a cell bank of T cell.</p><p id="p-0048" num="0040"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows one embodiment of a system for providing plural T cell products from a cell bank collection of T cell. In <figref idref="DRAWINGS">FIG. <b>2</b></figref>, &#x201c;Armored&#x201d; means that an exogenous gene relating to cytokine and/or chemokine secretion has been introduced.</p><p id="p-0049" num="0041"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows expression of CD3, &#x3b3;&#x3b4;TCR and &#x3b1;&#x3b2;TCR on the cellular membrane surface of i&#x3b3;&#x3b4;TC. The filled peaks show the results of the antibody non-staining group, and the blank peaks show the staining results using each antigen-specific antibody.</p><p id="p-0050" num="0042"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows expression of TCR-V&#x3b4;1 chain and TCR-V2&#x3b4; chain on the cellular membrane surface of i&#x3b3;&#x3b4;TC. The horizontal axis and the vertical axis respectively show the expression of TCR-V&#x3b2;1 chain (Vdelta1) and TCR-V&#x3b4;2 chain (Vdelta2).</p><p id="p-0051" num="0043"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows expression of CD3 and &#x3b3;&#x3b4;TCR molecule on the cellular membrane surface of V&#x3b3;9V&#x3b4;2-iTC. The horizontal axis and the vertical axis in the left Figure respectively show the expression of CD3 and pan-&#x3b3;&#x3b2;TCR. The horizontal axis and the vertical axis in the right Figure respectively show the expression of TCR-V&#x3b4;2 chain and TCR-V&#x3b3;9 chain.</p><p id="p-0052" num="0044"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows expression of CD3 and &#x3b3;&#x3b4;TCR molecule on the cellular membrane surface of V&#x3b3;9V&#x3b4;2-iHTC. The horizontal axis and the vertical axis in the left Figure respectively show the expression of CD3 and pan-&#x3b3;&#x3b4;TCR. The horizontal axis and the vertical axis in the right Figure respectively show the expression of CD3 and TCR-V&#x3b3;9 chain.</p><p id="p-0053" num="0045"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows cell-proliferation of i&#x3b3;&#x3b4;TC cells. The vertical axis shows cell number, and the horizontal axis shows days after the start of proliferation culture. Arrows show the day when stimulation was started with solid phased anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody.</p><p id="p-0054" num="0046"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows cell-proliferation of V&#x3b3;9V&#x3b4;2-iTC. The vertical axis shows cell number, and the horizontal axis shows days after the start of proliferation culture. Arrows show the day when stimulation was started with solid phased anti-CD3 agonist antibody/RetroNectin (registered trade mark).</p><p id="p-0055" num="0047"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows a proliferation curve of CD19-i&#x3b1;&#x3b2;CARTC stimulated with solid phased anti-CD3 agonist antibody/RetroNectin (registered trade mark). The vertical axis shows cell number, and the horizontal axis shows days after the start of proliferation culture. Arrows show the day when stimulation was started with solid phased anti-CD3 agonist antibody/RetroNectin (registered trade mark).</p><p id="p-0056" num="0048"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows cytotoxic activity of CAR T cells prepared by introducing a gene encoding anti-CD19-CAR or a gene encoding anti-BCMA-CAR into i&#x3b1;&#x3b2;TC (CD19i&#x3b1;&#x3b2;CARTC(A) and BCMAi&#x3b1;&#x3b2;CARTC(B), respectively) and i&#x3b1;&#x3b2;TC against CD19 positive Raji cell (A) or BCMA positive H929 cell(B).</p><p id="p-0057" num="0049"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows cytotoxic activity of CD19-CD30-i&#x3b1;&#x3b2;CARTC against CD19 positive Raji cancer cells. The vertical axis shows the percentage of the killed cells after 2 hr, and the horizontal axis shows the mixing ratio of effector cell (CD19i&#x3b1;&#x3b2;CARTC) and the target cell (CD19 positive Raji cancer cell).</p><p id="p-0058" num="0050"><figref idref="DRAWINGS">FIG. <b>12</b></figref> shows antigen specific cytotoxic activity of CD19/IL15i&#x3b3;&#x3b4;CARTC. Black and white circles respectively indicate the cytotoxic activity against CD19 positive Raji cancer cell and CD19 negative CCRF-CEM cancer cell. The vertical axis shows the percentage of the remaining cells after 2 hr, and the horizontal axis shows the mixing ratio of effector cell (CD19/IL15i&#x3b3;&#x3b4;CARTC), and the target cell (CD19 positive Raji cancer cell or CD19 negative CCRF-CEM cancer cell).</p><p id="p-0059" num="0051"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows cell proliferation of CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC. The vertical axis shows cell number, and the horizontal axis shows days after the start of proliferation culture. Arrows show the day when stimulation with solid phased anti-CD3 agonist antibody/RetroNectin (registered trade mark) was started.</p><p id="p-0060" num="0052"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows the effect of CD19/IL15i&#x3b3;&#x3b4;CARTC on prolonging the survival days of human CD19-expressing Nalm6 tumor xenograft mouse.</p><p id="p-0061" num="0053"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows the effect of CD19/IL15iV&#x3b3;9&#x3b4;2CARTC on prolonging the survival days of human CD19-expressing Nalm6 tumor xenograft mouse.</p><p id="p-0062" num="0054"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows one embodiment of a T cell product providing system including a cell bank of T cell.</p><p id="p-0063" num="0055"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows one embodiment of a hardware constitution contained in a T cell product selection part.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0013" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><heading id="h-0014" level="2">1. Master Cell Bank of T Cell, Working Cell Bank of T Cell, and T Cell Product Providing System</heading><p id="p-0064" num="0056">The present invention provides a master cell bank of T cell and/or a working cell bank of T cell. In the following, the term &#x201c;cell bank of T cell&#x201d; is sometimes used to encompass a master cell bank of T cell and a working cell bank of T cell. In another embodiment, the present invention provides a system for providing a T cell product, comprising a master cell bank of T cell and/or a working cell bank of T cell (hereinafter sometimes to be referred to as &#x201c;the provision system of the present invention&#x201d;).</p><p id="p-0065" num="0057">In the present specification, the &#x201c;cell bank&#x201d; means the same starting materials that have been characterised, which meet the quality standards and the like set by pharmaceutical authorities around the world in accordance with the guideline of ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) (ICH guideline Q5D). Generally, a cell bank is constructed by freezing cells filled in a suitable container. However, it is distinguished in the above-mentioned points from a frozen stock obtained by simply freezing cells. Where necessary, the cell bank is tested for quality evaluation in addition to the characterization. The method for constructing the cell bank and the test items for characterisation and quality evaluation of the constructed cell bank vary depending on the biological properties (e.g., auxotrophy), culture history, and test feasibility of the cells to be the subject of the cell bank, and are appropriately determined by those of ordinary skill in the art, or based on the content of discussions between those of ordinary skill in the art and regulatory authorities, and the like. Information relating to the construction method thereof and the results of characterisation and quality evaluation are presented to the pharmaceutical authorities when applying for the manufacturing and marketing approval in each country. The &#x201c;master cell bank&#x201d; means a seed stock to be the source of all production cell seeds, grown under certain culture conditions through a minimum number of passages, and dispensed into multiple ampoules. When the cell is T cell, the bank is called &#x201c;master cell bank of T cell&#x201d;. The &#x201c;working cell bank&#x201d; means cells obtained by pooling one or more master cell banks, further cultured under conditions confirmed to be sufficiently stable, and dispensed into multiple ampoules. When the cell is T cell, the bank is called &#x201c;working cell bank of T cell&#x201d; (in the present specification, master cell bank of T cell and working cell bank of T cell are sometimes referred to as &#x201c;cell bank of T cell&#x201d;). According to ICH Q5D, the tests of characterization are generally conducted on the master cell bank, and a part of tests of characterization is generally conducted on each working cell bank.</p><p id="p-0066" num="0058">The tests of characterization mainly evaluate the absence of contamination with an exogenous infectious factor. In particular, since contamination with exogenous virus can lead to serious consequences in clinical use, it is evaluated according to ICH Q5A(R1). Other tests include identity test to detect cross contamination with other cell line. In addition, karyotype analysis and tumorigenicity test may also be performed.</p><p id="p-0067" num="0059">The test items of quality evaluation include confirmation test using appropriate cell phenotype as T cell, purity test, production process-derived impurity test, and quantitative tests such as cell number, cell survival rate and the like.</p><p id="p-0068" num="0060">The cell bank of T cell can be constructed by a person who produces and/or provides a T cell product, or the cell bank constructed by others may be introduced and used for producing a T cell product.</p><p id="p-0069" num="0061">According to ICH Q5D, the two-step cell bank concept of constructing a working cell bank from a master cell bank is generally accepted as the most practical method for supplying cell substrates for continuous production of pharmaceutical products.</p><p id="p-0070" num="0062">A working cell bank is derived from a master cell bank in one or more containers. The working cell bank can be regenerated from the master cell bank where necessary. It is stated in ICH Q5D that appropriate confirmation of the eligibility of a newly constructed working cell bank is necessary by performing characterisation and the like.</p><p id="p-0071" num="0063">In one embodiment of the present invention, a master cell bank of T cell can be constructed by dispensing T cells into multiple storage containers (aseptic vial and the like), and freezing and stocking them. T cells in one container of this master cell bank of T cell can be thawed and appropriately subjected to a property analysis test. In addition, a working cell bank of T cell can be constructed by dispensing T cells from the same container or from another thawed container into multiple suitable containers, and freezing and stocking them.</p><p id="p-0072" num="0064">In one embodiment of the present invention, a T cell product can be produced by thawing T cells in one or more containers of a cell bank of T cell, introducing nucleic acid containing an exogenous gene into the T cells, and expansion culturing them.</p><p id="p-0073" num="0065">In the present invention, &#x201c;stocking&#x201d; means that a plurality of containers in which cells such as T cells are dispensed (allocated) are properly stored together, and storage conditions such as temperature, etc., balance, and the like are managed. The containers may be stored in one place or in multiple places.</p><p id="p-0074" num="0066">In the present invention, the &#x201c;T cell&#x201d; means a CD3 positive cell. Examples of the T cell usable in the present invention include cytotoxic T lymphocyte (CTL) which is a CD8 positive cell, helper T cell which is a CD4 positive cell, regulatory T cell, effector T cell, &#x3b3;&#x3b4;T cell which is T cell receptor (TCR)&#x3b3; chain and TORS chain positive cell, and the like. In addition, a CD4/CD8 double positive cell is also encompassed in a T cell. The TCR in T cell may be a TCR due to the expression of an endogenous TCR gene or a TCR due to the expression of an exogenous TCR gene. The exogenous TCR may be a variant of the TCR described below. The T cells in the cell bank of T cell provided by the present invention are preferably cytotoxic T cells, more preferably CD8&#x3b1;&#x3b2; positive cytotoxic T cells expressing CD8&#x3b1;&#x3b2;. In the present specification, the &#x201c;T cell product&#x201d; means T cells filled in a storage container (aseptic vial, blood transfusion bag, etc.), or such storage container appropriately packaged or labeled. While the T cell product may or may not be frozen, it is preferably frozen during long-term storage from the aspect of the stability of the T cells. In the present specification, a frozen T cell product is sometimes particularly referred to as a &#x201c;frozen T cell product&#x201d;. In the present specification, unless otherwise specified, the &#x201c;T cell product&#x201d; includes both a non-frozen T cell product and a frozen T cell product. As used herein, the &#x201c;T cell product&#x201d; includes both a product for clinical trials and a product for commercial use that are administered to mammalian test subjects including humans.</p><p id="p-0075" num="0067">As described above, conventional methods for providing a T cell product by using a master cell bank or working cell bank of iPS cell require extremely high human, time and financial costs. Particularly, when two or more kinds of T cell products are provided, the cost and time of each of them are accumulated and the influence thereof becomes more serious. In contrast, since the providing system of the present invention uses a master cell bank or a working cell bank of T cell, the human, time and financial costs can be extremely reduced as compared to conventional techniques particularly when providing two or more kinds of T cell products. Therefore, while the kind of the T cell product to be provided by the providing system of the present invention may be one, particularly superior effects are obtained when two or more kinds of T cell products are provided.</p><p id="p-0076" num="0068">In the present specification, being &#x201c;positive&#x201d; means that a protein or gene is expressed in an amount detectable by a method known in the art. Protein can be detected by an immunological assay using an antibody, such as ELISA, immunostaining, and flow cytometry. In the case of a protein that is intracellularly expressed and does not appear on the cell surface (e.g., transcription factor or subunit thereof, and the like), a reporter protein is expressed together with the protein, and the target protein can be detected by detecting the reporter protein. Gene can be detected by, for example, nucleic acid amplification method and/or nucleic acid detection method such as RT-PCR, biochip (e.g., microarray), RNAseq and the like.</p><p id="p-0077" num="0069">In the present specification, being &#x201c;negative&#x201d; means that the expression level of the protein or gene is less than the lower limit of detection by all or any of the above-mentioned known methods. The lower limit of detection of protein or gene expression may vary depending on each method.</p><p id="p-0078" num="0070">In the present specification, the &#x201c;gene expression&#x201d; encompasses both the synthesis of mRNA from a specific nucleotide sequence of the gene (also referred to as transcription or mRNA expression) and the synthesis of protein based on the information of the mRNA (also referred to as translation or protein expression). Unless otherwise specified, the &#x201c;gene expression&#x201d; or simple &#x201c;expression&#x201d; means expression of protein.</p><p id="p-0079" num="0071">In the present specification, the &#x201c;culture&#x201d; refers to maintaining, proliferating (growing) and/or differentiating cells in an in vitro environment. &#x201c;Culturing&#x201d; means maintaining, proliferating (growing) and/or differentiating cells extra-tissue or ex-vivo, for example, in a cell culture plate, dish or flask.</p><p id="p-0080" num="0072">T cells constituting a cell bank of T cell can be produced by inducing differentiation of stem cells with differentiation potency into T cells. Examples of the stem cell include pluripotent stem cell, multipotent stem cell, and the like. In the present specification, the &#x201c;pluripotent stem cell&#x201d; refers to a stem cell having the ability to differentiate into tissues and cells having various different forms and functions of a living body, and differentiate into cells of any lineage of three germ layers (endoderm, mesoderm, ectoderm). While the pluripotent stem cell is not particularly limited, for example, induced pluripotent stem cell (sometimes to be referred to as &#x201c;iPS cell&#x201d; in the present specification), embryonic stem cell (ES cell), embryonic stem cell derived from clone embryo obtained by nuclear transplantation (nuclear transfer Embryonic stem cell: ntES cell), pluripotent germ stem cell, embryonic germ cell (EG cell) and the like can be mentioned. In the present specification, the &#x201c;multipotent stem cell&#x201d; refers to a stem cell having the ability to differentiate into a plurality of limited number of lineages of cells. Examples of the &#x201c;multipotent stem cell&#x201d; include hematopoietic stem cell, pulp stem cell, stem cell derived from mouth cavity mucosa, hair follicle stem cell, somatic stem cell derived from culture fibroblast or myeloid stem cell, and the like. Preferred pluripotent stem cells are ES cell and iPS cell, and particularly preferred is iPS cell. When the above-mentioned pluripotent stem cell is ES cell or any cell derived from human embryo, the cell may be a cell produced by destroying the embryo or a cell prepared without destroying the embryo. Preferably, it is a cell prepared without destroying the embryo. The above-mentioned stem cell is preferably derived from a mammal (e.g., mouse, rat, hamster, guinea pig, dog, monkey, orangutan, chimpanzee, human), more preferably human. Therefore, the stem cell to be used in the present invention is most preferably human iPS cell.</p><p id="p-0081" num="0073">The &#x201c;induced pluripotent stem cell (iPS cell)&#x201d; refers to a cell obtained by introducing a specific factor (nuclear reprogramming factor) into a mammalian somatic cell or an undifferentiated stem cell and reprogramming them. Currently, there are various types of the &#x201c;induced pluripotent stem cell (iPS cell)&#x201d;, and iPS cell established by Yamanaka, et al. by introducing 4 factors of Oct3/4, Sox2, Klf4, c-Myc into mouse fibroblast (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), iPS cell derived from a human cell established by introducing similar 4 factors into human fibroblast (Takahashi K, Yamanaka S., et al., Cell, (2007) 131: 861-872.), Nanog-iPS cell established by selecting with the expression of Nanog as an index after introduction of the above-mentioned 4 factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.), iPS cell produced by a method free of c-Myc (Nakagawa M, Yamanaka S., et al., Nature Biotechnology, (2008) 26, 101-106), and iPS cell established by introducing 6 factors by a virus-free method (Okita K et al., Nat. Methods 2011 May; 8(5):409-12, Okita K et al., Stem Cells. 31(3):458-66.) can also be used. In addition, induced pluripotent stem cell established by Thomson et al. by introducing 4 factors of OCT3/4, SOX2, NANOG, and LIN28 (Yu J., Thomson J A. et al., Science (2007) 318: 1917-1920.), induced pluripotent stem cell produced by Daley et al. (Park I H, Daley G Q. et al., Nature (2007) 451: 141-146), induced pluripotent stem cell produced by et al. (JP-A-2008-307007) and the like can also be used.</p><p id="p-0082" num="0074">In addition, any of the induced pluripotent stem cells known in the art that are described in published papers (e.g., Shi Y., Ding S., et al., Cell Stem Cell, (2008) Vol 3, Issue 5, 568-574; Kim J B., Scholer H R., et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, D A., et al., Nature Biotechnology, (2008) 26, No 7, 795-797), or patents (e.g., JP-A-2008-307007, JP-A-2008-283972, US2008-2336610, US2009-047263, WO2007/069666, WO2008/118220, WO2008/124133, WO2008/151058, WO2009/006930, WO2009/006997, WO2009/007852) can be used. As the induced pluripotent stem cell line, various iPS cell lines established by NIH, RIKEN, Kyoto University and the like can be used. Examples of the human iPS cell line include HiPS-RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, Nips-B2 strain of RIKEN, 253G1 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 648A1 strain, iPS cell stock for regenerative medicine (e.g., Ff-I01s04 strain, QHJI strain, etc.) of Kyoto University, and the like.</p><p id="p-0083" num="0075">ES cell is a stem cell that is pluripotent and proliferative by self-replication and established from the inner cell mass of early mammalian embryos (e.g., blastocyst) such as human, mouse and the like. ES cell was discovered in mice in 1981 (M. J. Evans and M. H. Kaufman (1981), Nature 292:154-156), and ES cell line was subsequently established in primates such as human, monkey and the like (J. A. Thomson et al., (1998), Science 282:1145-1147; J. A. Thomson et al., (1995), Proc. Natl. Acad. Sci. USA, 92:7844-7848; J. A. Thomson et al., (1996), Biol. Reprod., 55:254-259; J. A. Thomson and V. S. Marshall (1998), Curr. Top. Dev. Biol., 38:133-165). ES cell can be established by removing the inner cell mass from the blastocyst of the fertilized egg of the target animal and culturing the inner cell mass on a fibroblast feeder. The methods for establishing and maintaining ES cells of human and monkey are described in, for example, U.S. Pat. No. 5,843,780; Thomson J A, et al., (1995), Proc Natl. Acad. Sci. USA. 92:7844-7848; Thomson J A, et al., (1998), Science. 282:1145-1147; Suemori H. et al., (2006), Biochem. Biophys. Res. Commun., 345:926-932; Ueno M. et al., (2006), Proc. Natl. Acad. Sci. USA, 103:9554-9559; Suemori H. et al., (2001), Dev. Dyn., 222:273-279; Kawasaki H. et al., (2002), Proc. Natl. Acad. Sci. USA, 99:1580-1585; Klimanskaya I. et al., (2006), Nature. 444:481-485 and the like. Alternatively, ES cell can also be established using only single blastomeres in the cleavage stage before blastocyst stage (Chung Y. et al., (2008), Cell Stem Cell 2: 113-117), or can also be established using embryos that have ceased development (Zhang X. et al., (2006), Stem Cells 24: 2669-2676.). As the &#x201c;ES cell&#x201d;, various mouse ES cell lines established by inGenious targeting laboratory, RIKEN (Inst. of Physical and Chemical Research) and the like can be used as the mouse ES cell, and various human ES cell lines established by University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Development and Cellartis and the like can be used as the human ES cell. For example, as the human ES cell line, CHB-1-CHB-12 strains, RUES1 strain, RUES2 strain, HUES1-HUES28 strains and the like provided by ESI Bio, H1 strain, H9 strain and the like provided by WiCell Research, KhES-1 strain, KhES-2 strain, KhES-3 strain, KhES-4 strain, KhES-5 strain, SSES1 strain, SSES2 strain, SSES3 strain and the like provided by RIKEN can be used.</p><p id="p-0084" num="0076">The nt ES cell is an ES cell derived from cloned embryo produced by the nuclear transfer technology and has almost the same properties as ES cells derived from fertilized eggs (Wakayama T. et al., (2001), Science, 292:740-743; S. Wakayama et al., (2005), Biol. Reprod., 72:932-936; Byrne J. et al., (2007), Nature, 450:497-502). That is, an ES cell established from the inner cell mass of blastocyst derived from a cloned embryo obtained by substituting the nucleus of an unfertilized egg with the nucleus of somatic cell is the nt ES (nuclear transfer ES) cell. For the production of the nt ES cell, a combination of nuclear transfer technique (Cibelli J. B. et al., (1998), Nature Biotechnol., 16:642-646) and ES cell production technique (above) is used (Kiyoka Wakayama et al. (2008), Experimental Medicine, Vol. 26, No. 5 (Special Edition), pp. 47-52). In the nuclear transfer, reprogramming is performed by injecting the nucleus of somatic cell into an enucleated unfertilized egg of mammal and culturing same for several hours.</p><p id="p-0085" num="0077">The pluripotency germ stem cell is a pluripotent stem cell derived from a germ stem cell (GS cell). Similar to ES cells, this cell can induce differentiation into cells of various lineages, and has properties such as the ability to produce a chimeric mouse when transplanted into mouse blastocyst, and the like (Kanatsu-Shinohara M. et al., (2003) Biol. Reprod., 69:612-616; Shinohara K. et al., (2004), Cell, 119:1001-1012). The cell can self-replicate in a culture medium containing a glial cell line-derived neurotrophic factor (GDNF), and can produce a germ stem cell by repeated passage under the same culture conditions as those for ES cell (Masanori Takebayashi et al. (2008), Experimental Medicine, Vol. 26, No. 5 (Special Edition), pp. 41-46, YODOSHA CO., LTD. (Tokyo, Japan)).</p><p id="p-0086" num="0078">The EG cell is a cell with pluripotency similar to that of ES cells, and is established from an embryonic primordial germ cell. It can be established by culturing primordial germ cells in the presence of a substance such as LIF, bFGF, stem cell factor, and the like (Matsui Y. et al., (1992), Cell, 70:841-847; J. L. Resnick et al., (1992), Nature, 359:550-551).</p><p id="p-0087" num="0000">1-1. Differentiation Induction into T Cell</p><p id="p-0088" num="0079">For differentiation induction of stem cell into T cell, a known method can be used without any particularly limitation as long as the differentiation into T cell can be performed. When a pluripotent stem cell is used as the stem cell, the above-mentioned differentiation induction into T cell may include, for example, (1) a process for differentiating pluripotent stem cells into hematopoietic progenitor cells, and (2) a process for differentiating the hematopoietic progenitor cells into T cells.</p><p id="p-0089" num="0000">(1) Process for Differentiating Induced Pluripotent Stem Cells into Hematopoietic Progenitor Cells</p><p id="p-0090" num="0080">In the present specification, the &#x201c;hematopoietic progenitor cell (HPC)&#x201d; means CD34 positive cell, preferably, CD34/CD43 double positive (DP) cell. In the present invention, hematopoietic progenitor cell and hematopoietic stem cell are not distinguished and show the same cell unless particularly indicated.</p><p id="p-0091" num="0081">The method of differentiating pluripotent stem cells into hematopoietic progenitor cells is not particularly limited as long as it can cause differentiation into hematopoietic progenitor cells. Examples thereof include a method including culturing pluripotent stem cells in a medium for induction of hematopoietic progenitor cells, as described in, for example, WO 2013/075222, WO 2016/076415 and Liu S. et al., Cytotherapy, 17 (2015); 344-358 and the like.</p><p id="p-0092" num="0082">In the present invention, a medium used for induction into hematopoietic progenitor cells is not particularly limited. A medium used for culturing animal cells can be prepared into a basal medium. Examples of the basal medium include, but are not limited to, Dulbecco's Medium (e.g., IMDM), Eagle's medium (e.g., DMEM, EMEM, BME, MEM, aMEM), Ham's medium (e.g., F10 medium, F12 medium), RPMI medium (e.g., RPMI-1640 medium, RPMI-1630 medium), MCDB medium (e.g., MCDB104, 107, 131, 151, 153 medium), Fischer's medium, 199 medium, culture medium for primate ES cell (culture medium for primate ES/iPS cell, Reprocell), medium for mouse ES cell (TX-WES culture medium, Thromb-X), serum-free medium (mTeSR, Stemcell Technologies), ReproFF, StemSpan (registered trade mark) SFEM, StemSpan (registered trade mark) H3000, StemlineII, ESF-B medium, ESF-C medium, CSTI-7 medium, Neurobasal medium (Thermo Fisher Scientific), StemPro-34 medium, StemFit (registered trade mark) (e.g., StemFit AKO3N, StemFit AKO2N) and the like. Furthermore, these media can be mixed as necessary and used and, for example, DMEM/F12 medium and the like can be mentioned.</p><p id="p-0093" num="0083">Where necessary, the basal medium may contain a medium additive and the like. Examples of the medium additive include serum, Vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compound (e.g., sodium selenite), fatty acid, trace elements, 2-mercaptoethanol, thioglycerol (e.g., &#x3b1;-monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trade mark)), non-essential amino acids, vitamins, growth factors, low-molecular-weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, and the like.</p><p id="p-0094" num="0084">In the present invention, &#x201c;Vitamin C&#x201d; means L-ascorbic acid and derivatives thereof, and &#x201c;L-ascorbic acid derivative&#x201d; means derivatives that become vitamin C by enzymatic reaction in the living body. Examples of the derivatives of L-ascorbic acid include vitamin C phosphate (e.g., ascorbic acid 2-phosphate), ascorbic acid glucoside, ascorbyl ethyl, vitamin C ester, ascorbyl tetrahexyldecanoate, ascorbyl stearate, and ascorbyl 2-phosphate 6-palmitate. Preferred is vitamin C phosphate. Examples of the vitamin C phosphate (e.g., ascorbic acid 2-phosphate) include salts of L-ascorbic acid phosphate such as L-ascorbic acid phosphate Na and L-ascorbic acid phosphate Mg.</p><p id="p-0095" num="0085">When Vitamin C is used, the Vitamin C is preferably added (supplied) every four days, every three days, every two days, or every day. Vitamin C is more preferably added every day. In one embodiment, Vitamin C is preferably added to the medium at an amount corresponding to 5 ng/ml to 500 ng/ml (e.g., an amount corresponding to 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, or 500 ng/ml). In another embodiment, Vitamin C is added to the culture medium at an amount corresponding to 5 &#x3bc;g/ml-500 &#x3bc;g/ml (e.g., an amount corresponding to 5 &#x3bc;g/ml, 10 &#x3bc;g/ml, 25 &#x3bc;g/ml, 50 &#x3bc;g/ml, 100 &#x3bc;g/ml, 200 &#x3bc;g/ml, 300 &#x3bc;g/ml, 400 &#x3bc;g/ml, 500 &#x3bc;g/ml).</p><p id="p-0096" num="0086">The medium to be used in process (1) may be further supplemented with at least one kind of cytokine selected from the group consisting of BMP4 (Bone morphogenetic protein 4), VEGF (vascular endothelial growth factor), SCF (Stem cell factor), TPO (thrombopoietin), FLT-3L (Flt3 Ligand) and bFGF (basic fibroblast growth factor). It is more preferably a culture supplemented with BMP4, VEGF and bFGF, and further preferably a culture supplemented with BMP4, VEGF, SCF and bFGF.</p><p id="p-0097" num="0087">When cytokine is used, its concentration in the medium may be, for example, 5 ng/ml-500 ng/ml for BMP4, 5 ng/ml-500 ng/ml for VEGF, 5 ng/ml-100 ng/ml for SCF, 1 ng/ml-100 ng/ml for TPO, 1 ng/ml-100 ng/ml for FLT-3L, and 5 ng/ml-500 ng/ml for bFGF.</p><p id="p-0098" num="0088">The aforementioned medium may be supplemented with a TGF&#x3b2; inhibitor. The TGF&#x3b2; inhibitor is a small molecule inhibitor that interferes with the signal transduction of TGF family and includes, for example, SB431542, SB202190 (both R. K. Lindemann et al., Mol. Cancer 2:20 (2003)), SB505124 (GlaxoSmithKline), NPC30345, SD093, SD908, SD208 (Scios), LY2109761, LY364947, LY580276 (Lilly Research Laboratories) and the like. For example, when the TGF inhibitor is SB431542, its concentration in the medium is preferably 0.5 &#x3bc;M-100 &#x3bc;M.</p><p id="p-0099" num="0089">The induced pluripotent stem cells may be cultured by adherent culture or suspension culture. In cases of adherent culture, the culturing may be carried out in a culture vessel coated with an extracellular matrix component, and/or may be co-cultured with feeder cells. While the feeder cell is not particularly limited, for example, fibroblast (mouse embryo fibroblast (MEF), mouse fibroblast (STO) and the like) can be mentioned. Feeder cells are preferably inactivated by a method known per se, for example, radiation (gamma-ray and the like) irradiation, treatment with anti-cancer agent (mitomycin C and the like) and the like. As the extracellular matrix component, fibrous proteins such as Matrigel (Niwa A, et al., PLoS One.6(7): e22261, 2011), gelatin, collagen, elastin and the like, glucosaminoglycan and proteoglycan such as hyaluronic acid, chondroitin sulfate and the like, cell adhesion proteins such as fibronectin, vitronectin, laminin and the like, and the like can be mentioned.</p><p id="p-0100" num="0090">Suspension culture means culturing cells in a state of non-adhesion to a culture container and is not particularly limited. To improve adhesiveness to the cells, a culture container free of an artificial treatment (e.g., coating treatment with extracellular matrix and the like), or a culture container subjected to a treatment for artificially suppressing adhesion (e.g., coating treatment with polyhydroxyethyl methacrylic acid (poly-HEMA) or non-ionic surface-active polyol (Pluronic F-127 etc.)) can be used. In the suspension culture, embryoid (EB) is preferably formed and cultured.</p><p id="p-0101" num="0091">In the present invention, hematopoietic progenitor cell can also be prepared from a sac-like structure (to be also referred to as ES-sac or iPS-sac) obtained by culturing pluripotent stem cells. As used herein, the &#x201c;sac-like structure&#x201d; is a pluripotent stem cell-derived three-dimensional saccular (with spaces inside) structure, which is formed by an endothelial cell population and the like and contains hematopoietic progenitor cells in the inside thereof.</p><p id="p-0102" num="0092">The temperature conditions are not particularly limited. The temperature is, for example, about 37&#xb0; C. to about 42&#xb0; C., preferably about 37&#xb0; C. to about 39&#xb0; C. The culture period may be appropriately determined by those skilled in the art by monitoring of the number of hematopoietic progenitor cells and/or the like. The number of days of the culture is not limited as long as hematopoietic progenitor cells can be obtained. Examples of the culture period include at least 6 days, not less than 7 days, not less than 8 days, not less than 9 days, not less than 10 days, not less than 11 days, not less than 12 days, not less than 13 days, and not less than 14 days. The culture period is preferably 14 days. While a longer culture period generally does not pose a problem in the production of hematopoietic progenitor cells, it is preferably not more than 35 days, more preferably not more than 21 days. The culture may be carried out under low-oxygen conditions, and the low-oxygen condition in the present invention means, for example, oxygen concentration of 15%, 10%, 9%, 8%, 7%, 6%, 5% or lower than these.</p><p id="p-0103" num="0093">(2) Step of Differentiating Hematopoietic Progenitor Cells into T Cells</p><p id="p-0104" num="0094">A method for differentiating hematopoietic progenitor cells into T cells is not particularly limited as long as it can differentiate hematopoietic progenitor cells into T cells. Examples thereof include a method for culturing hematopoietic progenitor cells under the same culture conditions as those in a method of inducing T cells from hematopoietic progenitor cells, as described in WO 2016/076415, WO 2017/221975 and the like.</p><p id="p-0105" num="0095">In the present invention, a medium for inducing differentiation into T cell is not particularly limited, and a medium used for culturing animal cells can be prepared into a basal medium. Where necessary, the basal medium may contain a medium additive and the like. Examples of the basal medium and the medium additive include those similar to the basal medium and the medium additive used in the above-mentioned process (1).</p><p id="p-0106" num="0096">When Vitamin C is used in process (2), Vitamin C may be the same as that described in process (1) and can be added similarly. In one embodiment, the concentration of Vitamin C in the medium or a culture medium is preferably 5 &#x3bc;g/ml-200 &#x3bc;g/ml. In another embodiment, vitamin C is added to the culture medium at an amount corresponding to 5 &#x3bc;g/ml-500 &#x3bc;g/ml (e.g., amount corresponding to 5 &#x3bc;g/ml, 10 &#x3bc;g/ml, 25 &#x3bc;g/ml, 50 &#x3bc;g/ml, 100 &#x3bc;g/ml, 200 &#x3bc;g/ml, 300 &#x3bc;g/ml, 400 &#x3bc;g/ml, 500 &#x3bc;g/ml).</p><p id="p-0107" num="0097">In process (2), p38 inhibitor and/or SDF-1 (Stromal cell-derived factor 1) are/is preferable. In the present invention, the &#x201c;p38 inhibitor&#x201d; means a substance that inhibits the functions of p38 protein (p38 MAP kinase). Examples thereof include, but are not limited to, chemical inhibitor of p38, dominant-negative mutant of p38 or nucleic acid encoding same and the like.</p><p id="p-0108" num="0098">Examples of the chemical inhibitor of p38 to be used in the present invention include, but are not limited to, SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole), and a derivative thereof, SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) and a derivative thereof, SB239063 (trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol) and a derivative thereof, SB220025 and a derivative thereof, PD169316, RPR200765A, AMG-548, BIRB-796, SC10-469, SCIO-323, VX-702 and FR167653. These compounds are commercially available and, for example, SB203580, SB202190, SC239063, SB220025 and PD169316 are available from Calbiochem, and SC10-469 and SCIO-323 are available from Scios and the like. the chemical inhibitor of p38 is preferably SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole), or a derivative thereof.</p><p id="p-0109" num="0099">Examples of the dominant-negative mutant of p38 to be used in the present invention include p38T180A obtained by point mutation of the 180-position threonine located in the DNA binding region of p38 to alanine, p38Y182F obtained by point mutation of the 182-position tyrosine of p38 in human and mouse to phenylalanine and the like. The p38 inhibitor is contained in a medium at, for example, about 1 &#x3bc;M-about 50 &#x3bc;M. When SB203580 is used as the P38 inhibitor, it may be contained in a medium at 1 &#x3bc;M-50 &#x3bc;M, 5 &#x3bc;M-30 &#x3bc;M, 10 &#x3bc;M-20 &#x3bc;M.</p><p id="p-0110" num="0100">SDF-1 to be used in the present invention may be not only SDF-1&#x3b1; or a mature form thereof, but also an isoform such as SDF-1&#x3b2;, SDF-1&#x3b3;, SDF-18, SDF-1c, SDF-14 and the like or a mature form thereof, or a mixture of these at any ratio or the like. Preferably, SDF-1a is used. SDF-1 is sometimes referred to as CXCL-12 or PBSF.</p><p id="p-0111" num="0101">In the present invention, one or several amino acids in the amino acid sequence of SDF-1 may be deleted, substituted, inserted and/or added as long as it has the activity as the chemokine (SDF-1 with such deletion, substitution, insertion and/or addition of amino acid is to be also referred to as &#x201c;SDF-1 mutant&#x201d;). Similarly, sugar chain may be deleted, substituted, inserted and/or added in SDF-1 or SDF-1 mutant. Examples of the mutant of the above-mentioned SDF-1 include those maintaining at least 4 cysteine residues (Cys30, Cys32, Cys55 and Cys71 in human SDF-1&#x3b1;) and having not less than 90% identity with amino acid sequence of a natural substance, though the amino acid mutation is not limited thereto. SDF-1 may be obtained from a mammal, for example, human or non-human mammal such as monkey, sheep, bovine, horse, swine, dog, cat, rabbit, rat, mouse and the like. For example, the protein registered as GenBank accession number:NP_954637 can be used as human SDF-1&#x3b1;, and the protein registered as GenBank accession number:NP_000600 can be used as SDF-1&#x3b2;.</p><p id="p-0112" num="0102">SDF-1 may be commercially available, purified from nature, or produced by peptide synthesis or genetic engineering techniques. SDF-1 is contained in a medium within the range of, for example, about 10 ng/ml to about 100 ng/ml. In addition, SDF-1 alternative having an SDF-1-like activity can also be used instead of SDF-1. Examples of such SDF-1 alternative include CXCR4 agonist, and a low-molecular-weight compound having a CXCR4 agonist activity and the like may be added to the medium instead of SDF-1.</p><p id="p-0113" num="0103">The culture medium used in process (2) may be further supplemented with at least one kind, preferably all, of cytokine selected from the group consisting of SCF, TPO (thrombopoietin), FLT-3L and IL-7. The concentration of these is, for example, 10 ng/ml to 100 ng/ml for SCF, 10 ng/ml to 200 ng/ml for TPO, 1 ng/ml to 100 ng/ml for IL-7, and 1 ng/ml to 100 ng/ml for FLT-3L.</p><p id="p-0114" num="0104">In process (2), the hematopoietic progenitor cells may be cultured by adherent culture or suspension culture. In cases of adherent culture, a coated culture vessel may be used, and/or the hematopoietic progenitor cells may be co-cultured with feeder cells and/or the like. Examples of the feeder cells for the co-culture include a bone-marrow stromal cell line, OP9 cells (available from Riken BioResource Center). The OP9 cell is preferably OP9-DL4 cell or OP9-DL1 cell, which constantly expresses DLL4 or DLL1 (e.g., Holmes R I and Zuniga-Pflucker J C. Cold Spring Harb Protoc. 2009(2)). In the present invention, in cases where OP9 cells are used as the feeder cells, DLL1, or a separately-prepared DLL4 or DLL1, or a fusion protein of DLL4 or DLL1, and Fc or the like, may be added to the medium to perform the co-culture. When feeder cells are used, the feeder cells are preferably appropriately replaced during the culture. The replacement of the feeder cells may be carried out by transferring the subject cells that are being cultured onto feeder cells that are preliminarily plated. The replacement may be carried out every five days, every four days, every three days, or every two days. When hematopoietic progenitor cells are obtained by suspension culture of embryoid, it is preferable to perform adhesion culture after dissociation into single cells. While the cells may be co-cultured with feeder cells, culturing is preferably carried out without using feeder cells.</p><p id="p-0115" num="0105">In the case of adhesion culture and when a culture container is coated, examples of the coating agent include Matrigel (Niwa A, et al. PLos One, 6(7):e22261, 2011)), collagen, gelatin, laminin, heparan sulfuric acid proteoglycan, RetroNectin (registered trade mark), fusion protein of DLL4 or DLL1, or DLL4 or DLL1, and Fc region of antibody (hereinafter sometimes referred to as Fc) and the like (e.g., DLL4/Fc chimera), entactin, and/or combination of these, and a combination of RetroNectin and fusion protein of DLL4 and Fc etc. is preferable.</p><p id="p-0116" num="0106">In process (2), the culture temperature conditions are not limited. The temperature is, for example, about 37&#xb0; C. to about 42&#xb0; C., preferably about 37&#xb0; C. to about 39&#xb0; C. The culture period may be appropriately determined by those skilled in the art by monitoring of the number of T cells and the like. The number of days of the culture is not limited as long as T cells can be obtained. Examples of the culture period typically include at least not less than 10 days, not less than 12 days, not less than 14 days, not less than 16 days, not less than 18 days, and not less than 20 days. The culture period is preferably 21 days. In addition, not more than 90 days is preferable, and not more than 42 days is more preferable.</p><p id="p-0117" num="0107">The cell population obtained by the above step includes T cells. Process (2) may further contain the following process (3).</p><heading id="h-0015" level="2">(3) Process for Condensing T Cells</heading><p id="p-0118" num="0108">A method for condensing T cells is not particularly limited as long as T cells can be condensed. For example, a method of culturing T cells under the same culture conditions as those in a step of inducing CD8 positive T cells from CD4CD8 double positive T cells, as described in WO 2016/076415, WO 2017/221975 and the like can be mentioned.</p><p id="p-0119" num="0109">In the present specification, &#x201c;concentrating&#x201d; refers to increasing the proportion of a particular constituent component in a composition such as a cell composition and the like, and &#x201c;concentrated&#x201d; when used to describe a cell composition such as a cell population means that the amount of a particular constituent component in the cell population has increased from that of the component in the cell population before being concentrated. For example, a composition such as cell population and the like can be concentrated for the target cell type. Thus, the proportion of the target cell type increase as compared to the proportion of the target cell present in the cell population before being concentrated. A cell population may also be concentrated for the target cell type by a cell selecting method or sorting method known in the art. The cell population may also be concentrated by a particular culture method, sorting, or a selecting process, described in the present specification. In a particular embodiment of the present invention, the cell population is concentrated by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% of the target cell population by a method of concentrating the target cell population.</p><p id="p-0120" num="0110">In the present specification, the &#x201c;cell population&#x201d; means two or more cells of the same type or different types. The &#x201c;Cell population&#x201d; also means a mass of cells of the same type or different types.</p><p id="p-0121" num="0111">In the present invention, the medium used for concentrating T cells is not particularly limited, and a medium used for culturing animal cells can be prepared into a basal medium. Where necessary, the basal medium may contain a medium additive and the like. Examples of the basal medium and medium additive include those similar to the basal medium used in the above-mentioned process (1).</p><p id="p-0122" num="0112">When Vitamin C is used in process (3), Vitamin C may be similar to those described in process (1) and can be added similarly. In one embodiment, the concentration of Vitamin C in the medium or culture medium is preferably 5 &#x3bc;g/ml-200 &#x3bc;g/ml. In another embodiment, vitamin C is added in an amount corresponding to 5 &#x3bc;g/ml-500 &#x3bc;g/ml in the culture medium (e.g., amount corresponding to 5 &#x3bc;g/ml, 10 &#x3bc;g/ml, 25 &#x3bc;g/ml, 50 &#x3bc;g/ml, 100 &#x3bc;g/ml, 200 &#x3bc;g/ml, 300 &#x3bc;g/ml, 400 &#x3bc;g/ml, 500 &#x3bc;g/ml).</p><p id="p-0123" num="0113">When hormone is used in process (3), examples of the hormone include corticosteroid. Corticosteroid is glucocorticoid or a derivative thereof, and cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclometasone dipropionate are recited as examples. Preferred is dexamethasone. When corticosteroid is dexamethasone, its concentration in the medium is 1 nM-100 nM.</p><p id="p-0124" num="0114">In process (3), the medium may contain a CD3/TCR complex agonist. The CD3/TCR complex agonist is not particularly limited as long as it is a molecule capable of transducing a signal from a CD3/TCR complex to a T cell by specifically binding to the CD3/TCR complex. Examples of the CD3/TCR complex agonist include CD3 agonist and/or TCR agonist. As the CD3 agonist, an anti-CD3 agonist antibody (to be also simply referred to as &#x201c;anti-CD3 antibody&#x201d;) or a fragment bonded thereto can be mentioned, and as the TCR agonist, at least one selected from the group consisting of an anti-TCR agonist antibody (to be also simply referred to as &#x201c;anti-TCR antibody&#x201d;) or a fragment bonded thereto, an MHC/antigen peptide complex or is a multimer thereof, and an MHC/superantigen complex or a multimer thereof can be mentioned. When an anti-CD3 antibody is used, the anti-CD3 antibody includes both a polyclonal antibody and a monoclonal antibody, preferably a monoclonal antibody. The antibody may belong to any immunoglobulin class of IgG, IgA, IgM, IgD and IgE, preferably IgG. As the anti-CD3 antibody, an antibody produced from OKT3 clone (OKT3), an antibody (UCHT1) produced from UCHT1 clone and the like can be mentioned, preferably UCHT1. The concentration of anti-CD3 antibody in the medium is, for example, 10 ng/ml-1000 ng/ml, preferably 50 ng/ml-800 ng/ml, more preferably 250 ng/ml-600 ng/ml. The above-mentioned CD3/TCR complex agonist may be commercially available, purified from nature, or produced by peptide synthesis or genetic engineering techniques or chemical synthesis methods. For example, OKT3 and UCHT1 can be purchased from ThermoFisher, GeneTex and the like.</p><p id="p-0125" num="0115">When cytokine is used in process (3), IL-2 and IL-7 and the like can be mentioned as the cytokine. When cytokine is IL-2, the concentration thereof in the medium is 10 U/ml-1000 U/mL, and when it is IL-7, the concentration thereof in the medium is 1 ng/ml-1000 ng/mL.</p><p id="p-0126" num="0116">In process (3), the culture temperature conditions are not particularly limited. The temperature is, for example, about 37&#xb0; C. to about 42&#xb0; C., preferably about 37&#xb0; C. to about 39&#xb0; C. The culture period can be appropriately determined by those skilled in the art by monitoring the number of T cells and the like. The number of days is not limited as long as cells can be concentrated. The culture period is, for example, not less than 1 day, not less than 2 days, not less than 3 days, not less than 4 days, not less than 5 days, preferably not less than 6 days. It is preferably not more than 28 days, more preferably not more than 14 days.</p><p id="p-0127" num="0117">In T cells constituting a cell bank of T cell, the expression of endogenous gene may be appropriately regulated. Specifically, in the T cells constituting a cell bank of T cell, the expression of at least one kind (e.g., one kind, two kinds, three kinds, six kinds, nine kinds) of HLA (Human Leukocyte Antigen) gene is preferably suppressed or the HLA gene is preferably deleted to reduce rejection in allogeneic transplantation. Therefore, in one embodiment of the present invention, the provision system of the present invention contains T cell in which the expression of at least one kind of HLA gene is suppressed. In the present specification, the suppression of the expression of HLA gene also includes deletion of the gene.</p><p id="p-0128" num="0118">As the above-mentioned HLA gene, specifically, one or more kinds of HLA genes selected from the group consisting of class I HLA (i.e., HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G) gene and class II HLA (i.e., HLA-DR, HLA-DQ and HLA-DP) gene can be mentioned. Alternatively, the gene expression important for the above-mentioned expression of the HLA gene and the presentation thereof on the cell surface may be suppressed. Examples of the gene include B2M gene encoding B2M, which is an important protein for presenting HLA class 1 HLA on the cell surface, and CIITA gene encoding CIITA, which is an important protein for the expression of class II HLA gene. On the other hand, since a HLA gene expression-suppressed cell is easily targeted by natural killer (NK) cells due to the suppression of HLA gene expression, it is also preferable to avoid being targeted by NK cell by overexpressing CD47 gene, or suppressing the expression of only two genes, HLA-A gene and HLA-B gene and maintaining the expression of HLA-C gene, HLA-E gene, HLA-F gene and HLA-G gene, which are important for avoiding NK cell attacks (in this case, the expression of class II HLA gene may or may not be suppressed, but it is preferable to suppress the gene expression in view of immunocompatibility. In a preferred embodiment, therefore, the combination of HLA genes whose expression is to be suppressed includes (i) combination of HLA-A gene and HLA-B gene, (ii) combination of HLA-A gene, HLA-B gene, HLA-DR gene, HLA-DQ gene and HLA-DP gene, and (iii) combination of HLA-A gene, HLA-B gene, HLA-C gene, HLA-E gene, HLA-F gene, HLA-G gene, HLA-DR gene, HLA-DQ gene and HLA-DP gene. HLA, which is a human major histocompatibility complex (MHC), has been described as an example in the above. Even when a non-human MHC is used, it is preferable to suppress expression of at least one kind of MCH gene in the same manner.</p><p id="p-0129" num="0119">As a method for suppressing the expression of HLA gene, a known method can be appropriately used. For example, the expression of HLA gene can be knocked down by introducing HLA mRNA, B2M mRNA, and/or siRNA, shRNA, miRNA, antisense oligo nucleic acid, ribozyme that targets CIITA mRNA into cells at the stage of differentiation from pluripotent cells into T cells (e.g., pluripotent stem cell, hematopoietic progenitor cell (CD34+/CD43+), ProT cells (CD4&#x2212;/CD8&#x2212;), CD3+/CD4+/CD8+T cells, CD3+/CD4&#x2212;/CD8+T cells, or other cells (e.g., CD3&#x2212;/CD4+/CD8+ cell, etc.) etc.), or introducing a nucleic acid encoding the molecule into the cells by the below-mentioned method. Alternatively, HLA gene, B2M gene, and/or CIITA gene in the cells may be knocked out by genome editing (e.g., CRISPR system, TALEN, ZFN and the like).</p><p id="p-0130" num="0120">In the T cells constituting a cell bank of T cell, it is preferable to suppress expression of the TCR chain by siRNA, or suppress expression of TCR in the T cells by introducing exogenous TCR known to be harmless for the test subject to be administered with the T cells. When the aforementioned method by siRNA is applied to this method, to avoid the effect of siRNA on exogenous TCR, it is preferable that the nucleotide sequence of the nucleic acid encoding TCR is a sequence (codon conversion type sequence) different from the nucleotide sequence corresponding to the RNA acted on by the siRNA suppressing the expression of the endogenous TCR chain. These methods are described in, for example, WO 2008/153029. The aforementioned base sequence can be produced by introducing a silent mutation into a nucleic acid encoding TCR obtained naturally or chemically synthesizing artificially designed nucleic acid. To avoid mispairing with the endogenous TCR chain, a part or all of the constant regions of the nucleic acid encoding the introduced TCR may also be substituted with a constant region derived from an animal other than the test subject.</p><p id="p-0131" num="0121">In the T cells constituting a cell bank of T cell, moreover, a nucleic acid containing an exogenous gene may be introduced, or the exogenous gene product may be expressed.</p><p id="p-0132" num="0122">The above-mentioned exogenous gene is not particularly limited, and an exogenous gene encoding protein, cytokine, chemokine and the like that can contribute to the regulation of the function of T cells can be used. Examples of the above-mentioned exogenous gene include a gene encoding a chimeric antigen receptor (CAR) (hereinafter to be also referred to as &#x201c;CAR gene&#x201d;), a gene encoding an exogenous T cell receptor (TCR) (hereinafter to be also referred to as &#x201c;TCR gene&#x201d;) and the like. The above-mentioned CAR and TCR expressed from genes introduced into cells can recognize and bind to antigen and/or antigen-HLA complex. In the present specification, the nucleic acid encoding TCR is a nucleic acid containing a base sequence encoding one strand that forms TCR and a base sequence encoding the other strand.</p><p id="p-0133" num="0123">The term &#x201c;capable of binding&#x201d; as used herein means &#x201c;having an ability to bind&#x201d; and refers to a capability to form a non-covalent complex with one or more other molecules. Various methods and assays to determine binding capability are known in the art. Binding is usually a binding with high affinity, wherein the binding affinity as measured in KD values preferably is less than 1 &#x3bc;M, more preferably less than 100 nM, even more preferably less than 10 nM, even more preferably less than 1 nM, even more preferably less than 100 pM, even more preferably less than 10 pM, even more preferably less than 1 pM. The term &#x201c;KD&#x201d; or &#x201c;KD value&#x201d; relates to the equilibrium dissociation constant as known in the art and indicates the intermolecular binding affinity. A smaller KD value shows higher binding affinity.</p><p id="p-0134" num="0124">The TCR used in the present invention encompasses not only one in which &#x3b1; chain and &#x3b2; chain of TCR constitute a heterodimer (i.e., &#x3b1;&#x3b2;TCR), or &#x3b3; chain and &#x3b4; chain of TCR constitute a heterodimer (i.e., &#x3b3;&#x3b4;TCR), but also one in which they constitute a homodimer. Furthermore, one lacking a part of or whole constant region and one with recombination of an amino acid sequence may also be used.</p><p id="p-0135" num="0125">The constant region of the above-mentioned TCR chain may be the constant region of the TCR chain of the cytotoxic T lymphocyte (CTL) clone, from which it is derived, wherein the region has been subjected to a predetermined modification. Examples of the modification include, but are not limited to, replacing particular amino acid residues in the constant region of the TCR of the CTL clone with cysteine residues, thereby enhancing efficiency of dimer expression by disulfide bond between TCR chains and the like.</p><p id="p-0136" num="0126">The above-mentioned TCR may be a variant. In the following, unless otherwise specified, TCR includes variants thereof. Examples of the variant include variant of the T cell receptor developed by the present inventor and consisting of a combination of two polypeptides containing the constant region of a TCR chain selected from the group consisting of a chain, &#x3b2; chain, &#x3b3; chain and &#x3b4; chain and the like. TCR variant is characterized in that it does not include a complementarity determining region (CDR) of TCR&#x3b1; chain and &#x3b2; chain, or a complementarity determining region (CDR) (preferably a part or all of the variable region containing CDR) of the same kind of chain, and that it does not include a complementarity determining region (CDR) of T cell receptor chain from which the constant region derives, or a complementarity determining region (CDR) (preferably a part or all of the variable region containing CDR) of the same kind of chain. Accordingly, the above-mentioned variant does not include a natural type or artificial type (e.g., animal species from which constant region and variable region are derived are different) of &#x3b1;&#x3b2;TCR, &#x3b3;&#x3b4;TCR, or TCR variants in which amino acids are further added to TCR of these. For example, when a polypeptide corresponding to at least one of the chains of the variant of the present invention contains the constant region of the T cell receptor &#x3b1; chain, the polypeptide does not contain the complementarity determining region of the T cell receptor a chain, preferably a part or all of the variable region containing the complementarity determining region. However, it may contain TCR chain other than &#x3b1; chain and &#x3b2; chain, for example, CDR and variable region of &#x3b3; chain and &#x3b4; chain. Similarly, when a polypeptide corresponding to at least one of the chains of the above-mentioned variant contains the constant region of the T cell receptor &#x3b2; chain, the polypeptide does not contain the complementarity determining region of the T cell receptor &#x3b2; chain, preferably a part or all of the variable region containing the complementarity determining region. However, it may contain TCR chain other than &#x3b1; chain and &#x3b2; chain, for example, CDR and variable region of &#x3b3; chain and &#x3b4; chain. The same applies to &#x3b3; chain and &#x3b4; chain.</p><p id="p-0137" num="0127">A membrane transfer signal peptide (hereinafter to be referred to as &#x201c;signal peptide&#x201d;) may be added to the above-mentioned TCR. As the signal peptide, CD8, Immunoglobulin-H (IGH), CD4, membrane transfer signal peptide derived from a gene encoding various peptides having transmembrane domain and/or an amino acid sequence obtained by deletion, substitution, insertion and/or addition of one or several (e.g., 2, 3, 4, 5) amino acids in the amino acid sequence of the signal peptide, or a signal peptide composed of an amino acid sequence having identity with the amino acid sequence of the signal peptide can be used. When a signal peptide is added, the binding position and the number of signal peptides are not particularly limited.</p><p id="p-0138" num="0128">In the present invention, the &#x201c;chimeric antigen receptor (CAR)&#x201d; means a fusion protein containing an antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain. The antigen-binding domain of CAR includes a short chain antibody (scFv) in which the light chain (VL) and heavy chain (VH) of the variable region of the antibody are linked in tandem via a spacer such as a linker (e.g., linker composed of G and S (GS linker)). The cells expressing CAR recognize the antigen in the scFV region and then transduce the recognition signal thereof into T cells through the intracellular signal transduction domain. Introduction of CAR into the cells makes it possible to impart specificity to the antigen of interest. In addition, since CAR can directly recognize antigen molecules without depending on HLA class I or class II, a high immune response can also be induced against cells with decreased HLA class I or class II gene expression. As the antigen targeted by the aforementioned CAR, the same antigens as the above-mentioned antigens targeted by the aforementioned TCR can be mentioned.</p><p id="p-0139" num="0129">Examples of the transmembrane domain of CAR include, but are not limited to, transmembrane domains derived from one or more proteins selected from the group consisting of &#x3b1; chain, &#x3b2; chain or &#x3b6; chain of TCR, CD28, CD3c chain, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, 4-1BB (CD137) and CD154 and the like. The transmembrane domain of the molecule from which the first intracellular signal transduction domain linked to the antigen binding domain is derived may be used. For example, when the molecule from which the first intracellular signal transduction domain linked to the antigen binding domain is derived is CD28, the transmembrane domain may also be derived from CD28. Alternatively, an artificially designed transmembrane domain may also be used.</p><p id="p-0140" num="0130">Examples of the intracellular signal transduction domain of CAR include, but are not limited to, intracellular domains derived from one or more proteins selected from the group consisting of CD3&#x3b6; chain (TCR&#x3b6; chain), FcR&#x3b3; chain, FcR&#x3b2; chain, CD3&#x3b3; chain, CD3&#x3b4; chain, CD3&#x3b5; chain, CD5, CD22, CD79a, CD79b and CD66d. Of these, an intracellular signal transduction domain derived from CD3&#x3b6; chain is preferable. The intracellular signal transduction domain may further contain an intracellular domain of a co-stimulatory molecule. Examples of the co-stimulatory molecule include intracellular domains of one or more kinds of proteins selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and CD83. The strength and duration of CAR activity can be controlled by selecting the type and number of co-stimulatory molecule to be bound (e.g., Mol Ther. 2009; 17:1453-1464.).</p><p id="p-0141" num="0131">A spacer may be incorporated between the antigen-binding domain and transmembrane domain of CAR or between the intracellular transduction domain and transmembrane domain of CAR. As the spacer, a peptide generally consisting of not more than 300 amino acids, preferably 10-100 amino acids, most preferably 25-50 amino acids, can be used. Specific examples thereof include, but are not limited to, peptides containing a hinge region derived from IgG1, and CH2CH3 region of immunoglobulin and a part of CD3 and the like.</p><p id="p-0142" num="0132">Examples of specific CAR include, but are not limited to, a first generation CAR in which scFv and CD3&#x3b6; chain are linked via a spacer, a second generation CAR in which a transmembrane domain derived from CD28 and an intracellular domain are incorporated between the scFV and CD3&#x3b6; chain of the first generation CAR to enhance the ability to activate T cells, and a third generation CAR in which the intracellular domain of a co-stimulatory molecule (4-1BB or OX40) different from CD28 is incorporated between the intracellular domain of CD28 and CD3&#x3b6; chain of the second generation.</p><p id="p-0143" num="0133">More specific examples of CAR used in the present invention include a chimeric antigen receptor containing scFv recognizing CD19 as an antigen binding domain, transmembrane domain of CD8 as a transmembrane domain, intracellular domain derived from CD28 as an intracellular signal transduction domain, an intracellular domain derived from CD30, an intracellular domain derived from 4-1BB, and an intracellular domain derived from CD3&#x3b6; chain. The order of the above-mentioned intracellular domains contained in the intracellular signal transduction domain is not particularly limited and, for example, the order of the intracellular domain derived from CD28, the intracellular domain derived from CD30 or the intracellular domain derived from 4-1BB, and the intracellular domain derived from CD3&#x3b6; chain is adopted. More specifically, the chimeric antigen receptor in the present invention is composed of, for example, the amino acid sequence shown in SEQ ID NO: 4 or 5, or an amino acid sequence obtained by deletion, substitution, insertion and/or addition of one or two or more (preferably, about 1-100, preferably about 1-50, further preferably about 1-10, particularly preferably 1-several (2, 3, 4 or 5)) amino acids in the amino acid sequence shown in SEQ ID NO: 4 or 5.</p><p id="p-0144" num="0134">Examples of the intracellular domain derived from CD30 include an amino acid sequence obtained by deletion, substitution, insertion and/or addition of one or two or more (preferably, about 1-100, preferably about 1-50, further preferably about 1-10, particularly preferably 1-several (2, 3, 4 or 5)) amino acids in the amino acid sequence shown in SEQ ID NO: 7. When the amino acid sequence is deleted, substituted, inserted and/or added as described above, the location of the deletion, substitution, insertion and/or addition is not particularly limited as long as the function of the intracellular domain of CD30 is maintained.</p><p id="p-0145" num="0135">Examples of the antigen targeted by the above-mentioned TCR and CAR include, but are not limited to, tumor antigens. The tumor antigen may be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). Specific examples of such tumor antigen include one or more kinds of antigens selected from the group consisting of differentiated antigens such as MART-1/MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2 and the like, tumor-specific multilineage antigens such as WT1, Glypican-3, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15 and the like, fetal antigens such as CEA and the like, overexpressed tumor genes or mutated tumor suppressive genes such as p53, Ras, HER-2/neu and the like, unique tumor antigens caused by chromosome translocation such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR and the like, and virus antigens such as Epstein Barr virus antigen EBVA, human papilloma virus (HPV) antigens E6 and E7 and the like. As other tumor antigens, TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, &#x3b2;-catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, &#x3b1;-fetoprotein, &#x3b2;-HCG, BCA225, BTAA, CA 125, CA 15-3/CA 27.29/BCAA, CA 195, CA 242, CA-50, CAM43, CD68/P1, CO-029, FGF-5, G250, Ga733/EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90/Mac-2 binding protein/cyclophilin C-associated protein, TAAL6, TAG72, TLP and TPS can be mentioned.</p><p id="p-0146" num="0136">It can be confirmed by a known method that the above-mentioned TCR or CAR (hereinafter sometimes to be abbreviated as &#x201c;TCR etc.&#x201d;) specifically recognizes antigen and can bind thereto. A suitable method includes, for example, dextramer assay, ELISPOT assay and the like. By performing the ELISPOT assay, it can be confirmed that T cells expressing TCR on the cell surface recognize the target antigen by the TCR etc. and the signal thereof has been transmitted into the cells.</p><p id="p-0147" num="0137">Previously, the present inventors found that cytotoxic activity increases in cells expressing a fusion protein containing IL-15 and IL-15R&#x3b1; (hereinafter sometimes to be abbreviated as &#x201c;IL-15/IL-15R&#x3b1;&#x201d;) together with the above-mentioned CAR, as compared to the cells expressing CAR alone. Therefore, from the aspect of cytotoxic activity, T cells constituting a cell bank of T cell preferably express IL-15/IL-15R&#x3b1;, and more preferably express the above-mentioned CAR. To obtain T cells expressing IL-15/IL-15R&#x3b1;, the IL-15/IL-15R&#x3b1; gene is introduced into cells at the stage of differentiation from pluripotent cells into T cells (e.g., pluripotent stem cell, hematopoietic progenitor cell (CD34+/CD43+), ProT cells (CD4&#x2212;/CD8&#x2212;), CD3+/CD4+/CD8+T cells, CD3+/CD4&#x2212;/CD8+T cells, or other cells (e.g., CD3&#x2212;/CD4+/CD8+ cell, etc.) etc.). It is preferable to introduce IL-15/IL-15R&#x3b1; into the cell in the form of a nucleic acid encoding same. The introduction can be performed in the same manner as in the above-mentioned nucleic acid introduction step.</p><p id="p-0148" num="0138">In the IL-15 signal transduction system, IL-15R&#x3b1; expressed on antigen-presenting cells generally binds to IL-15 and IL-15 is presented to IL-15 receptor consisting of a common &#x3b3; chain (&#x3b3;c) with IL-15R&#x3b2; on CD8-positive and CD4-negative cell (trans-presentation), whereby the cytotoxic activity of CD8 positive CD4 negative cell is maintained. Therefore, when the T cell expressing IL-15/IL-15R&#x3b1; is CD8 positive CD4 negative, the cell can transmit the IL-15 signal into its own cell via the IL-15 receptor. Alternatively, the T cell expressing IL-15/IL-15R&#x3b1; can transmit the IL-15 signal into other CD8 positive CD4 negative cells via the IL-15 receptor. As described above, since IL-15/IL-15R&#x3b1; can maintain cytotoxic activity of CD8 positive CD4 negative cell, it is expected to show a continuous cytotoxic effect on cells targeted by CAR.</p><p id="p-0149" num="0139">IL-15/IL-15R&#x3b1; may be a transmembrane type protein or a secretor protein. It is known that, in IL-15R&#x3b1;, the IL-15 binding domain of 1-65 amino acids from the N-terminal of the mature protein is the region responsible for binding to IL-15 (Wei X. et al., J. Immunol., 167: 277-282, 2001). Therefore, the transmembrane type protein may be a protein that retains the IL-15 binding domain and retains the transmembrane domain of IL-15R&#x3b1;. On the other hand, the secretor protein may be a protein that maintains the IL-15 binding domain and lacks the transmembrane domain of IL-15R&#x3b1; (e.g., protein consisting of 1-65 amino acid residues, 1-85 amino acid residues, or 1-182 amino acid residues of IL-15R&#x3b1;, peptide containing an amino acid sequence not less than 85% (e.g., 90%, 95%, 97%, 98%, 99%) identical with the amino acid sequence, and the like).</p><p id="p-0150" num="0140">A spacer may be incorporated between IL-15 and IL-15R&#x3b1; of IL-15/IL-15R&#x3b1;. As the spacer, a peptide generally consisting of not more than 300 amino acids, preferably 10-100 amino acids, most preferably 20-50 amino acids, can be used. Specific examples thereof include, but are not limited to, the aforementioned GS linker and the like.</p><p id="p-0151" num="0141">IL-15/IL-15R&#x3b1; is not particularly limited as long as it is a protein in which IL-15 and IL-15R&#x3b1; are fused, and specific examples thereof include a peptide consisting of SEQ ID NO: 7. While IL-15/IL-15R is not particularly limited as long as it can bind to the IL-15 receptor and transmit the IL-signal into the cell, for example, a peptide containing an amino acid sequence having a homology or identity of not less than about 90%, preferably not less than about 95%, more preferably not less than about 97%, particularly preferably not less than about 98%, most preferably not less than about 99%, with the amino acid sequence shown in SEQ ID NO: 7 can be mentioned. As used herein, the &#x201c;homology&#x201d; or &#x201c;identity&#x201d; means the proportion (%) of the same amino acid and similar amino acid residue (same amino acid residues in the case of identity) to all overlapping amino acid residues in the optimal alignment where two amino acid sequences are aligned using a mathematic algorithm known in the relevant technical field (preferably, the algorithm is such that a gap can be introduced into one or both of the sequences for the optimal alignment). The &#x201c;similar amino acid&#x201d; means amino acids having similar physicochemical properties and, for example, amino acids classified in the same group such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids having a hydroxyl group (Ser, Thr), amino acids having a small side chain (Gly, Ala, Ser, Thr, Met) and the like can be mentioned. It is predicted that the substitution with such similar amino acids does not change the phenotype of the protein (that is, conservative amino acid substitution). Specific examples of the conservative amino acid substitution are well known in the technical field and are described in various documents (e.g., Bowie et al., Science, 247: 1306-1310 (1990)). The homology or identity of the amino acid sequence in the present specification can be calculated using homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool), and under the following conditions (expectancy=10; accept gap; matrix=BLOSUM62; filtering=OFF).</p><p id="p-0152" num="0142">An exogenous gene can be introduced by a known method. When the introduced nucleic acid is in the form of a DNA, for example, calcium phosphate coprecipitation method, PEG method, electroporation method, microinjection method, lipofection method and the like can be used. For example, the methods described in Cell Engineering additional volume 8, New Cell Engineering experiment protocol, 263-267 (1995) (published by Shujunsha), Virology, vol. 52, 456 (1973), Folia Pharmacol. Jpn., vol. 119 (No. 6), 345-351 (2002) and the like can be used. When a virus vector is used, the nucleic acid is introduced, together with a packaging vector as necessary, into a suitable packaging cell (e.g., Plat-E cell) and complementation cell line (e.g., 293 cell), a virus vector produced in the culture supernatant is recovered, and cells are infected with the vector by an appropriate method suitable for each virus vector, whereby the vector is introduced into the cells. As the virus vector, retrovirus vector (including lentivirus vector and pseudo type vector), adenovirus vector, adeno-associated virus vector, herpes virus vector, Sendaivirus vector, episomal vector and the like can be mentioned. A transposon expression system (PiggyBac system) may also be used. As the plasmid vector, animal cell expression plasmid (e.g., pa1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo) and the like can be mentioned. Specifically, when a retrovirus vector is used as the vector, a specific means is disclosed in WO 2007/69666, Cell, 126, 663-676 (2006) and Cell, 131, 861-872 (2007) and the like. Particularly, when a retrovirus vector is used, highly efficient transfection into various cells is possible by using a recombinant fibronectin fragment CH-296 (manufactured by Takara Bio Inc.). When the introduced nucleic acid is in the form of DNA and a viral vector is used, the kind of the viral vector can be appropriately selected depending on the type of cell to be introduced. When the target cell is a T cell, a retrovirus vector is preferably used, and a gamma retrovirus vector is more preferably used. When the target cell is an iPS cell, a lentivirus vector is preferably used.</p><p id="p-0153" num="0143">The introduction nucleic acid may also be directly introduced into cells in the form of RNA and used to express the introduced gene in the cells. As a method for introducing RNA, a known method can be used and, for example, a lipofection method, an electroporation method, or the like can be preferably used. When the reprogramming factor is in the form of a protein, it can be introduced into a cell by a method such as lipofection, fusion with cellular membrane-penetrating peptide (e.g., HIV-derived TAT and polyarginine), microinjection and the like, and the like.</p><p id="p-0154" num="0144">The above-mentioned TCR etc. are introduced into the cells in the form of a nucleic acid encoding TCR etc. In addition, a fusion protein containing IL-15 and IL-15R&#x3b1; is also introduced into a cell in the form of a nucleic acid encoding the fusion protein. The nucleic acid and a nucleic acid for suppressing the expression of the above-mentioned HLA gene may be DNA or RNA, or DNA/RNA chimera, and preferably DNA. In addition, the nucleic acid may be double-stranded or single-stranded. In the case of double strands, double-stranded DNA, double-stranded RNA or DNA:RNA hybrid may be used. When the nucleic acid is RNA, T is to be read as U as regards the RNA m sequence. In addition, the nucleic acid may contain natural nucleotide, modified nucleotide, nucleotide analogue, or a mixture of these as long as it can express polypeptide in vitro or in a cell.</p><p id="p-0155" num="0145">The above-mentioned nucleic acid can be constructed by a method known per se. For example, based on the amino acid sequence or nucleic acid sequence of known TCR or CAR, a DNA strand is chemically synthesized, or synthesized partially overlapping oligo DNA short chains are connected using PCR method or Gibson Assembly method, whereby a DNA encoding the full length or a part of the TCR or CAR can be constructed. The nucleic acid for suppressing the expression of HLA gene, and the nucleic acid encoding a fusion protein containing IL-15 and IL-15R&#x3b1; can also be constructed in the same manner.</p><p id="p-0156" num="0146">The above-mentioned nucleic acid can be incorporated into an expression vector. The vector may be a vector that integrates or does not integrate into the genome of the target cell. In one embodiment the vector that does not integrate into the genome is capable of replicating outside the genome of the target cell. The vector may be present in multiple copies outside the genome of the target cell. In another embodiment of the invention, the vector integrates into the genome of the target cell. Alternatively, the introduced nucleic acid can also be integrated into the genome by homologous recombination using genome editing (e.g., CRISPR system, TALEN, ZFN etc.) and the like. In preferable embodiments, nucleic acid such as vector and the like are integrated at a pre-defined location of the genome of the target cell.</p><p id="p-0157" num="0147">Examples of the promoter to be used in the above-mentioned vector include EF1&#x3b1; promoter, CAG promoter, SR&#x3b1; promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney mouse leukemia virus) LTR, HSV-TK (simple herpes virus thymidine kinase) promoter, TCR V &#x3b1; gene promoter, TCR V &#x3b2; gene promoter and the like. Of these, EF1&#x3b1; promoter, CAG promoter, MoMuLV LTR, CMV promoter, SR&#x3b1; promoter and the like are preferable.</p><p id="p-0158" num="0148">The above-mentioned vector may contain transcription and translation regulatory sequence, ribosome binding site, enhancer, replication origin, polyA addition signal, selection marker gene and the like on demand besides the above-mentioned promoters. Examples of the selection marker gene include dihydrofolate reductase gene, neomycin resistance gene, puromycin resistance gene and the like.</p><p id="p-0159" num="0149">In one embodiment of the present invention, heterodimers of &#x3b1; chain and &#x3b2; chain of TCR can be constructed in the target cell and on the cell surface by introducing an expression vector containing a nucleic acid encoding the &#x3b1; chain of TCR and a nucleic acid encoding &#x3b2; chain of TCR into the target cell. In this case, the nucleic acid encoding the &#x3b1; chain of TCR and the nucleic acid encoding &#x3b2; chain of TCR may be incorporated into separate expression vectors or a single expression vector. When they are incorporated into a single expression vector, these two kinds of nucleic acids are preferably incorporated via a sequence enabling polycistronic expression. Using a sequence enabling polycistronic expression, plural genes incorporated in one kind of expression vector can be more efficiently expressed. Examples of the sequence enabling polycistronic expression include 2A sequence (e.g., foot-and-mouth disease virus (FMDV)-derived 2A sequence (F2A), horse rhinitis A virus (ERAV)-derived 2A sequence (E2A), Porcine teschovirus (PTV-1)-derived 2A sequence (P2A), Thosea asigna virus (TaV)-derived 2A sequence (T2A sequence) (PLoS ONE3, e2532, 2008, Stem Cells 25, 1707, 2007), internal ribosome entry site (IRES) (U.S. Pat. No. 4,937,190) and the like. From the aspect of uniform expression levels, P2A sequence and T2A sequence are preferable. The same applies to the case of using an expression vector containing a nucleic acid encoding the &#x3b3; chain of TCR and a nucleic acid encoding the &#x3b4; chain of TCR.</p><p id="p-0160" num="0150">An exogenous gene to be introduced into T cells constituting a cell bank of T cell can be introduced into a cell that occurs during the process of differentiating stem cell (e.g., iPS cell or ES cell) into T cell. As used herein, the cell that occurs during the process of differentiating stem cell (e.g., iPS cell or ES cell) into T cell also includes a stem cell (e.g., iPS cell or ES cell) and T cell.</p><p id="p-0161" num="0151">In one embodiment of the present invention, the exogenous gene to be introduced into T cell constituting the cell bank of T cell is introduced into iPS cell, hematopoietic progenitor cell and/or T cell.</p><p id="p-0162" num="0152">In one embodiment of the present invention, before constituting the cell bank of T cell, the T cell obtained above can be expansion cultured as necessary by the method shown in the below-mentioned &#x201c;1-5. Expansion culture&#x201d;.</p><p id="p-0163" num="0153">A master cell bank of T cell can be constructed by dispensing the T cells obtained by the above-mentioned method into plural preservation containers (aseptic vial and the like), and stocking them. The stocked T cells are preferably frozen.</p><p id="p-0164" num="0154">One container of T cells in the master cell bank of T cell can be thawed as necessary and subjected to a property analysis test as appropriate. A working cell bank of T cell can be constructed as necessary by expansion culturing T cells prepared from the same container or from another container by the method shown in &#x201c;1-5. Expansion culture&#x201d; described later, dispensing the obtained T cells in a plurality of containers for each expansion culture, and stocking them. The stocked T cells are preferably frozen.</p><p id="p-0165" num="0155">Therefore, the provision system of the present invention may include a step of constructing a master cell bank of T cell and/or a working cell bank of T cell (hereinafter to be also referred to as &#x201c;cell bank of T cell construction step&#x201d;). In the following, the part constituted to execute the construction step of a cell bank of T cell is sometimes referred to as a &#x201c;cell bank of T cell-construction part&#x201d;.</p><heading id="h-0016" level="2">1-2. Freezing T Cells</heading><p id="p-0166" num="0156">As described above, the T cells in the cell bank of T cell are preferably frozen. T cells can also be frozen by a known method. Examples of the method include, but are not limited to, placing the container containing the T cells in a freezer (e.g., ultra-low temperature freezer), and bringing the cells into contact with a low temperature medium (e.g., liquid nitrogen, etc.) and preserving same in a freezer or cryopreservation system (e.g., locator, etc.). The freezing temperature is typically not more than 0&#xb0; C., preferably not more than &#x2212;20&#xb0; C., more preferably not more than &#x2212;40&#xb0; C., further preferably not more than &#x2212;80&#xb0; C. The cooling rate in the freezing operation is typically a cooling rate of 1-5 hr, preferably 2-4 hr, particularly about 3 hr, from the start of cooling at 4&#xb0; C. to reach &#x2212;80&#xb0; C. Such cooling rate can be achieved by providing a freezing means set to a desired temperature in contact with a container containing T cells directly or after accommodating the container in a freezing treatment container. The freezing treatment container may have a function of controlling the rate of temperature decrease inside the container to a predetermined speed. As the freezing treatment container, BICELL (registered trade mark) (Japan) and the like can be used. The above-mentioned cooling rate can be achieved by using a freezer whose cooling rate can be controlled by setting a program or the like. As such freezer, any known freezer, for example, a program freezer (e.g., KryoMed (Thermo Fisher), PDF-2000G (Strex), KRYO-560-16 (Asahi Life Science)), and the like can be used.</p><p id="p-0167" num="0157">The freezing operation can be performed using a culture medium in which colonies were immersed, a physiological buffer solution, or the like as a cryoprotective solution, and treating the solution by adding a cryoprotective agent, or replacing the culture medium with a cryoprotective solution containing a cryoprotective agent. When replacing the culture medium with a cryoprotective solution, the cryoprotective solution may be added after substantially removing all the culture medium, or the cryoprotective solution may be added while leaving a part of the culture medium. The cryoprotective solution may be commercially available and, for example, CryoStor (registered trade mark) CS10, and STEM-CELLBANKER (registered trade mark) (ZENOAQ) can be mentioned.</p><p id="p-0168" num="0158">The cryoprotective agent is not particularly limited and examples thereof include dimethyl sulfoxide (DMSO), ethylene glycol (EG), propylene glycol (PG), 1,2-propanediol (1,2-PD), 1,3-propanediol (1,3-PD), butyleneglycol (BG), isopreneglycol (IPG), dipropylene glycol (DPG), glycerol and the like. The cryoprotective agent may be used alone or two kinds or three kinds or more may be used in combination. Moreover, the cryoprotective agent may be used in combination with an extracellular cryoprotective agent. Examples of the extracellular cryoprotective agent include polyethylene glycol, carboxymethylcellulose sodium, polyvinylpyrrolidone, hydroxyethylstarch (HES), dextran, albumin and the like.</p><p id="p-0169" num="0159">The concentration of the cryoprotective agent added to the culture medium, or the concentration of the cryoprotective agent in the cryoprotective solution, is typically 2-20% (v/v), preferably 5-15%, more preferably 8-13%, of the total culture medium or cryoprotective solution. The above-mentioned concentration can be appropriately adjusted by the kind of the cryoprotective agent. For example, when DMSO is used as the cryoprotective agent, concentration of DMSO is typically 2-20% (v/v), preferably 2.5-12.5%, more preferably 5-10%, of the total culture medium or cryoprotective solution.</p><p id="p-0170" num="0160">Specific examples of the cryoprotective agent and the freezer are as mentioned above. As the container containing T cells, a cryopreservation container can be used. Specific examples of the cryopreservation container include aseptic vial (e.g., glass ampoule, polymer vial (AT-closed vial) etc.) and the like.</p><heading id="h-0017" level="2">1-3. Preparation of T Cell</heading><p id="p-0171" num="0161">In the present invention, a cell bank of T cell generally contains one or more containers in which T cells are dispensed and frozen. Thus, the preparation of T cell also includes a process of collecting one or more containers from a cell bank of T cell and thawing the T cells, a process of washing the thawed cells as necessary, a process of preculturing and cultivating the cells, a process of maintenance culturing the cells, and the like. Each of the above-mentioned processes may be performed by the same entity or by different entities.</p><p id="p-0172" num="0162">The aforementioned method for thawing T cells can be performed by a known method. For example, a container containing frozen T cells collected from a cell bank of T cell is contacted with a solid, liquid or gaseous medium (e.g., water, culture medium) having a temperature higher than the freezing temperature by using a water bath, an incubator, or the like. The method is not limited to this method. The temperature of the medium is typically 4&#xb0; C.-50&#xb0; C., preferably 30&#xb0; C.-40&#xb0; C., more preferably 36&#xb0; C.-38&#xb0; C. The thawing time is typically within 2 minutes, particularly 20 seconds, whereby a decrease in the survival rate of the cell can be drastically suppressed. The thawing time can be adjusted by, for example, changing the thawing means, temperature of immersion medium, volume or composition of the culture medium or cryoprotective solution during freezing, and the like.</p><p id="p-0173" num="0163">The cells can be washed by a known method. For example, the method includes, but is not limited to, suspending the cells in a cell washing (e.g., culture medium or biological buffer etc. containing serum, serum components (serum albumin and the like)), centrifuging same, discarding the supernatant, and collecting the precipitated cells. In the process of washing the cells, the cycle of suspending, centrifugation, and recovery may be performed once or plural times (e.g., 2, 3, 4, 5 or more). In one embodiment of the present invention, the process of washing the cells is performed immediately after the process of thawing the T cells collected from a cell bank of T cell. Examples of commercially available cell washing that can be used in the present invention include CELLOTION (Japan ZENYAKU KOGYO) and the like.</p><p id="p-0174" num="0164">In the present invention, a medium for the aforementioned preculture and maintenance culture is not particularly limited, and a medium used for culturing animal cells can be prepared into a basal medium. Where necessary, the basal medium may contain a medium additive and the like. As the basal medium and medium additive, those recited in the above-mentioned 1-1., process (1), can be mentioned.</p><p id="p-0175" num="0165">The preculture and maintenance culture can be performed for an appropriate culture period according to the purpose. The culture period is preferably not less than 1 day (e.g., 5, 6, 7 days) and not more than 10 days (e.g., 7, 8, 9, 10 days). The culture temperature is not particularly limited and is 30&#xb0; C.-40&#xb0; C., preferably 37&#xb0; C. Culture is performed in the presence of CO<sub>2</sub>-containing air and the CO<sub>2 </sub>concentration is preferably 2-5%.</p><p id="p-0176" num="0000">1-4. Introduction of Nucleic Acid into T Cell Prepared from a Cell Bank of T Cell</p><p id="p-0177" num="0166">The provision system of the present invention may include a step of introducing a nucleic acid containing an exogenous gene into T cells prepared from a cell bank of T cell (hereinafter to be also referred to as &#x201c;nucleic acid introduction step&#x201d;). In the present specification, &#x201c;include a step&#x201d; or &#x201c;include a process&#x201d; means that a part that is constituted to perform the step or process is contained. In the following, a part that is constituted to perform the nucleic acid introduction step is sometimes referred to as a &#x201c;nucleic acid introduction part&#x201d;.</p><p id="p-0178" num="0167">A method for introducing a nucleic acid in the nucleic acid introduction step, an exogenous gene and a nucleic acid containing same are as described above.</p><p id="p-0179" num="0168">The exogenous gene to be introduced in the nucleic acid introduction step may be the same as or different from the exogenous gene already introduced into the T cells constituting a cell bank of T cell.</p><p id="p-0180" num="0169">The nucleic acid introduction part may be provided with a basal medium, a culture container, and a sterile space, and may be configured so that a nucleic acid containing an exogenous gene can be introduced into the above-mentioned prepared T cells. In the present specification, the sterile space means a sterile internal space defined by a clean chamber, a clean bench, a sterile room, and the like, and also includes a sterile internal space defined by the entire nucleic acid introduction part and a sterile space that is a part of the internal space of the nucleic acid introduction part. The device, medium, etc. provided in the nucleic acid introduction part are appropriately selected according to the property of the device, the method of introducing nucleic acid, and the like. The nucleic acid introduction part may be provided as necessary with one or more kinds of medium additive, clean bench, incubator, bioreactor for cell culture, microscope, centrifuge, aspirator, nucleic acid to be introduced, nucleic acid encoding protein for genome editing, and the like, pipette, tube, buffering agent (e.g., acetate buffer, phosphate buffer, citrate buffer, citric acid phosphate buffer, boric acid buffer, tartaric acid buffer, tris buffer, phosphate buffered saline, McIlvaine buffer etc.), gene transfer adjuvant and the like, and further provided with other reagents, device and the like according to the kind of the nucleic acid introduction method.</p><p id="p-0181" num="0170">Specific examples of the above-mentioned basal medium and medium additive provided to the nucleic acid introduction part are as mentioned above. Examples of the culture container include petri dish, flask, plastic bag, Teflon (registered trade mark) bag, dish, petri dish, tissue culture dish, multidish, microplate, microwell plate, Multiplate, multiwell plate, chamber slide, cell culture flask, spinner flask, tube, tray, culture bag, roller bottle and the like that are generally used for cell culture. The material of these culture containers is not particularly limited and, for example, glass, polyvinyl chloride, cellulose type polymers such as ethylcellulose, acetylcellulose and the like, plastic such as polystyrene, polymethyl methacrylate, polycarbonate, polysulfone, polyurethane, polyester, polyamide, polystyrene, polypropylene, polyethylene, polybutadiene, poly(ethylene-vinylacetate) copolymer, poly(butadiene-styrene) copolymer, poly(butadiene-acrylonitrile) copolymer, poly(ethylene-ethylacrylate) copolymer, poly(ethylene-methacrylate) copolymer, polychloroprene, styrole resin, chlorosulfonated polyethylene, ethylenevinyl acetate, acrylic block copolymer and the like, and the like can be mentioned.</p><p id="p-0182" num="0171">As the above-mentioned other reagent and device, when, for example, nucleic acid introduction is performed by a calcium phosphate coprecipitation method, the nucleic acid introduction part may be provided with one or more kinds of various reagents and solutions (e.g., CaCl<sub>2 </sub>and its solution, HCl and its solution, NaCl and its solution, MgCl<sub>2 </sub>and its solution, Na<sub>2</sub>HPO<sub>4 </sub>and its solution, KH<sub>2</sub>PO<sub>4 </sub>and its solution, NP- and its solution, HEPES and its solution, DMSO and its solution etc.) and the like. For example, when an electroporation method is used, the nucleic acid introduction part may be provided with one or more kinds of electroporator, electrode (e.g., platinum electrode, cuvette electrode, petri dish platinum plate electrode etc.), electroporation plate, chamber (e.g., electrode chamber, plate chamber etc.), and the like. For example, when a lipofection method is used, it may be provided with one or more kinds of transfection reagents (e.g., Lipofectamine (invitrogen), jetPEI (Polyplus-transfection), Xfect&#x2122; (Clontech TaKaRa cellartis), GenomONE&#x2122; (ISHIHARA SANGYO KAISHA)), Trans IT (Mirus Bio LLC), RmesFect/RmesFect Stem (OZ BIOSCIENCES) etc.) and the like. For example, when nucleic acid introduction is performed using a virus vector, the nucleic acid introduction part may be provided with one or more kinds of various virus vectors, packaging vector plasmid, packaging (e.g., Plat-E cell), complementary cell line, laboratory of biosafety level 2 and the like recited above.</p><heading id="h-0018" level="2">1-5. Expansion Culture</heading><p id="p-0183" num="0172">The provision system of the present invention may include a step of expansion culturing T cells prepared from a master cell bank of T cell or T cells obtained by introducing a nucleic acid containing an exogenous gene into the T cells (hereinafter to be also referred to as &#x201c;expansion culture step&#x201d;). In the following, the part constituted to execute the expansion culture step is sometimes referred to as a &#x201c;expansion culture part&#x201d;.</p><p id="p-0184" num="0173">In the present specification, the &#x201c;expansion culture&#x201d; m means culturing for the purpose of proliferating a desired cell population and increasing the cell number. The increase in cell number may be achieved by increasing the number of cells by proliferation to exceed the decrease in number by death, and it does not require proliferation of all cells in the cell population. The increase in the cell number may be 1.1 times, 1.2 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, times, 40 times, 50 times, 100 times, 300 times, 500 times, 1,000 times, 3,000 times, 5,000 times, 10,000 times, 100,000 times, or not less than 1,000,000 times, compared to that before the start of expansion culture.</p><p id="p-0185" num="0174">The expansion culture step can be performed by a known method. However, from the aspect of cell proliferation efficiency, it is preferable to perform the expansion culture step by a method including a process of stimulating T cells with a CD30 agonist, which was found by the present inventors. The T cells can be stimulated with a CD30 agonist by culturing the T cells in the presence of a CD30 agonist. Thus, a method including a process of stimulating T cells in the presence of a CD30 agonist is preferable. Therefore, in one embodiment of the present invention, the expansion culture step may include a process of culturing T cells in the presence of a CD30 agonist. When the expansion culture is performed in the presence of a CD30 agonist, the culture medium preferably contains a CD3/TCR complex agonist, and fibronectin or a variant thereof as well. CD3/TCR complex agonist and CD30 agonist can each stimulate CD3/TCR complex and CD30.</p><p id="p-0186" num="0175">The proliferative capacity of T cell differentiated from iPS cell is lower than that of iPS cell. Therefore, even if a master cell bank and/or working cell bank are/is constructed in the stage of T cell, it has been difficult to supply T cells and T cell products in an amount sufficient to achieve the expected therapeutic effect by administering to one or more humans. The present invention overcomes such difficulty. Furthermore, using a method including the above-mentioned process of stimulating T cells with a CD30 agonist in the expansion culture step, it becomes possible to supply T cell products more stably by constructing a master cell bank and/or a working cell bank at the stage of T cell.</p><p id="p-0187" num="0176">In the present specification, &#x201c;stimulation&#x201d; means that a certain substance binds to various receptors and the like to activate a signal pathway at the downstream thereof.</p><p id="p-0188" num="0177">In the present invention, a medium used for expansion culture step of T cells is not particularly limited, and a medium used for culturing animal cells can be prepared into a basal medium. Where necessary, the basal medium may contain a medium additive and the like. As the basal medium and medium additive, those recited in the above-mentioned 1-1., process (1), can be mentioned. The culture can be performed, for example, in a CO<sub>2 </sub>incubator under a CO<sub>2 </sub>concentration atmosphere of about 1-about 10%, preferably about 2-about 5% at about 30-about 40&#xb0; C., preferably about 37&#xb0; C. The culture period can be appropriately determined by those skilled in the art by monitoring the number of T cells and the like. The number of days is not limited as long as T cells can be obtained. The culture period is, for example, not less than 3 days, not less than 5 days, not less than 7 days, not less than 10 days, not less than 14 days, not less than 21 days, preferably not less than 5 days and not more than 15 days. It is preferably not more than 30 days, more preferably not more than 21 days. The culture period is, for example, 3-30 days, 5-30 days, 7-30 days, 10-30 days, 14-30 days, 21-30 days, 3-21 days, 5-21 days, 7-21 days, 10-21 days, 14-21 days, 3-15 days, 5-15 days, 7-15 days, 10-15 days, 14-15 days, or the like.</p><p id="p-0189" num="0178">When vitamin C is used in the expansion culture step, Vitamin C may be the same as that described in process (2-1) and can be added similarly. In one embodiment, the concentration of vitamin C in the medium or culture medium is preferably 5 &#x3bc;g/ml-200 &#x3bc;g/ml. In another embodiment, vitamin C is added to the culture medium at an amount corresponding to &#x3bc;g/ml-500 &#x3bc;g/ml (e.g., amount corresponding to 5 &#x3bc;g/ml, 10 &#x3bc;g/ml, 25 &#x3bc;g/ml, 50 &#x3bc;g/ml, 100 &#x3bc;g/ml, 200 &#x3bc;g/ml, 300 &#x3bc;g/ml, 400 &#x3bc;g/ml, 500 &#x3bc;g/ml).</p><p id="p-0190" num="0179">When a CD3/TCR complex agonist is used in the expansion culture step, CD3/TCR complex agonist used in this step may be the same as that described in the above-mentioned 1-1., process (3). The concentration of the CD3/TCR complex agonist in the medium is also the same as that described in the above-mentioned 1-1., process (3).</p><p id="p-0191" num="0180">Fibronectin or a variant thereof is preferably present in the medium in the expansion culture step. Such fibronectin is not particularly limited as long as it is a molecule capable of binding to T cells. The variant of fibronectin is not particularly limited as long as it is a molecule capable of binding to VLA-5 and VLA-4 on the surface of T cells, and examples thereof include RetroNectin. Fibronectin and a variant thereof may be present in any form in the medium. For example, they may be contained in the medium during culture, or may be immobilized on a culture container, and are preferably immobilized on a culture container.</p><p id="p-0192" num="0181">When fibronectin or a variant thereof is contained in a medium, the medium may be the same as that containing a CD3/TCR complex agonist. The presence or absence of serum, additive and the like may be the same as that in the medium containing a CD3/TCR complex agonist. When fibronectin or a variant thereof is contained in a medium, the lower limit of the concentration of fibronectin or a variant thereof may be not less than 10 ng/ml, preferably not less than 100 ng/ml, and the upper limit may be not more than 10000 &#x3bc;g/ml, preferably not more than 1000 &#x3bc;g/ml.</p><p id="p-0193" num="0182">In the expansion culture step, the medium also preferably contains a CD30 agonist. The CD30 agonist is not particularly limited as long as it is a molecule capable of transducing a signal from a CD30 into a cell by specifically binding to CD30. Examples of the CD30 agonist include at least one selected from the group consisting of anti-CD30 agonist antibody (to be also simply referred to as &#x201c;anti-CD30 antibody&#x201d;) or a fragment bonded thereto and CD30 ligand or a fragment bonded thereto.</p><p id="p-0194" num="0183">Like the CD3/TCR complex agonist, the CD30 agonist used in the expansion culture step may be present in any form as long as it can be present in contact with CD30 during culturing. For example, it may be contained in the medium during culture, or may be immobilized on a culture container, and is preferably contained in the medium.</p><p id="p-0195" num="0184">When a CD30 agonist is contained in a medium, the medium may be the same as that containing a CD3/TCR complex agonist. The presence or absence of serum, additive and the like may be the same as that in the medium containing a CD3/TCR complex agonist. When a CD30 agonist is contained in a medium, the concentration of the CD30 agonist in the medium can be appropriately determined by those of ordinary skill in the art according to the CD30 agonist. For example, when the CD30 agonist is an anti-CD30 agonist antibody or a bond fragment thereof, the concentration of the anti-CD30 agonist antibody or a bond fragment thereof in the medium is generally 1 ng/ml-10000 ng/ml, preferably 30 ng/ml-300 ng/ml.</p><p id="p-0196" num="0185">When the CD30 agonist is immobilized on a culture container, the culture container may be the same as that on which the CD3/TCR complex agonist is immobilized. In addition, a method of immobilizing the CD30 agonist on the culture container may be the same as that of immobilizing the CD3/TCR complex agonist. The lower limit of the concentration of a CD30 agonist solution when the CD30 agonist is immobilized on a culture container may be not less than 0.1 ng/ml, preferably not less than 1 ng/ml, and the upper limit may be not more than 10000 ng/ml, preferably not more than 1000 ng/ml. The concentration is, for example, 0.1-10000 ng/ml, 1-10000 ng/ml, 0.1-1000 ng/ml, 1-1000 ng/ml, 30 ng/ml-300 ng/ml, or the like.</p><p id="p-0197" num="0186">When cytokine is used in the expansion culture step, cytokine may be IL-2, IL-7, IL-12, IL-15, IL-18, IL-21 or the like. Only one kind of these may be used or plural kinds (preferably all kinds) thereof may be used. When cytokine is IL-2, the concentration thereof in the medium may be 10 U/ml-1000 U/ml or 0.01 ng/mL-1000000 ng/mL, when cytokine is IL-7, the concentration thereof in the medium may be 0.1 ng/ml-1000 ng/ml, 1 ng/ml-500 ng/ml, 5 ng/ml-100 ng/ml (e.g., 10 ng/ml). The concentration of IL-12 in the medium may be 0.1 ng/ml-1000 ng/ml, 1 ng/ml-500 ng/ml, 5 ng/ml-100 ng/ml (e.g., 50 ng/ml), the concentration of IL-15 in the medium may be 0.1 ng/ml-1000 ng/ml, 1 ng/ml-500 ng/ml, 5 ng/ml-100 ng/ml (e.g., 10 ng/ml), the concentration of IL-18 in the medium may be 0.1 ng/ml-1000 ng/ml, 1 ng/ml-500 ng/ml, 5 ng/ml-100 ng/ml (e.g., 50 ng/ml), and the concentration of IL-21 in the medium may be 0.1 ng/ml-1000 ng/ml, 1 ng/ml-500 ng/ml, 5 ng/ml-100 ng/ml (e.g., 20 ng/ml).</p><p id="p-0198" num="0187">In the expansion culture step, a TNF family cytokine may be contained as cytokine in the medium. Examples of the TNF family cytokine include TNF-&#x3b1;, TNF-&#x3b2;, lymphotoxin a, Fas ligand, TRAIL, TWEAK, TL1A, RANK ligand, OX40 ligand, APRIL, AITRL, BAFF, 4-1BBL and CD40 ligand and the like, and TL1A is preferable. When TL1A is used, the concentration thereof in the medium may be 5 ng/ml-500 ng/ml, preferably 10 ng/ml-300 ng/ml, more preferably 20 ng/ml-200 ng/ml (e.g., 50 ng/ml).</p><p id="p-0199" num="0188">In the expansion culture step, moreover, an apoptosis inhibitor may be further contained in the medium. As the apoptosis inhibitor, a protease inhibitor can be mentioned, for example, caspase inhibitor. As the caspase inhibitor, Pan Caspase FMK inhibitor Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone) (hereinafter sometimes referred to as &#x201c;Z-VAD-FMK&#x201d;) is preferable, and the concentration thereof in the medium may be 1 &#x3bc;M-1000 &#x3bc;M, preferably 1 &#x3bc;M-500 &#x3bc;M, more preferably 1 &#x3bc;M-200 &#x3bc;M, particularly preferably 1 &#x3bc;M-50 &#x3bc;M (e.g., 10 &#x3bc;M).</p><p id="p-0200" num="0189">In the present invention, the obtained T cells may be used after isolation, or may be used as it is (namely, as a cell population possibly containing other cell type). When isolated, isolation can be performed using at least one molecule selected from the group consisting of &#x3b1;TCR, &#x3b2;TCR and CD3 as an index, and the isolation method used may be a method well known to those of ordinary skill in the art. Examples thereof include, but are not limited to, a method using an antibody for &#x3b1;TCR, &#x3b2;TCR and CD3 (bound with magnetic beads and the like as necessary) and isolation by flow cytometry or magnetic cell separation method, a purification method using an affinity column on which a desired antigen is immobilized and the like.</p><p id="p-0201" num="0190">When used as it is, the ratio of the T cells in the cell population may be increased by using a method well known to those of ordinary skill in the art. Examples of the method for increasing the ratio of the T cells in the cell population include, but are not limited to, the methods of Front. Immunol., 5:636 (2014), National Publication of International Patent Application No. 2017-537625, National Publication of International Patent Application No. 2003-529363 and the like.</p><p id="p-0202" num="0191">Therefore, the expansion culture part is provided with a basal medium, a culture container, a sterile space, and preferably a CD3 agonist, and constituted to perform expansion culture of T cells. The device, medium and the like to be provided to the nucleic acid introduction part are appropriately selected according to the property of the device, method of expansion culture, and the like. When a CD3 agonist is used, the culture container and CD30 agonist may be provided on the expansion culture part such that CD30 is immobilized on the culture container. The expansion culture part may be provided with, as necessary, one or more kinds of CD3/TCR complex agonist, fibronectin or a variant thereof, apoptosis inhibitor, medium additive, clean bench, incubator, bioreactor for cell culture, microscope, centrifuge, aspirator, pipette, tube, buffering agent (e.g., acetate buffer, phosphate buffer, citrate buffer, citric acid phosphate buffer, boric acid buffer, tartaric acid buffer, tris buffer, phosphate buffered saline, McIlvaine buffer etc.) and the like, and further provided with other reagents, device and the like according to the kind of the culture method. When cytokine is used as a medium additive, preferable cytokine is, for example, IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, TNF family cytokine or the like.</p><p id="p-0203" num="0192">Specific examples of the above-mentioned basal medium, medium additive, CD3 agonist, CD3/TCR complex agonist, fibronectin or a variant thereof and apoptosis inhibitor to be provided to the expansion culture part are as mentioned above. Specific examples of the culture container include the same one described in 1-4. A T cell product can be produced by filling the expansion cultured T cells in an appropriate storage container (sterile vial, blood transfusion bag, etc.), labeling the container as necessary, and packaging the container.</p><heading id="h-0019" level="2">1-6. Production of Frozen T Cell Product</heading><p id="p-0204" num="0193">The provision system of the present invention may include a step of producing a frozen T cell product from the aforementioned expansion cultured T cells (hereinafter to be also referred to as &#x201c;frozen T cell product production step&#x201d;). In the following, the part constituted to execute the frozen T cell product production step is sometimes referred to as a &#x201c;frozen T cell product production part&#x201d;.</p><p id="p-0205" num="0194">The frozen T cell product production step can be performed by a method similar to 1-2.</p><p id="p-0206" num="0195">Therefore, the frozen T cell product production part may be provided with at least a cryoprotective agent, a cryopreservation container, a freezer and/or a cryoprotective system (e.g., Locator etc.), and constituted to produce a frozen stock of expansion cultured T cells. The frozen stock production part may be provided with, as necessary, one or more kinds of low temperature medium (e.g., liquid nitrogen etc.), pipette, tube, buffering agent (e.g., acetate buffer, phosphate buffer, citrate buffer, citric acid phosphate buffer, boric acid buffer, tartaric acid buffer, tris buffer, phosphate buffered saline, McIlvaine buffer etc.) and the like.</p><p id="p-0207" num="0196">Specific examples of the cryoprotective agent and freezer to be provided to the frozen T cell product production part are as mentioned above. Specific examples of the cryopreservation container include, vial (e.g., glass ampoule, plastic tube etc.) and the like.</p><heading id="h-0020" level="2">1-7. Construction of T Cell Product Collection</heading><p id="p-0208" num="0197">The provision system of the present invention may include a step of constructing a T cell product collection including two or more kinds of T cell products by collecting T cell products (hereinafter to be also referred to as &#x201c;T cell product collection construction step&#x201d;). In the following, the part constituted to execute the T cell product collection construction step is sometimes referred to as a &#x201c;T cell product collection construction part&#x201d;.</p><p id="p-0209" num="0198">The T cell products constituting the T cell product collection may be frozen T cell products. From the aspect of the stability of T cells, a frozen T cell product is preferable for long-term storage.</p><p id="p-0210" num="0199">The T cell product collection construction step can also be performed by a known method. Such method includes construction by producing two or more kinds of T cell products by the above-mentioned method, attaching a label or the like so that the kind of the T cell products can be distinguished, and storing the products. The kind of the collection can also be increased by further adding different kinds of T cell products to the constructed T cell product collection. For easy storage, it is preferable to store in the same space (e.g., in the same freezer, in the same room, in the same building, on the same site, etc.); however, it may be stored in a physically separate space. Any method may be used to distinguish the kind of a T cell product as long as the kind can be distinguished. For example, a label and the like may be attached to the container, or when stored in other freezer or cryoprotective system, a label and the like may be attached to the freezer or cryoprotective system, or management software and the like may be used to distinguish the products and the like.</p><p id="p-0211" num="0200">Therefore, the T cell product collection construction part may be provided with at least T cell products to be collected, and constituted to construct a T cell product collection including two or more kinds of T cell products by collecting T cell products constructed as mentioned above. In addition, the T cell product collection construction part may be provided, as necessary, with one or more kinds of label, freezer, cryoprotective system, management software and the like. Specific examples of the freezer are as described above.</p><heading id="h-0021" level="2">1-8. Identification of Antigen</heading><p id="p-0212" num="0201">The provision system of the present invention may include a step of identifying a tumor-specific antigen or a tumor-associated antigen (hereinafter to be simply referred to as &#x201c;antigen&#x201d;) expressed in a tumor of the test subject (hereinafter to be also referred to as &#x201c;antigen identification step&#x201d;). In the following, the part constituted to execute the antigen identification step is sometimes referred to as an &#x201c;antigen identification part&#x201d;.</p><p id="p-0213" num="0202">The antigen identification step can also be performed by a known method. Examples of the method include collecting a biological sample such as tumor tissue section, body fluid (e.g., blood, serum, plasma etc.) containing tumor cells, and the like from a test subject, extracting mRNA from the sample, synthesizing cDNA from the mRNA as necessary, and identifying the nucleic acid by a nucleic acid amplification method and/or nucleic acid detection method such as digital PCR (e.g., ddPCR), RT-PCR, biochip (e.g., microarray), RNAseq and the like. PCR can be performed using, for example, a primer set capable of amplifying mRNA of a tumor-specific antigen or a tumor-associated antigen, and a PCR device. When RNAseq is used, PCR can be performed using a next-generation sequencer.</p><p id="p-0214" num="0203">Therefore, the antigen identification part may be constituted to be able to identify a tumor-specific antigen or tumor-associated antigen expressed in the tumor of the subject. For example, the antigen identification part is provided with at least the above-mentioned primer set and the PCR device, at least the above-mentioned biochip, or at least the above-mentioned next-generation sequencer.</p><p id="p-0215" num="0204">Examples of the above-mentioned next generation sequencer include, but are not limited to, the device manufactured by illumina (e.g., MiSeq, HiSeq2500), the device manufactured by Thermo Fisher Scientific (e.g., Ion Proton, Ion PGM), the device manufactured by Roche Diagnostic (e.g., GS FLX+, GS Junior) and the like.</p><heading id="h-0022" level="2">1-9. Selection of T Cell Product</heading><p id="p-0216" num="0205">In the provision system of the present invention, information of the test subject is obtained, and an appropriate T cell product can be selected based on the information. Therefore, the provision system of the present invention may include a step of obtaining test subject information and/or a step of selecting a T cell product suitable for the test subject. In the following, the part constituted to execute the test subject information obtaining step is sometimes referred to as a &#x201c;test subject information obtaining part&#x201d;.</p><p id="p-0217" num="0206">The information of the test subject is not particularly limited and includes, for example, genetic information (e.g., HLA gene-related information, abnormal gene information, etc.) of the test subject, diagnosis result, history, drug administration history, age, gender, blood type, height, body weight, and when the test subject has a tumor, information of tumor-specific or tumor-associated antigen expressed in the tumor.</p><p id="p-0218" num="0207">One embodiment of the present invention may include a step of selecting a T cell product expressing a CAR or an exogenous TCR that recognizes and binds to the antigen identified from the information of the test subject from a T cell product collection containing two or more kinds of T cell products (hereinafter to be also referred to as &#x201c;T cell product selection step&#x201d;). In the following, the part constituted to execute the T cell product selection step is sometimes referred to as a &#x201c;T cell product selection part&#x201d;. The T cell product in the T cell product selection step may be a frozen T cell product. From the aspect of the stability of T cells, a frozen T cell product is preferable.</p><p id="p-0219" num="0208">The step of selecting a T cell product expressing a CAR or an exogenous TCR that recognizes and binds to the identified antigen from a T cell product collection containing T cell products is encompassed in concept in the step of selecting a T cell product suitable for the test subject based on the obtained information of the test subject. The test subject information obtaining part includes an antigen identification part. In one embodiment of the present invention, the T cell product selection step can select a cell bank of T cell containing T cells that express appropriate CAR, exogenous TCR, cytokine, chemokine, and the like, based on, for example, the content of the production plan of the T cell product to be provided.</p><p id="p-0220" num="0209">T cell product selection step can be performed by a known method. The method includes selecting, based on the material (paper medium or electronic data medium) showing the identification results by the above-mentioned antigen identification step, a T cell product containing T cells that express a CAR or an exogenous TCR that recognize and bind to the identified antigen from a list of T cell products prepared in advance. When multiple kinds of tumor-specific antigens or tumor-associated antigens are expressed in the antigen identification step, a T cell product containing T cells can be selected based on the evaluation criteria such as one having the highest expression level or one expected to be most effective with the T cell product. Only one kind of T cell product may be selected, or two or more kinds may be selected. These steps may use software designed for the selection of the above-mentioned T cell product. T cell product can be selected according to instructions (prescription, etc.) from a doctor or medical institution.</p><p id="p-0221" num="0210">Therefore, the T cell product selection part is provided with at least a material showing the identification results in the antigen identification step, and may be constituted to select a T cell product expressing a CAR or an exogenous TCR that recognizes and binds to the identified antigen from a T cell product collection containing T cell products. The T cell product selection part may be provided, as necessary, with one or more kinds of a list of T cell products, the above-mentioned software designed for selection of the T cell product and the like.</p><p id="p-0222" num="0211">The construction part of a cell bank of T cell, construction part of a cell bank collection of T cell (described later), cell bank of T cell selection part (described later), frozen T cell product production part, T cell product collection construction part and T cell product selection part manage information relating to T cells constituting the cell bank of T cell and T cell product (hereinafter to be referred to as &#x201c;T cell-related information&#x201d;). The T cell-related information includes production records, property analysis results, quality evaluation results, storage temperature control records, production plans, and the like relating to the T cells. When the T cell is an iPS cell-derived T cell, the production records, property analysis results, quality evaluation results, storage temperature records, specific gene information, and the like relating to the iPS cell are included. When the T cell is a T cell into which a nucleic acid encoding an exogenous gene has been introduced, information on the exogenous gene (e.g., kind of protein and cytokine encoded by the exogenous gene, etc.) and the like are included. In the cell bank of T cell selection part and T cell product selection part, a cell bank of T cell and a T cell product are each selected based on the contents of the production plan of the T cell product to be provided. In the cell bank of T cell selection part and T cell product selection part, a cell bank of T cell and a T cell product may be appropriately selected based on the information of the test subject obtained in the test subject information obtaining part. Therefore, the cell bank of T cell selection part and the T cell product selection part can be used even when only one kind of cell bank of T cell and/or T cell product is involved.</p><p id="p-0223" num="0212">One aspect of the present invention is described by reference to <figref idref="DRAWINGS">FIG. <b>16</b></figref>. In the present specification and the drawings, the constituent elements having substantially the same functional constituent are designated by the same symbols to omit duplicate description.</p><p id="p-0224" num="0213">As shown in <figref idref="DRAWINGS">FIG. <b>16</b></figref>, the T cell product provide system <b>100</b> prepares T cells from a cell bank of T cell <b>102</b> to provide a T cell product <b>131</b>. The cell bank of T cell <b>102</b> may be constructed by the cell bank of T cell construction part <b>101</b>. When two or more kinds of cell banks of T cell are constructed, they may be collected by the cell bank collection of T cell-construction part <b>111</b> to construct the cell bank collection of T cell <b>112</b>.</p><p id="p-0225" num="0214">The prepared T cells may be introduced with a desired exogenous gene into the nucleic acid introduction part <b>103</b> as necessary. Further, the T cells may be expansion cultured in the expansion culture part <b>104</b> if necessary. Further, the T cells may be frozen in the frozen T cell product production part <b>105</b> to provide a frozen T cell product <b>106</b> if necessary. When two or more kinds of frozen T cell products are produced, they may be collected by the T cell product collection construction part <b>121</b> to construct a T cell product collection <b>122</b>.</p><p id="p-0226" num="0215">In the cell bank of T cell selection part <b>154</b> and the T cell product selection part <b>155</b>, an appropriate cell bank of T cell and T cell product can be selected as the T cell product <b>131</b> to be provided based on the T cell-related information <b>171</b>. Such T cell-related information is managed by the cell bank of T cell construction part <b>101</b>, the cell bank collection of T cell-construction part <b>111</b>, the cell bank of T cell selection part <b>154</b>, the T cell product collection construction part <b>121</b>, and the T cell product selection part <b>155</b>.</p><p id="p-0227" num="0216">Furthermore, to provide a T cell product more suitable for the treatment and/or prevention of the subject, the test subject information <b>151</b> is obtained by the test subject information obtaining part <b>152</b>, and an appropriate T cell product <b>131</b> can be selected by the T cell product selection part <b>155</b> based on the information of the test subject. The T cell product <b>131</b> is the same as the T cell product <b>106</b> when the T cell product is one kind, and one or more kinds of T cell products contained in the T cell product collection <b>122</b> when selected from the T cell product collection <b>122</b>. The test subject information obtaining part may include an antigen identification part <b>153</b>. An appropriate cell bank of T cell <b>161</b> may be selected by the cell bank of T cell selection part <b>154</b> based on the information obtained in the test subject information obtaining part <b>152</b>. The cell bank of T cell <b>161</b> is the same as the cell bank of T cell <b>102</b> when the cell bank of T cell is one kind, and when selected from the cell bank collection of T cell <b>112</b>, the cell bank of T cell <b>161</b> may be one or more kinds included in the cell bank collection of T cell <b>112</b>. T cells can be prepared from the cell bank of T cell <b>161</b> and the T cell product can be provided in the same manner as described above.</p><p id="p-0228" num="0217">Next, the constitution of hardware that can be included in the test subject information obtaining part, the cell bank of T cell construction part, the cell bank of T cell selection part and/or the T cell product selection part is described. Since the cell bank of T cell selection part and the T cell product selection part have the same hardware constitution, the hardware constitution that can be included in the T cell product selection part is described here.</p><p id="p-0229" num="0218"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows one embodiment of a hardware constitution that can be included in the T cell product selection part <b>200</b>. As shown in <figref idref="DRAWINGS">FIG. <b>17</b></figref>, the T cell product selection part <b>200</b> includes processor <b>201</b>, memory <b>202</b>, auxiliary storage device <b>203</b>, I/F (Interface) device <b>204</b>, communication device <b>205</b>, and drive device <b>206</b>. The hardware of the T cell product selection part <b>200</b> are connected to each other via bus <b>207</b>.</p><p id="p-0230" num="0219">The processor <b>201</b> has various arithmetic units such as CPU (Central Processing Unit) and GPU (Graphics Processing Unit). The processor <b>201</b> reads and executes programs such as various software installed in the auxiliary storage device <b>203</b> on the memory <b>202</b>.</p><p id="p-0231" num="0220">The memory <b>202</b> has a main storage device such as ROM (Read Only Memory) and RAM (Random Access Memory). The processor <b>201</b> and memory <b>202</b> form a computer, and the processor <b>201</b> realizes various functions by executing programs such as various software read on the memory <b>202</b>.</p><p id="p-0232" num="0221">The auxiliary storage device <b>203</b> stores programs such as various software, various information (e.g., T cell-related information, test subject information, etc.) and data used when the programs such as various software are executed by the processor <b>201</b>.</p><p id="p-0233" num="0222">The I/F device <b>204</b> is a connection device that connects an operation device <b>210</b> and a display device <b>211</b> to the T cell product selection part <b>200</b>. The I/F device <b>204</b> receives various instructions to the T cell product selection part <b>200</b> via the operating device <b>210</b>. In addition, the I/F device <b>204</b> outputs the processing result by the T cell product selection part <b>200</b> via the display device <b>211</b>.</p><p id="p-0234" num="0223">The communication device <b>205</b> is a communication device for communicating with other device via the network.</p><p id="p-0235" num="0224">The drive device <b>206</b> is a device for setting the recording medium <b>212</b>. The recording medium <b>212</b> here includes a medium such as CD-ROM, flexible disk, magneto-optical disk, or the like that optically, electrically, or magnetically records information. In addition, the recording medium <b>212</b> may include a semiconductor memory or the like for electrically recording information such as ROM or flash memory.</p><p id="p-0236" num="0225">The programs such as various software to be installed in the auxiliary storage device <b>203</b> are installed by, for example, setting the distributed recording medium <b>212</b> in the drive device <b>206</b>, and reading the programs such as various software recorded in the recording medium <b>212</b> by the drive device <b>206</b>. Alternatively, programs such as various software installed in the auxiliary storage device <b>203</b> may be installed by being downloaded from the network via the communication device <b>205</b>.</p><heading id="h-0023" level="2">1-10. Use of T Cell Product</heading><p id="p-0237" num="0226">The T cell product provided by the provision system of the present invention may exhibit cytotoxic activity against cancer cell, cancer stem cell, tumor cell and the like, and can therefore be used for the prevention or treatment of cancer or tumor and can be administered to the test subject. In the present specification, the test subject means a mammal (e.g., mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human) to which a T cell product is administered in a clinical trial or the like. The test subject is preferably human.</p><p id="p-0238" num="0227">Cancers and tumors that are prevented or treated by the above-mentioned T cell products are described, for example, in &#x201c;Daniel Baumhoer et al., Am J. Clin Pathol, 2008, 129, 899-906&#x201d; and the like. Specific examples thereof include, but are not limited to, liver cancer (e.g., hepatoma), ovarian cancer (e.g., ovary clear cell adenocarcinoma), childhood cancer, lung cancer (e.g., squamous cell carcinoma, small cell lung cancer), testis cancer (e.g., nonseminomas germ cell tumor), soft tissue tumor (e.g., liposarcoma, malignant fibrous histiocytoma), uterine cancer (e.g., cervix intraepithelial tumor, cervix squamous cell carcinoma), melanoma, adrenal gland tumor (e.g., adrenal gland adenoma), neurotic tumor (e.g., schwannoma), gastric cancer (e.g., adenocarcinoma of stomach), renal cancer (e.g., Grawitz tumor), breast cancer (e.g., invasive lobular carcinoma, mucous cancer), thyroid cancer (e.g., medullar cancer), laryngeal cancer (e.g., squamous cell carcinoma), urinary bladder cancer (e.g., invasive transitional cell carcinoma) and the like.</p><p id="p-0239" num="0228">The T cells to be contained in the above-mentioned T cell product may be cultured and/or stimulated using an appropriate medium and/or a stimulating molecule before administration to a test subject. Examples of the stimulating molecule include, but are not limited to, cytokines, suitable protein, other components and the like. Examples of the cytokines include IL-2, IL-7, IL-12, IL-15, IFN-&#x3b3; and the like, and IL-2 can be preferably used. While the concentration of IL-2 in the medium is not particularly limited, for example, it is preferably 0.01-1&#xd7;10<sup>5 </sup>U/mL, more preferably 1-1&#xd7;10<sup>4 </sup>U/mL. Examples of the suitable protein include CD3 ligand, CD28 ligand, anti-CD3 antibody, anti-CD30 antibody, and anti-IL-4 antibody. Besides these, a lymphocyte stimulating factor such as lectin and the like can also be added. Furthermore, serum or plasma may be added to the medium. While the amount of addition to these media is not particularly limited, 0% by volume-20% by volume can be mentioned. In addition, the amount of serum or plasma to be used can be changed according to the culturing stage. For example, serum or plasma concentration can be reduced stepwise. The origin of serum or plasma may be either autologous or allogeneic, and autologous one is preferable from the aspect of safety.</p><p id="p-0240" num="0229">The above-mentioned T cells are preferably used by parenteral administration to the test subject. Examples of the method for parenteral administration include intravenous, intraarterial, intramuscular, intraperitoneal, and subcutaneous administration and the like. While the dose is appropriately selected according to the condition, body weight, age and the like of the test subject, the medicament is generally administered such that the cell number is generally 1&#xd7;10<sup>6</sup>-1&#xd7;10<sup>10 </sup>cells, preferably 1&#xd7;10<sup>7</sup>-1&#xd7;10<sup>9 </sup>cells, more preferably 5&#xd7;10<sup>7</sup>-5&#xd7;10<sup>9 </sup>cells, per dose to a test subject with body weight 60 kg. The T cells may be administered once or in plural portions.</p><p id="p-0241" num="0000">2. Construction Method of Master Cell Bank of T Cell and/or Working Cell Bank of T Cell</p><p id="p-0242" num="0230">The present invention also provides a method for constructing the above-mentioned master cell bank of T cell and/or working cell bank of T cell (hereinafter sometimes referred to as &#x201c;the cell bank construction method of the present invention&#x201d;). In one embodiment of the present invention, when the above-mentioned exogenous gene is CAR gene, the cell bank construction method of the present invention includes (I) a process of differentiating an induced pluripotent stem cell free of a chimeric antigen receptor (CAR) gene into a T cell for CAR-T therapy, (II) a process of stocking the differentiated T cells, and (III) a process of characterisation of the differentiated T cells. While the above-mentioned processes (II) and (III) are generally performed in this order, process (II) may be performed after process (III). In another embodiment, when the above-mentioned exogenous gene is TCR gene, the cell bank construction method of the present invention includes (i) a process of differentiating an induced pluripotent stem cell free of a TCR gene into a T cell for TCR-T therapy, (ii) a process of stocking the differentiated T cells, and (iii) a process of characterisation of the differentiated T cells. While the above-mentioned processes (ii) and (iii) are generally performed in this order, process (ii) may be performed after process (iii). Each of the above-mentioned processes may be performed by the same entity or different entities.</p><p id="p-0243" num="0231">In another embodiment of the present invention, a master cell bank of T cell and/or a working cell bank of T cell constructed by the cell bank construction method of the present invention (hereinafter sometimes referred to as &#x201c;the cell bank of T cell of the present invention&#x201d;) is provided.</p><p id="p-0244" num="0000">2-1. Differentiation Induction of Induced Pluripotent Stem Cell Free of CAR Gene or Exogenous TCR Gene into T Cell</p><p id="p-0245" num="0232">The processes (I) and (i) of the above-mentioned 2. can be performed using induced pluripotent stem cell free of CAR gene and/or exogenous TCR gene and according to the method described in processes (1) and (2) of the above-mentioned 1-1. For CAR-T therapy in process (I) means use for the treatment or prophylaxis with CAR expressed in T cells, and excludes treatment or prophylaxis with exogenous TCR and endogenous TCR expressed in T cells. The T cell may contain an exogenous TCR gene introduced for purposes other than therapeutic or preventive purposes, for example, the purpose of suppressing the expression of endogenous TCR gene and for the purpose of efficiently producing uniform T cells, described in the above-mentioned 1-1. Similarly, for TCR-T therapy in process (i) means use for the treatment or prophylaxis with exogenous TCR expressed in T cells, and excludes treatment or prophylaxis with exogenous CAR and endogenous TCR expressed in T cells. The T cell may contain an exogenous TCR gene introduced for purposes other than therapeutic or preventive purposes, for example, the purpose of suppressing the expression of endogenous TCR gene and the like, described in the above-mentioned 1-1.</p><p id="p-0246" num="0233">The description of CAR and TCR in the above-mentioned processes (I) and (i), specific examples of the antigen targeted by TCR and CAR, definition of each term such as T cell and the like, and the like are as described in the above-mentioned 1. and 1-1. Specific examples of the T cell obtained by differentiation induction in the above-mentioned process are as described in the above-mentioned 1. The T cell is preferably cytotoxic T cell, more preferably CD84-positive cytotoxic T cell that expresses CD8&#x3b1;&#x3b2;.</p><heading id="h-0024" level="2">2-2. Stock of Differentiated T Cells</heading><p id="p-0247" num="0234">The processes (III) and (iii) in the above-mentioned 2. can be performed using T cells obtained in the above-mentioned 2-1., and according to the method described in the above-mentioned 1-1. and 1-2.</p><p id="p-0248" num="0235">The induced pluripotent stem cells to be used for the cell bank construction method of the present invention and the cell bank of T cell of the present invention can be established by the method described in the above-mentioned 1-1. The T cell to be used for the aforementioned induced pluripotent stem cell or the processes (II) and (ii) of the above-mentioned 2. is preferably a T cell showing a suppressed expression of at least one kind of HLA gene as in the cell described in the above-mentioned 1-1. Specific HLA gene and combination, the definition of suppression of the gene expression and a suppression method, and the like are as described in the above-mentioned 1-1.</p><heading id="h-0025" level="2">2-3. Characterisation of T Cell</heading><p id="p-0249" num="0236">The test items for characterisation in processes (III) and (iii) in the above-mentioned 2. vary depending on the biological properties (e.g., auxotrophy), culture history, and test feasibility of the cells to be the subject of the cell bank, and are appropriately determined by those of ordinary skill in the art, or based on the content of discussions between those of ordinary skill in the art and regulatory authorities, and the like. Information relating to the construction method thereof and the results of characterisation and quality evaluation are presented to the pharmaceutical authorities when applying for the manufacturing and marketing approval in each country. The characterisation of a cell bank of T cell mainly evaluates the absence of contamination with an exogenous infectious factor. In particular, since contamination with exogenous virus can lead to serious consequences in clinical use, it is thoroughly evaluated according to ICH Q5A(R1). Other tests include identity test to detect cross contamination with other cell line. In addition, karyotype analysis and tumorigenicity test may also be performed.</p><p id="p-0250" num="0237">The test items of quality evaluation include confirmation test using appropriate cell phenotype as T cell, purity test, production process-derived impurity test, and quantitative tests such as cell number, cell survival rate and the like.</p><heading id="h-0026" level="2">2-4. Construction of Cell Bank Collection of T Cell</heading><p id="p-0251" num="0238">The provision system of the present invention may include a step of constructing a master cell bank collection of T cell and/or a working cell bank collection of T cell containing two or more kinds of master cell banks of T cell and/or working cell banks of T cell (hereinafter to be also referred to as &#x201c;a cell bank collection of T cell&#x201d;) by collecting master cell banks of T cell and/or a working cell banks of T cell (hereinafter to be also referred to as &#x201c;a cell bank collection of T cell construction step&#x201d;). In the present specification, the part constituted to execute the cell bank collection of T cell construction step is sometimes referred to as a &#x201c;cell bank collection of T cell construction part&#x201d;.</p><p id="p-0252" num="0239">When a cell bank of T cell that is used for providing one or more T cell products may not be sufficient, or when it is appropriate to use a T cell product from a different type of cell bank of T cell depending on the characteristics of the test subject of administration, a separately-constructed cell bank of T cell can be added to an existing cell bank of T cell. By constructing a cell bank collection of T cell by collecting from plural cell banks of T cell, a more stable and robust T cell product provision system can be provided.</p><p id="p-0253" num="0240">The cell bank collection of T cell construction step can also be performed by a known method. Such method includes construction by producing two or more kinds of the cell banks of T cell by the above-mentioned cell bank construction method of the present invention, attaching a label or the like so that the kind of the cell bank of T cell can be distinguished, and storing the products. The kind of the collection can also be increased by further adding a different kind of a cell bank of T cell to the constructed cell bank of T cell. For easy storage, it is preferable to store in the same space (e.g., in the same freezer, in the same room, in the same building, on the same site, etc.); however, it may be stored in a physically separate space. Any method may be used to distinguish the kind of a cell bank of T cell as long as the kind can be distinguished. For example, a label and the like may be attached to the cryopreservation container, or when stored in other freezer or cryoprotective system, a label and the like may be attached to the freezer or cryoprotective system, or management software and the like may be used to distinguish the products and the like.</p><p id="p-0254" num="0241">Therefore, the cell bank collection of T cell-construction part may be provided with at least cell bank of T cell to be collected, and constituted to construct a cell bank collection of T cell including two or more kinds of cell banks of T cell by collecting cell banks of T cell constructed as mentioned above. In addition, the cell bank collection of T cell-construction part may be provided, as necessary, with one or more kinds of label, freezer, cryoprotective system, management software and the like. Specific examples of the freezer are as described above. The construction of a cell bank collection of T cell may be performed by the same entity as the entity constructing a cell bank of T cell or different entities. The cell bank collection of T cell may contain a cell bank of T cell constructed by a different entity.</p><heading id="h-0027" level="2">2-4-1. Selection of Cell Bank of T Cell</heading><p id="p-0255" num="0242">The provision system of the present invention may include a step of selecting a cell bank of T cell for producing a T cell product to be provided from a cell bank collection of T cell containing cell banks of T cell (hereinafter to be also referred to as &#x201c;a cell bank of T cell selection step&#x201d;). In the present specification, the part constituted to execute the selection step of a cell bank of T cell is sometimes referred to as a &#x201c;cell bank of T cell selection part&#x201d;.</p><p id="p-0256" num="0243">The selection step of the cell bank of T cell can be performed by a known method. According to the method, a cell bank of T cell which contains T cell that expresses an appropriate T cell receptor can be selected based on the contents of the production plan of the T cell product to be provided.</p><p id="p-0257" num="0244">In one embodiment of the present invention, information of the test subject is obtained, and an appropriate cell bank of T cell can be selected based on the information. Therefore, the provision system of the present invention may include a step of obtaining information of the test subject (hereinafter to be also referred to as &#x201c;test subject information obtaining step&#x201d;) and/or a step of selecting a cell bank of T cell suitable for the test subject. In the following, the part constituted to execute the test subject information obtaining step is sometimes referred to as a &#x201c;test subject information obtaining part&#x201d;.</p><p id="p-0258" num="0245">The information of the test subject is not particularly limited and includes, for example, genetic information (e.g., HLA gene-related information, abnormal gene information, etc.), diagnosis result, history, drug administration history, age, gender, blood type, height, body weight, and when the test subject has a tumor, information of tumor-specific or tumor-associated antigen expressed in the tumor, of the test subject.</p><heading id="h-0028" level="2">3. Method for Producing T Cell Product</heading><p id="p-0259" num="0246">In another embodiment, the present invention provides a method for producing a T cell product (hereinafter sometimes referred to as &#x201c;the production method of T cell product of the present invention&#x201d;). The method includes (A) a process of preparing a T cell from the cell bank of T cell of the present invention, (B) a process of introducing CAR gene or exogenous TCR gene into the prepared T cell, and (C) a process of expansion culturing the T cell into which the CAR gene or exogenous TCR gene has been introduced. The production method of a T cell product of the present invention may further include (D) a process of freezing the expansion cultured T cells. In addition, a T cell product produced by the production method of a T cell product of the present invention (hereinafter sometimes referred to as &#x201c;the T cell product of the present invention&#x201d;) is also provided. Each of the above-mentioned processes may be performed by the same entity or by different entities.</p><heading id="h-0029" level="2">3-1. Preparation of T Cell</heading><p id="p-0260" num="0247">Process (A) of the above-mentioned 3. can be performed using the cell bank of T cell of the present invention and according to the method described in the above-mentioned 1-3.</p><heading id="h-0030" level="2">3-2. Introduction of Nucleic Acid</heading><p id="p-0261" num="0248">The process (B) of the above-mentioned 3. can be performed using the T cells prepared by the method of the above-mentioned 3-1. and according to the method described in the above-mentioned 1-4. T cells used in process (B) preferably express IL-15/IL-15R&#x3b1;. The kind of the nucleic acid, explanations on CAR, TCR and IL-15/IL-15R&#x3b1;, definition of each term, specific examples of the antigen targeted by TCR and CAR, and the like are as described in the above-mentioned 1-1. Thus, in one embodiment, T cells contained in the production method of the frozen stock of the present invention, or T cells contained in the T cell frozen stock of the present invention may be characterized in that the aforementioned CAR or exogenous TCR recognizes and binds to tumor-specific antigen or tumor-associated antigen of the above-mentioned 1-1.</p><heading id="h-0031" level="2">3-3. Expansion Culture</heading><p id="p-0262" num="0249">The process (C) of the above-mentioned 3. can be performed using the T cells into which a nucleic acid has been introduced by the method of the above-mentioned 3-2. and according to the method described in the above-mentioned 1-5. The method of expansion culture, specific examples of the compound used in the expansion culture, concentration of the compound in the medium, definition of each term and the like are as described in the above-mentioned 1-5. In one embodiment, therefore, the production method of the frozen stock of the present invention may include a process of culturing the aforementioned T cells in the presence of a CD30 agonist.</p><heading id="h-0032" level="2">3-4. Freezing of T Cell</heading><p id="p-0263" num="0250">The process (D) of the above-mentioned 3. can be performed using the T cells expansion cultured by the method the above-mentioned 3-3. and according to the method described in the above-mentioned 1-2.</p><heading id="h-0033" level="2">4. Construction Method of T Cell Product Collection</heading><p id="p-0264" num="0251">In another embodiment, the present invention provides a method for constructing a T cell product collection containing two or more kinds of T cell products (hereinafter sometimes referred to as &#x201c;construction method of T cell product collection of the present invention&#x201d;), and the method may include a process of collecting the T cell product of the present invention. In addition, a T cell product collection constructed by the construction method of the T cell product collection of the present invention (hereinafter sometimes referred to as &#x201c;the T cell product collection of the present invention&#x201d;) is also provided. The T cell product constituting the T cell product collection of the present invention may be a frozen T cell product. From the aspect of the stability of T cells, a frozen T cell product is preferable.</p><p id="p-0265" num="0252">The process of collecting the T cell product of the present invention can be performed using the T cell product of the present invention and according to the method described in the above-mentioned 1-7. The T cell product contained in the T cell product collection may be produced by the same entity as the entity that constructs the T cell product collection, or produced by a different entity. Therefore, the T cell product collection may contain a T cell product produced by a different entity.</p><heading id="h-0034" level="2">5. Production Method of T Cell Product</heading><p id="p-0266" num="0253">The present invention also provides a method for producing a T cell product (hereinafter sometimes referred to as &#x201c;the production method of the T cell product of the present invention&#x201d;), and the method may include a process of constructing a master cell bank of T cell and/or a working cell bank of T cell.</p><p id="p-0267" num="0254">Specific examples of T cell, T cell product, master cell bank, working cell bank and the like and the definition of the terms are as described in the above-mentioned 1-1. In addition, the above-mentioned pluripotent stem cell, T cell, T cell product, master cell bank and working cell bank can be produced and constructed by, for example, the method described in the above-mentioned 1. and 2., and the like. The production method of the T cell product of the present invention may include (a) a process of differentiating pluripotent stem cell into T cell, (b) a process of stocking the differentiated T cell, (c) a process of characterisation of the differentiated T cell, (d) a process of preparing T cell from the cell stock, (e) a process of introducing a nucleic acid containing the exogenous gene into a T cell, and/or (f) a process of expansion culturing a T cell. In addition, the T cell to be used in the production method of the T cell product of the present invention may be a T cell in which the expression of at least one kind of HLA gene is suppressed. Specific HLA gene and combination, the definition of suppression of the gene expression and a suppression method and the like are as described in the above-mentioned 1-1. Each of the above-mentioned processes may be performed by the same entity or by different entities.</p><p id="p-0268" num="0255">The process (a) of the above-mentioned 5. can be performed using the pluripotent stem cell described in the above-mentioned 1-1. and according to the method described in the processes (1) and (2) of the above-mentioned 1-1. The above-mentioned pluripotent stem cell is preferably an induced pluripotent stem cell, more preferably a human induced pluripotent stem cell. The induced pluripotent stem cells to be used for the cell bank construction method of the present invention and the cell bank of T cell of the present invention can be established by the method described in the above-mentioned 1-1. The process (b) of the above-mentioned 5. can be performed using the T cells differentiated in the above-mentioned process (1) and according to the method described in the above-mentioned 1-1. and 1-2. The process (c) of the above-mentioned 5. can be performed using the T cells differentiated by the above-mentioned process (1) and according to the method described in the above-mentioned 2-2. The above-mentioned process (d) can be performed using the cell stock produced in the above-mentioned process (c) and according to the method described in the above-mentioned 1-3.</p><p id="p-0269" num="0256">The process (e) of the above-mentioned 5. can be performed using the T cells differentiated by the aforementioned process (a), the cells stocked in the aforementioned process (b), the T cells subjected to the property analysis in the aforementioned process (c), or T cells prepared by the aforementioned process (d) and according to the method described in the above-mentioned 1-4. T cells used in process (e) preferably express IL-15/IL-15R&#x3b1;. The kind of the nucleic acid, explanations on CAR, TCR and IL-15/IL-15R&#x3b1;, definition of each term, specific examples of the antigen targeted by TCR and CAR, and the like are as described in the above-mentioned 1-1. Thus, in one embodiment, T cells contained in the production method of the frozen stock of the present invention, or T cells contained in the T cell frozen stock of the present invention may be characterized in that the aforementioned CAR or exogenous TCR recognizes and binds to tumor-specific antigen or tumor-associated antigen of the above-mentioned 1-1.</p><p id="p-0270" num="0257">The process (f) of the above-mentioned 5. can be performed using the T cells into which a nucleic acid has been introduced by the aforementioned process (e) and according to the method described in the above-mentioned 1-5. The method of expansion culture, specific examples of the compound used in the expansion culture, concentration of the compound in the medium, definition of each term and the like are as described in the above-mentioned 1-5. In one embodiment, therefore, the production method of the T cell product of the present invention may include a process of stimulating a T cell by culturing the cell in the presence of a CD30 agonist.</p><heading id="h-0035" level="2">6. Provision Method of T Cell Product</heading><p id="p-0271" num="0258">Furthermore, the present invention provides a method for providing a T cell product suitable for a test subject (hereinafter sometimes referred to as &#x201c;the provision method of the present invention&#x201d;). To provide a T cell product suitable for a test subject, information of the test subject is obtained and an appropriate cell bank of T cell and/or an appropriate T cell product can be selected based on the information. Therefore, the provision method of the present invention includes (p) a process of obtaining information of a test subject, and (q) a process of selecting an appropriate cell bank of T cell and/or an appropriate T cell product based on the obtained information of the test subject. Using the selected cell bank of T cell, process (e) and/or process (f) in the above-mentioned 5. are/is performed to produce a T cell product and the T cell product can be provided to the test subject. According to the provision method of the present invention, when a test subject has a tumor, information relating to a tumor-specific antigen or tumor-associated antigen expressed in the tumor is obtained, and an appropriate T cell product can be selected based thereon. Therefore, the provision method of the present invention includes (x) a process of identifying a tumor-specific antigen or a tumor-associated antigen expressed in the tumor of a test subject, and (y) a process of selecting a T cell product that expresses a CAR or an exogenous TCR that recognizes and binds to the identified antigen from the T cell product collection of the present invention. The (x) a process of identifying a tumor-specific antigen or a tumor-associated antigen expressed in the tumor of a test subject, and (y) a process of selecting a T cell product that expresses a CAR or an exogenous TCR that recognizes and binds to the identified antigen from the T cell product collection of the present invention are conceptually encompassed in (p) a process of obtaining information of a test subject, and (q) a process of selecting an appropriate T cell product based on the obtained information of the test subject. The kind and definition of the terms such as T cell, T cell product, test subject and the like are as described in the above-mentioned 1-1. to 1-10. Each of the above-mentioned processes may be performed by the same entity or by different entities.</p><p id="p-0272" num="0259">The process (x) of the above-mentioned 6. can be performed using the biological sample of the test subject and according to the method described in the above-mentioned 1-8. Specific examples of the biological sample of the test subject are as described in the above-mentioned 1-8.</p><p id="p-0273" num="0260">The process (y) of the above-mentioned 6. can be performed based on the identification results of the aforementioned process (x) and according to the method described in the above-mentioned 1-9. The explanation and definition of CAR and TCR, specific examples of tumor-specific antigen and tumor-associated antigen, specific examples of the evaluation criteria and the like are as described in the above-mentioned 1-1. and 1-9.</p><p id="p-0274" num="0261">Specific examples of the cancer and tumor to be prevented or treated with a T cell product provided by the provision method of the present invention are as described in the above-mentioned 1-10. In addition, the culture and/or stimulation method of T cells contained in the above-mentioned T cell product, administration route, dose, the type of test subject and the like are also as described in the above-mentioned 1-1-10.</p><p id="p-0275" num="0262">The present invention is more specifically explained by the following Examples. The scope of the present invention is not limited by the Examples.</p><heading id="h-0036" level="1">EXAMPLE</heading><heading id="h-0037" level="1">Example 1</heading><heading id="h-0038" level="2">1. Preparation of iPS Cell</heading><p id="p-0276" num="0263">As the iPS cell, iPS cells (Ff-I01s04 strain: derived from peripheral blood mononuclear cell of healthy individual) provided by the Center for iPS Cell Research and Application (CiRA), Kyoto University, was used. iPS cell culture was performed according to the protocol distributed by CiRA, &#x201c;Human iPS cell culture under feeder-free conditions&#x201d;.</p><p id="p-0277" num="0000">2. Introduction of T Cell Receptor (TCR) Gene into iPS Cell</p><heading id="h-0039" level="2">2-1. Introduction of WT1-TCR Gene</heading><p id="p-0278" num="0264">A gene in which TAK1-derived TRB gene and TRA gene encoding HLA-A*24:02-restricted WT1 specific TCR supplied by Professor Masataka Yasukawa, Graduate School of Medicine, Ehime University, are linked by a P2A sequence (WT1-TCR) was introduced into iPS cells. Gene transfer into iPS cells was performed by incorporation into CS-UbC-RfA-IRES2-hK01 lentivirus vector supplied by Inst. of Physical and Chemical Research and infecting the iPS cells. In the following, iPS cells into which the WT1-TCR gene has been introduced are sometimes referred to as &#x201c;WT1&#x3b1;&#x3b2;-iPSC&#x201d;.</p><heading id="h-0040" level="2">2-2. Introduction of V&#x3b3;9V&#x3b4;2-TCR Gene</heading><p id="p-0279" num="0265">A gene (V&#x3b3;9V&#x3b4;2TCR G115) in which the TRG gene and TRD gene encoding G115 &#x3b3;&#x3b4; T cell clone-derived V&#x3b3;9V&#x3b4;2 T cell receptor were linked by a P2A sequence was introduced into iPS cells. V&#x3b3;9V&#x3b4;2TCR G115 is an artificially-synthesized oligo DNA encoding a polypeptide (SEQ ID NO: 1) designed to align in the order shown in Table 1 from the N-terminal.</p><p id="p-0280" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 1</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry/><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>1</entry><entry>(G115derived from) TRG</entry><entry>315</entry></row><row><entry/><entry>2</entry><entry>P2A</entry><entry>22</entry></row><row><entry/><entry>3</entry><entry>(G115derived from) TRD</entry><entry>292</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0281" num="0266">A sequence encoding neomycin resistance gene was removed from pLVSIN-CMV Neo (Clontech), and a lentiviral vector using pLVSIN-Ub in which CMV promoter was replaced with human ubiquitin promoter was prepared. An artificial oligo DNA encoding V&#x3b3;9V&#x3b4;2TCR G115 synthesized above was incorporated into the multicloning site of pLVSIN-Ub lentivirus vector. Using the plasmid and Lenti-X&#x2122; 293 T cell line (Clontech) and Lenti-X&#x2122; Packaging Single Shots (VSV-G), a lentiviral vector was prepared. The prepared lentivirus vector was used to infect the iPS cells prepared in [Example 1], 1, whereby the V&#x3b3;9V&#x3b4;2-TCR gene was introduced into the iPS cells. In the following, iPS cells into which the V&#x3b3;9V&#x3b4;2TCR G115 gene has been introduced are sometimes referred to as &#x201c;V&#x3b3;9V&#x3b4;2-iPSC&#x201d;.</p><heading id="h-0041" level="1">Example 2</heading><p id="p-0282" num="0267">1. Differentiation of iPS Cell into Hematopoietic Progenitor Cell (HPC)</p><p id="p-0283" num="0268">For differentiation of iPS cell into hematopoietic progenitor cell (HPC), a suspended cell population differentiated according to a known method (e.g., methods described in Cell Reports 2(2012)1722-1735 and WO 2017/221975) was used. Specifically, iPS cell, WT1&#x3b1;&#x3b2;-iPSC and V&#x3b3;9V&#x3b4;2-iPSC obtained in [Example 1] 1., [Example 1] 2-1. and [Example 1] 2-2. were respectively seeded at 3&#xd7;10<sup>5 </sup>cells/well in an ultra-low adhesion-treated 6 well plate, 10 ng/ml BMP4, 50 ng/ml bFGF, 15 ng/ml VEGF, 2 &#x3bc;M SB431542 were added to EB medium (StemPro34 added with 10 pg/ml human insulin, 5.5 pg/ml human transferrin, 5 ng/ml sodium selenit, 2 mM L-glutamine, 45 mM a-monothioglycerol, and 50 pg/ml ascorbic acid 2-phosphate), and the cells were cultured for 5 days under low-oxygen conditions (5% O<sub>2</sub>). Then, 50 ng/ml SCF, 30 ng/ml TPO, 10 ng/ml Flt3L were added, and the cells were cultured for 5-9 days (&#x2212;Day 14) to give a suspended cell population. The medium was changed every two or three days during the culture period. The above-mentioned suspended cell population containing HPC was stained using the antibody set of Table 2. The cell populations that underwent the above-mentioned staining were subjected to sorting by FACSAria.</p><p id="p-0284" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 2</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>anti-CD34 antibody</entry><entry>Abcam PE/Cy7</entry></row><row><entry/><entry>anti-CD43 antibody</entry><entry>BD APC</entry></row><row><entry/><entry>anti-CD45 antibody</entry><entry>BioLegend BV510</entry></row><row><entry/><entry>anti-CD14 antibody</entry><entry>BioLegend APC/eFluor780</entry></row><row><entry/><entry>anti-CD235a antibody</entry><entry>BD FITC</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>2. Introduction of V&#x3b3;9V62-TCR Gene into HPC</p><p id="p-0285" num="0269">A gene (V&#x3b3;9V&#x3b4;2TCR G115) in which the TRG gene and TRD gene encoding G115 &#x3b3;&#x3b4; T cell clone-derived V&#x3b3;9V&#x3b4;2 T cell receptor were linked by a P2A sequence was introduced into the cell fraction obtained in [Example 2] 1. The gene was introduced in the same manner as in [Example 1] 2-2. In the following, HPC cell in which V&#x3b3;9V&#x3b4;2TCR G115 gene has been introduced into HPC is sometimes referred to as &#x201c;V&#x3b3;9V&#x3b4;2-iHPC&#x201d;.</p><heading id="h-0042" level="1">Example 3</heading><p id="p-0286" num="0270">1. Differentiation of HPC into T Cell</p><p id="p-0287" num="0271">The cell fraction obtained in [Example 2] 1. and V&#x3b3;9V&#x3b4;2-iHPC obtained in [Example 2] 2. were differentiated into lymphoid cells according to a known method (e.g., the methods described in Journal of Leukocyte Biology 96(2016)1165-1175 and WO 2017/221975). To be specific, the hematopoietic progenitor cell population was seeded at 2000 cells/well in a 48-well-plate coated with Recombinant h-DLL4/Fc chimeric protein (Sino Biological) and Retronectin (Takara Bio Inc.) and cultured under 5% CO<sub>2</sub>, 37&#xb0; C. conditions. The medium was changed every two or three days during the culture period. As the medium, aMEM medium added with 15% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin, 55 &#x3bc;M 2-mercaptoethanol, 50 &#x3bc;g/ml ascorbic acid 2-phosphate, 10 &#x3bc;g/ml human insulin, 5.5 &#x3bc;g/ml human transferrin, 5 ng/ml sodium selenite, 50 ng/ml SCF, 50 ng/ml IL-7, 50 ng/ml Flt3L, 100 ng/ml TPO, 15 &#x3bc;M SB203580, 30 ng/ml SDF-1&#x3b1; was used. The cells were passaged to a similarly-coated 48-well plate on day 7 and day 14 from the start of the culturing. All cells were recovered on day 21 from the start of the culturing and the presence of CD45(+), CD3(+) fractions was confirmed by a flow cytometer. The obtained cells were seeded in a 24-well plate and cultured under 5% CO<sub>2</sub>, 37&#xb0; C. conditions. As the medium, aMEM medium added with 15% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin, 50 ng/ml ascorbic acid 2-phosphate, 10 &#x3bc;g/ml human insulin, 5.5 &#x3bc;g/ml human transferrin, 5 ng/mL sodium selenite, 500 ng/mL anti-CD3 antibody (UCHT1 or OKT3 clone), 10 nM dexamethasone (Fuji Pharma: 10171-H02H), 100 U/ml IL-2, 10 ng/mL IL-7. All cells were recovered on day 27 from the start of the culturing (Day 41). In the following, a T cell differentiated from the iPS cell obtained in [Example 1] 1. is sometimes referred to as &#x201c;i&#x3b3;&#x3b4;TC&#x201d;, a T cell differentiated from WT1&#x3b1;&#x3b2;-iPSC obtained in [Example 1] 2-1., is sometimes referred to as &#x201c;iWT1&#x3b1;&#x3b2;TC&#x201d;, a T cell differentiated from V&#x3b3;9V&#x3b4;2-iPSC obtained in [Example 1] 2-2., is sometimes referred to as &#x201c;V&#x3b3;9V&#x3b4;2-iTC&#x201d;, and a T cell differentiated from V&#x3b3;9V&#x3b4;2-iHPC obtained in [Example 1] 2., is sometimes referred to as &#x201c;V&#x3b3;9V&#x3b4;2-iHTC&#x201d;.</p><p id="p-0288" num="0272">i&#x3b3;&#x3b4;TC was stained using the antibody set shown in Table 3 (<figref idref="DRAWINGS">FIGS. <b>3</b> and <b>4</b></figref>).</p><p id="p-0289" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="63pt" align="left"/><colspec colname="1" colwidth="154pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="1" rowsep="1">TABLE 3</entry></row><row><entry/><entry namest="offset" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>V&#x3b4;1 Myltenyi FITC</entry></row><row><entry/><entry>V&#x3b4;2 Myltenyi APC</entry></row><row><entry/><entry>&#x3b3;&#x3b4;TCR BD BV510</entry></row><row><entry/><entry>CD3 BioLegend APC/Cy7</entry></row><row><entry/><entry>&#x3b1;&#x3b2;TCR eBioscience FITC</entry></row><row><entry/><entry namest="offset" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0290" num="0273">As regards i&#x3b3;&#x3b4;TC, the expression of CD3, V&#x3b4;TCR, &#x3b1;&#x3b2;TCR, TCR-V&#x3b4;1 chain, and TCR-V&#x3b4;2 chain on the surface of cell membrane was measure by a flow cytometer (<figref idref="DRAWINGS">FIGS. <b>3</b> and <b>4</b></figref>).</p><p id="p-0291" num="0274">As regards V&#x3b3;9V&#x3b4;2-iTC (<figref idref="DRAWINGS">FIG. <b>5</b></figref>) and V&#x3b3;9V&#x3b4;2-iHTC (<figref idref="DRAWINGS">FIG. <b>6</b></figref>), the expression of CD3, V&#x3b4;TCR, TCR-V&#x3b4;1 chain and TCR-V&#x3b4;2 chain on the surface of cell membrane was measure by a flow cytometer.</p><heading id="h-0043" level="1">Example 4</heading><heading id="h-0044" level="2">Expansion Culture of T Cell</heading><p id="p-0292" num="0275">1. Expansion Culture of i&#x3b3;&#x3b4;TC</p><heading id="h-0045" level="2">1-1. Expansion Culture</heading><p id="p-0293" num="0276">i&#x3b3;&#x3b4;TC obtained in [Example 3] was suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 4 to &#x3b1;-MEM medium containing 15% FBS, and the suspension was seeded in a plate containing anti-CD3 antibody (UCHT1) and RetroNectin immobilized thereon and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter (registered trade mark) NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine shown in Table 5 to &#x3b1;-MEM medium containing 15% FBS, added to a non-solidified G-Rex (registered trade mark) 6-well plate (WILSONWOLF) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. Thereafter, a part of the cells were collected from the plate 4 to 6 times on any of days 5, 6, 7, 8, 9, 10, 11, 14 of culture, and the number of cells was measured using NucleoCounter (registered trade mark) NC-200. The cells were immobilized on the culture plate with anti-CD3 antibody and RetroNectin by the following method. An anti-CD3 antibody (UCHT1, final concentration 3000 ng/mL) and RetroNectin (final concentration 150 &#x3bc;g/mL) dissolved in PBS at necessary concentrations were added to the plate and the plate was stood overnight at 4&#xb0; C.</p><heading id="h-0046" level="2">1-2. Proliferation Rate</heading><p id="p-0294" num="0277">The proliferation rate of the number of i&#x3b3;&#x3b4;TC cells when the expansion culture of [Example 4] 1-1., was repeated 5 times is shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref>. i&#x3b3;&#x3b4;TC can be expansion cultured at least not less than 10<sup>11 </sup>times, and can be used as T cells constituting the master cell bank of T cell and/or working cell bank of T cell.</p><p id="p-0295" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="63pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 4</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>product name</entry><entry>manufacturer</entry><entry>Final conc</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>Insulin-Transferrin-</entry><entry>Invitrogen</entry><entry>1 x</entry></row><row><entry/><entry>Selenium Supplements</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="35pt" align="right"/><colspec colname="4" colwidth="28pt" align="left"/><tbody valign="top"><row><entry/><entry>Ascorbic acid 2-phosphate</entry><entry>sigma</entry><entry>50</entry><entry>&#x3bc;g/ml</entry></row><row><entry/><entry>IL-2</entry><entry>Peprotech</entry><entry>15</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-7</entry><entry>Peprotech</entry><entry>10</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-15</entry><entry>Peprotech</entry><entry>10</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-21</entry><entry>Peprotech</entry><entry>20</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-12</entry><entry>Merck</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-18</entry><entry>MBL</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>TL-1A</entry><entry>Peprotech</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>Z-VAD-FMK</entry><entry>R&#x26;D</entry><entry>10</entry><entry>&#x3bc;M</entry></row><row><entry/><entry>Human CD30 Antibody</entry><entry>R&#x26;D</entry><entry>300</entry><entry>ng/ml</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0296" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="63pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 5</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>product name</entry><entry>manufacturer</entry><entry>Final conc</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>Insulin-Transferrin-</entry><entry>Invitrogen</entry><entry>1 x</entry></row><row><entry/><entry>Selenium Supplements</entry></row><row><entry/><entry>Ascorbic acid 2-phosphate</entry><entry>sigma</entry><entry>50 &#x3bc;g/ml</entry></row><row><entry/><entry>IL-2</entry><entry>Peprotech</entry><entry>15 ng/ml</entry></row><row><entry/><entry>IL-7</entry><entry>Peprotech</entry><entry>10 ng/ml</entry></row><row><entry/><entry>IL-15</entry><entry>Peprotech</entry><entry>10 ng/ml</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0047" level="2">2. Expansion Culture of V&#x3b3;9V&#x3b4;2-iTC</heading><heading id="h-0048" level="2">2-1. Expansion Culture</heading><p id="p-0297" num="0278">V&#x3b3;9V&#x3b4;2-iTC obtained in [Example 3] was suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 6 to &#x3b1;-MEM medium containing 15% FBS, and the suspension was seeded in a plate containing anti-CD3 antibody (OKT3) and RetroNectin immobilized thereon and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter (registered trade mark) NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine shown in Table 5 to &#x3b1;-MEM medium containing 15% FBS, added to a non-solidified G-Rex (registered trade mark) 6-well plate (WILSONWOLF) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. Thereafter, a part of the cells were collected from the plate 4 to 6 times on any of days 5, 6, 7, 8, 9, 10, 11, 14 of culture, and the number of cells was measured using NucleoCounter (registered trade mark) NC-200. The cells were immobilized on the culture plate with anti-CD3 antibody and RetroNectin by the method of [Example 4] 1-1.</p><heading id="h-0049" level="2">2-2. Proliferation Rate</heading><p id="p-0298" num="0279">The proliferation rate of the number of V&#x3b3;9V&#x3b4;2-iTC cells when [Example 4] 2-1., was repeated 5 times is shown in <figref idref="DRAWINGS">FIG. <b>8</b></figref>. V&#x3b3;9V&#x3b4;2-iTC can be expansion cultured at least not less than 10<sup>12 </sup>times, and can be used as T cells constituting the master cell bank of T cell and/or working cell bank of T cell.</p><p id="p-0299" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="63pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 6</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>product name</entry><entry>manufacturer</entry><entry>Final conc</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>Insulin-Transferrin-</entry><entry>Invitrogen</entry><entry>1 x</entry></row><row><entry/><entry>Selenium Supplements</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="28pt" align="right"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry/><entry>Ascorbic acid 2-phosphate</entry><entry>sigma</entry><entry>50</entry><entry>&#x3bc;g/ml</entry></row><row><entry/><entry>IL-2</entry><entry>Peprotech</entry><entry>15</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-7</entry><entry>Peprotech</entry><entry>10</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-15</entry><entry>Peprotech</entry><entry>10</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-21</entry><entry>Peprotech</entry><entry>20</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-12</entry><entry>Merck</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>IL-18</entry><entry>MBL</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>TL-1A</entry><entry>Peprotech</entry><entry>50</entry><entry>ng/ml</entry></row><row><entry/><entry>Z-VAD-FMK</entry><entry>R&#x26;D</entry><entry>10</entry><entry>&#x3bc;M</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0050" level="2">3. Expansion Culture of WT1&#x3b1;&#x3b2;-iTC</heading><heading id="h-0051" level="2">3-1. Expansion Culture</heading><p id="p-0300" num="0280">iWT1&#x3b1;&#x3b2;TC obtained in [Example 3] was suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 6 to &#x3b1;-MEM medium containing 15% FBS, and the suspension was seeded in a plate containing anti-CD3 antibody (OKT3) and RetroNectin immobilized thereon and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter (registered trade mark) NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine shown in Table 5 to &#x3b1;-MEM medium containing 15% FBS, added to a non-solidified G-Rex (registered trade mark) 6-well plate (WILSONWOLF) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. Thereafter, a part of the cells was collected from the plate 4 to 6 times on any of days 5, 6, 7, 8, 9, 10, 11, 14, 17 of culture, and the number of cells was measured using NucleoCounter (registered trade mark) NC-200. The cells were immobilized on the culture plate with anti-CD3 antibody and RetroNectin by the following method. An anti-CD3 antibody (OKT3, final concentration 3000 ng/mL) and RetroNectin (final concentration 150 &#x3bc;g/mL) dissolved in PBS at necessary concentrations were added to the plate and the plate was stood overnight at 4&#xb0; C.</p><heading id="h-0052" level="2">3-2. Proliferation Rate</heading><p id="p-0301" num="0281">The proliferation rate of the number of iWT1&#x3b1;&#x3b2;TC cells when the expansion culture of [Example 4] 3-1., was repeated 4 times is shown in <figref idref="DRAWINGS">FIG. <b>9</b></figref>. iWT14TC can be expansion cultured at least not less than 10<sup>10 </sup>times, and can be used as T cells constituting the master cell bank of T cell and/or working cell bank of T cell.</p><heading id="h-0053" level="1">Example 5</heading><heading id="h-0054" level="2">1. Construction of Master Cell Bank of T Cell</heading><p id="p-0302" num="0282">The T cell culture medium obtained in [Example 4] is replaced with a cryoprotective solution (CryoStor CS10) containing a cryoprotective agent, and dispensed to a plurality of storage containers (sterile vials (polymer vials (AT-closed vial))). The T cells are frozen by standing the container containing the T cells in a freezer. A program freezer, CryoMed (Thermo Fisher), is used as the freezer. By stocking same, a frozen master cell bank of T cell is constructed.</p><heading id="h-0055" level="2">2. Construction of Working Cell Bank of T Cell</heading><p id="p-0303" num="0283">A container containing T cells is recovered from the frozen master cell bank of T cell of [Example 5] 1. The container is immersed in a water bath at about 37&#xb0; C. for about sec to thaw the T cells. The cells obtained by thawing are suspended in an appropriate amount of a medium containing cytokine shown in Table 5, added to a 6-well plate (WILSONWOLF) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. After culturing for 3 days from day 1, T cells are expansion cultured by the method of [Example 4], thawed in the same manner as described above and stocked to construct a working cell bank of T cell.</p><heading id="h-0056" level="2">3. Property Analysis and Quality Evaluation</heading><p id="p-0304" num="0284">In the same manner as in [Example 5] 2., one container containing T cells is recovered from the master cell bank of T cell and/or working cell bank of T cell, and the T cells are thawed. The obtained T cells are subjected to property analysis and quality evaluation.</p><heading id="h-0057" level="2">4. Construction of Cell Bank Collection of T Cell</heading><p id="p-0305" num="0285">Plural kinds of master cell banks of T cells obtained in [Example 5] 1., are collected, labeled so that the kind of master cell bank of T cell can be distinguished, and stored, whereby a master cell bank collection of T cell is constructed.</p><heading id="h-0058" level="1">Example 6</heading><heading id="h-0059" level="2">1. Preparation of T Cell</heading><p id="p-0306" num="0286">In the same manner as in [Example 5] 2., one container was collected from master cell bank of T cell and/or working cell bank of T cell and T cells were thawed. The T cells obtained by thawing were suspended in an appropriate amount of a medium containing cytokine shown in Table 5, added to a 6-well plate, and cultured at 5% CO<sub>2</sub>/37&#xb0; C. After culturing for 3 days from day 1, the cells were suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 4 or Table 6 to &#x3b1;-MEM medium containing 15% FBS, seeded in a plate containing anti-CD3 antibody (UCHT1 or OKT3) and RetroNectin immobilized thereon and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter (registered trade mark) NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine shown in Table 5 to &#x3b1;-MEM medium containing 15% FBS, added to a non-solidified cell culture flask (25 cm<sup>2 </sup>or 75 cm<sup>2</sup>) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for one day to prepare T cells.</p><p id="p-0307" num="0000">2. Introduction of Nucleic Acid into T Cell</p><heading id="h-0060" level="2">2-1. Introduction of Anti-CD19-CAR Gene</heading><p id="p-0308" num="0287">As a gene encoding anti-CD19-CAR, an oligo DNA encoding a polypeptide (SEQ ID NO: 2) designed to align in the order shown in Table 7 from the N-terminal was artificially synthesized.</p><p id="p-0309" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 7</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>lead sequence of immunoglobulin</entry><entry>22</entry></row><row><entry/><entry>heavy chain</entry></row><row><entry>2</entry><entry>variable region of anti-CD19</entry><entry>104</entry></row><row><entry/><entry>antibody (FMC63) light chain</entry></row><row><entry>3</entry><entry>GGGGS linker</entry><entry>15</entry></row><row><entry>4</entry><entry>variable region of anti-CD19</entry><entry>120</entry></row><row><entry/><entry>antibody (FMC63) heavy chain</entry></row><row><entry>5</entry><entry>CD8-derived sequence (including</entry><entry>83</entry></row><row><entry/><entry>transmembrane region)</entry></row><row><entry>6</entry><entry>intracellular domain region of CD28</entry><entry>41</entry></row><row><entry>7</entry><entry>intracellular domain region of 4-1BB</entry><entry>47</entry></row><row><entry>8</entry><entry>intracellular domain region of CD3&#x3b6;</entry><entry>112</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0310" num="0288">The artificial oligo DNA synthesized in the above was incorporated into the multicloning site of pMEI-5 retrovirus vector. The production of the virus vector was outsourced to Unitech. iWT1&#x3b1;&#x3b2;TC produced in [Example 3] was infected with the produced retrovirus vector carrying a gene encoding anti-CD19-CAR, whereby iPS cell-derived anti-CD19-CART cells (hereinafter sometimes to be referred to as &#x201c;CD19iWT1&#x3b1;&#x3b2;CARTC&#x201d;) was produced.</p><heading id="h-0061" level="2">2-2. Introduction of Anti-BCMA-CAR Gene</heading><p id="p-0311" num="0289">As a gene encoding anti-BCMA-CAR, an oligo DNA encoding a polypeptide (SEQ ID NO: 3) designed to align in the order shown in Table 8 from the N-terminal was artificially synthesized.</p><p id="p-0312" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 8</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>lead sequence of immunoglobulin</entry><entry>19</entry></row><row><entry/><entry>heavy chain</entry></row><row><entry>2</entry><entry>variable region of anti-BCMA</entry><entry>111</entry></row><row><entry/><entry>antibody light chain</entry></row><row><entry>3</entry><entry>linker</entry><entry>18</entry></row><row><entry>4</entry><entry>variable region of anti-BCMA-anti-</entry><entry>117</entry></row><row><entry/><entry>body weight chain</entry></row><row><entry>5</entry><entry>CD8-derived sequence (including</entry><entry>86</entry></row><row><entry/><entry>transmembrane region)</entry></row><row><entry>6</entry><entry>intracellular domain region of CD28</entry><entry>41</entry></row><row><entry>7</entry><entry>intracellular domain region of 4-1BB</entry><entry>47</entry></row><row><entry>8</entry><entry>intracellular domain region of CD3&#x3b6;</entry><entry>112</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0313" num="0290">The artificial oligo DNA synthesized in the above was incorporated into the multicloning site of pMEI-5 retrovirus vector. The production of the virus vector was outsourced to Unitech. iWT1&#x3b1;&#x3b2;TC produced in [Example 3] was infected with the produced retrovirus vector carrying a gene encoding anti-BCMA-CAR, whereby iPS cell-derived anti-BCMA-CART cells (hereinafter sometimes to be referred to as &#x201c;BMCAiWT1&#x3b1;&#x3b2;CARTC&#x201d;) was produced.</p><heading id="h-0062" level="2">2-3. Introduction of Anti-CD19-CAR Gene Containing CD30-Derived Intracellular Domain</heading><p id="p-0314" num="0291">As an anti-CD19-CAR gene containing CD30-derived intracellular domain, an oligo DNA encoding a polypeptide (SEQ ID NO: 4) designed to align in the order shown in Table 9 from the N-terminal was artificially synthesized.</p><p id="p-0315" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 9</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>lead sequence of immunoglobulin</entry><entry>22</entry></row><row><entry/><entry>heavy chain</entry></row><row><entry>2</entry><entry>variable region of anti-CD19</entry><entry>104</entry></row><row><entry/><entry>antibody (FMC60) light chain</entry></row><row><entry>3</entry><entry>GGGGS linker</entry><entry>15</entry></row><row><entry>4</entry><entry>variable region of anti-CD19</entry><entry>120</entry></row><row><entry/><entry>antibody (FMC60) heavy chain</entry></row><row><entry>5</entry><entry>CD8-derived sequence (including</entry><entry>83</entry></row><row><entry/><entry>transmembrane region)</entry></row><row><entry>6</entry><entry>intracellular domain region of CD28</entry><entry>41</entry></row><row><entry>7</entry><entry>intracellular domain region (SEQ</entry><entry>87</entry></row><row><entry/><entry>ID NO: 6) of CD30</entry></row><row><entry>8</entry><entry>intracellular domain region of CD3C</entry><entry>112</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0316" num="0292">An artificial oligo DNA synthesized above was incorporated into the multicloning site of pMY retrovirus vector. Using FLYRD18 cells for retrovirus vector production, a virus vector was produced. WT1&#x3b1;&#x3b2;-iTC produced in [Example 1], 3., was infected with the produced retrovirus vector carrying an anti-CD19-CAR gene containing a CD30-derived intracellular domain, whereby iPS cell-derived anti-CD19-CART cell containing a CD30-derived intracellular domain (hereinafter sometimes to be referred to as &#x201c;CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC&#x201d;) was produced.</p><heading id="h-0063" level="2">2-4. Introduction of Anti-CD19-CAR Gene</heading><p id="p-0317" num="0293">As a gene encoding anti-CD19-CAR, an oligo DNA encoding a polypeptide (SEQ ID NO: 5) designed to align in the order shown in Table 10 from the N-terminal was artificially synthesized.</p><p id="p-0318" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 10</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="112pt" align="left"/><colspec colname="3" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>lead sequence of immunoglobulin</entry><entry>22</entry></row><row><entry/><entry>heavy chain</entry></row><row><entry>2</entry><entry>variable region of anti-CD19</entry><entry>104</entry></row><row><entry/><entry>antibody (FMC63) light chain</entry></row><row><entry>3</entry><entry>GGGGS linker</entry><entry>15</entry></row><row><entry>4</entry><entry>variable region of anti-CD19</entry><entry>120</entry></row><row><entry/><entry>antibody (FMC63) heavy chain</entry></row><row><entry>5</entry><entry>CD8-derived sequence (including</entry><entry>83</entry></row><row><entry/><entry>transmembrane region)</entry></row><row><entry>6</entry><entry>intracellular domain region of 4-1BB</entry><entry>47</entry></row><row><entry>7</entry><entry>intracellular domain region of CD3&#x3b6;</entry><entry>112</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0319" num="0294">An artificial oligo DNA synthesized above was incorporated into the multicloning site of pMY retrovirus vector. Using FLYRD18 cells for retrovirus vector production, a virus vector was produced. i&#x3b3;&#x3b4;TC produced in [Example 3] was infected with the produced retrovirus vector carrying a gene encoding anti-CD19-CAR, whereby iPS cell-derived anti-CD19-CART cell (hereinafter sometimes to be referred to as &#x201c;CD19i&#x3b3;&#x3b4;CARTC&#x201d;) was produced.</p><heading id="h-0064" level="1">Example 7</heading><heading id="h-0065" level="2">1. Cytotoxic Activity Etc. of T Cells</heading><heading id="h-0066" level="2">1-1. Cytotoxic Activity of CD19iWT140CARTC and BMCAiWT1&#x3b1;&#x3b2;CARTC</heading><p id="p-0320" num="0295">The cytotoxic activity of CD19iWT1&#x3b1;&#x3b2;CARTC and BMCAiWT1&#x3b1;&#x3b2;CARTC obtained in [Example 6] 2-1. and 2-2. against CD19 positive Raji cancer cell and BCMA positive H929 cancer cell, respectively, was evaluated. CD19iWT1&#x3b1;&#x3b2;CARTC or iWT1&#x3b1;&#x3b2;TC was blended at a proportion of 16-fold relative to the Raji cell. The cytotoxic activity of CD19iWT1&#x3b1;&#x3b2;CARTC was evaluated based on the target cell death 2 hr later. In addition, BCMAiWT1&#x3b1;&#x3b2;CARTC or iWT1&#x3b1;&#x3b2;TC was blended at a proportion of 16-fold relative to the H929 cell. The cytotoxic activity of BCMAiWT1&#x3b1;&#x3b2;CARTC was evaluated based on the target cell death 2 hr later. It was shown that CD19iWT1&#x3b1;&#x3b2;CARTC and BMCAiWT1&#x3b1;&#x3b2;CARTC have cytotoxic activity against CD19 positive Raji cancer cell and BCMA positive H929 cancer cell, respectively, and that two kinds of CART can be produced from the same iWT1&#x3b1;&#x3b2;TC (<figref idref="DRAWINGS">FIG. <b>10</b></figref>).</p><p id="p-0321" num="0296">1-2. Cytotoxic activity of CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC The cytotoxic activity of CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC obtained in [Example 6] 2-3. against CD19 positive Raji cancer cell was evaluated. CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC was blended at a proportion of 0.5, 1, 2, 4, 8, 16-fold relative to the Raji cell. The cytotoxic activity of CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC was evaluated based on the target cell death 2 hr later. It was shown that CD19-CD30-iWT1&#x3b1;&#x3b2;CARTC has cytotoxic activity against CD19 positive Raji cancer cell and that different CART can be produced from iWT1&#x3b1;&#x3b2;TC (<figref idref="DRAWINGS">FIG. <b>11</b></figref>).</p><heading id="h-0067" level="2">1-3. Cytotoxic Activity of CD19i&#x3b3;&#x3b4;CARTC</heading><p id="p-0322" num="0297">The cytotoxic activity of CD19i&#x3b3;&#x3b4;CARTC obtained in [Example 6], 2-4., was evaluated. Using CD19-positive Raji cell and CD19 negative CCRF-CEN cell as target cells, CD19i&#x3b3;&#x3b4;CARTC was blended at a proportion of 0.5, 1, 2, 4, 8, 16-fold relative to the target cell. The cytotoxic activity of CD19&#x3b3;&#x3b4;CARTC was evaluated based on the target cell death 2 hr later. It was shown that CD19i&#x3b3;&#x3b4;CARTC has cytotoxic activity against CD19 positive Raji cell, does not have cytotoxic activity against CD19 negative CCRF-CEN cell, and has antigen specific cytotoxic activity (<figref idref="DRAWINGS">FIG. <b>12</b></figref>).</p><heading id="h-0068" level="1">Example 8</heading><heading id="h-0069" level="2">1. Introduction of Anti-CD19-CAR Gene and IL-15R&#x3b1;/IL-15 Gene</heading><p id="p-0323" num="0298">As IL-15R&#x3b1;/IL-15 gene, an oligo DNA encoding a polypeptide (SEQ ID NO: 7) designed to align in the order shown in Table 11 from the N-terminal was artificially synthesized.</p><p id="p-0324" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="126pt" align="left"/><colspec colname="3" colwidth="49pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 11</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>order from</entry><entry/><entry>amino acid</entry></row><row><entry>N-terminal</entry><entry>gene</entry><entry>number</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="126pt" align="left"/><colspec colname="3" colwidth="49pt" align="char" char="."/><tbody valign="top"><row><entry>1</entry><entry>lead sequence of human IL-2</entry><entry>23</entry></row><row><entry>2</entry><entry>C-terminal sequence of human IL-15</entry><entry>114</entry></row><row><entry>3</entry><entry>GGGGS linker</entry><entry>24</entry></row><row><entry>4</entry><entry>C-terminal sequence of human IL-15RA</entry><entry>239</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0325" num="0299">An artificial oligo DNA synthesized above was incorporated into the multicloning site of pMY retrovirus vector. Using FLYRD18 cells for retrovirus vector production, a virus vector was produced. i&#x3b3;&#x3b4;TC and V&#x3b3;9V&#x3b4;2-iTC produced in [Example 3] were infected with the produced retrovirus vector carrying IL-15R&#x3b1;/IL-15 gene and the retrovirus vector carrying an anti-CD19-CAR gene and produced in [Example 6] 2-4., whereby CD19/IL15i&#x3b3;&#x3b4;CARTC and CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC were respectively produced.</p><heading id="h-0070" level="1">[Example 9] 1. T Cell Product</heading><heading id="h-0071" level="2">1-1. Expansion Culture of T Cells (CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC)</heading><p id="p-0326" num="0300">CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC obtained in [Example 8] was suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 6 to &#x3b1;-MEM medium containing 15% FBS, and the suspension was seeded in a plate containing anti-CD3 antibody (UCHT1) and RetroNectin immobilized thereon and cultured at 5% CO<sub>2</sub>/37&#xb0; C. for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter (registered trade mark) NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine shown in Table 5 to &#x3b1;-MEM medium containing 15% FBS, added to a non-solidified G-Rex (registered trade mark) 6-well plate (WILSONWOLF) and cultured at 5% CO<sub>2</sub>/37&#xb0; C. Thereafter, a part of the cells was collected from the plate 4 to 6 times on any of days 5, 6, 7, 8, 9, 10, 11, 14, 17 of culture, and the number of cells was measured using a hemocytometer. The cells were immobilized on the culture plate with anti-CD3 antibody and RetroNectin by the following method. An anti-CD3 antibody (UCHT1, final concentration 3000 ng/mL) and RetroNectin (final concentration 150 &#x3bc;g/mL) dissolved in PBS at necessary concentrations were added to the plate and the plate was stood overnight at 4&#xb0; C.</p><heading id="h-0072" level="2">1-2. Proliferation Rate</heading><p id="p-0327" num="0301">The proliferation rate of the number of CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC cells when the expansion culture of [Example 9] 1-1., was repeated 3 times is shown in <figref idref="DRAWINGS">FIG. <b>13</b></figref>. CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC could be expansion cultured at least not less than 10<sup>9 </sup>times.</p><p id="p-0328" num="0302">In this way, CAR-T cells can be expansion cultured and provided from the master cell bank of T cell and/or working cell bank of T cell to produce a large amount of T cell product (e.g., CAR-T cell product). The expansion cultured various T cells are filled in an appropriate storage container (sterile vial, blood transfusion bag, and the like), the container is labeled and packaged to produce a T cell product.</p><heading id="h-0073" level="2">1-3. Freezing of T Cell Product</heading><p id="p-0329" num="0303">A container containing expansion cultured various T cells is frozen in the same manner as in [Example 5] 1., to produce a frozen T cell product.</p><heading id="h-0074" level="2">1-4. Construction of T Cell Product Collection</heading><p id="p-0330" num="0304">A T cell product collection is constructed by labeling the frozen T cell products obtained above so that the kind thereof can be distinguished, and storing them.</p><heading id="h-0075" level="1">Example 10</heading><heading id="h-0076" level="2">1. Identification of Antigen</heading><p id="p-0331" num="0305">A biological sample such as a tumor tissue section, a body fluid (e.g., blood, serum, plasma, etc.) that may contain tumor cell, and the like is collected from a test subject, mRNA is extracted from the sample, and cDNA is synthesized as necessary from the mRNA and identified using the cDNA and a nucleic acid amplification method and/or a nucleic acid detection method such as digital PCR (e.g., ddPCR), RT-PCR, biochip (e.g., microarray), RNAseq and the like.</p><heading id="h-0077" level="2">2. Selection of T Cell Product</heading><p id="p-0332" num="0306">Based on the material (paper medium or electronic data medium) showing the identification result in [Example 10] 1., a T cell product containing T cells expressing a CAR or an exogenous TCR that recognizes and binds to the identified antigen is selected from a list of T cell products prepared in advance.</p><heading id="h-0078" level="1">Example 11</heading><heading id="h-0079" level="2">1. Number of Survival Day Extending Effect of CD19/IL15i&#x3b3;&#x3b4;CARTC</heading><p id="p-0333" num="0307">5&#xd7;10<sup>5 </sup>Nalm6 cells (ATCC) were transplanted to NOD/Shi-scid, IL-2R&#x3b3;KO (NOG) mice (Central Institute for Experimental Animals, female, 7-8-week-old) from the tail vein to prepare Nalm6 xenograft mice. On day 4 post-transplantation, a suspension of CD19/IL15i&#x3b3;&#x3b4;CARTC (5&#xd7;10<sup>6 </sup>(cells)) in 0.1 mL of HBSS-buffer or an equal amount of HBSS-buffer was administered from the tail vein, and the number of days of survival was confirmed. All mice transplanted with CD19 positive Nalm6 cancer cells via the tail vein died within 3 weeks in the control administration group, whereas all mice survived for at least 6 weeks in the CD19/IL15i&#x3b3;&#x3b4;CARTC administration group (<figref idref="DRAWINGS">FIG. <b>14</b></figref>).</p><heading id="h-0080" level="2">2. Antitumor Effect of CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC</heading><p id="p-0334" num="0308">5&#xd7;10<sup>5 </sup>luciferase-expressing Nalm6 cells (ATCC) were transplanted to NOD/Shi-scid, IL-2R&#x3b3;KO (NOG) mice (Central Institute for Experimental Animals, female, 7-8-week-old) from the tail vein to prepare luciferase-expressing Nalm6 xenograft mice. On day 4 post-transplantation, a suspension of CD19/IL15iV&#x3b3;9V&#x3b4;2CARTC (107 (cells)) obtained in [Example 6], 1-2., in 0.2 mL of HBSS-buffer or an equal amount of HBSS-buffer was administered from the tail vein, and the number of days of survival was confirmed. All mice transplanted with CD19 positive Nalm6 cancer cells via the tail vein died within 3 weeks in the control administration group, whereas all mice survived for at least 6 weeks in the CD19/IL15i&#x3b3;&#x3b4;CARTC administration group (<figref idref="DRAWINGS">FIG. <b>15</b></figref>).</p><heading id="h-0081" level="1">INDUSTRIAL APPLICABILITY</heading><p id="p-0335" num="0309">According to the present invention, a system for providing a high quality, off-the-shelf allogenic T cell product (particularly, plural kinds of CAR-T cell products), that can reduce human, time and financial costs and minimize difference between lots, and a method for providing same are provided. The thus-provided T cell product is useful for the prophylaxis or treatment of diseases such as cancer, tumor and the like.</p><p id="p-0336" num="0310">This application is based on a patent application No. 2019-212718 filed in Japan (filing date: Nov. 25, 2019), the contents of which are incorporated in full herein.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000915A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A system for providing a T cell product, comprising a master cell bank of T cell and/or a working cell bank of T cell.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell derived from an induced pluripotent stem cell.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell with suppressed expression of at least one kind of HLA gene.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a step of introducing a nucleic acid comprising the exogenous gene into a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The system according to <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the exogenous gene is a CAR gene or an exogenous TCR gene.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the T cell product comprises two or more kinds thereof.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a step of expansion culturing a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The system according to <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the step of expansion culturing the T cell comprises a process of stimulating the cell with a CD30 agonist.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The system according to <claim-ref idref="CLM-00008">claim 8</claim-ref>, further comprising a step of producing a frozen T cell product comprising the expansion cultured T cell.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The system according to <claim-ref idref="CLM-00006">claim 6</claim-ref>, further comprising a step of constructing a T cell product collection comprising two or more kinds of T cell products by collecting T cell products.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The system according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a step of identifying a tumor-specific antigen or a tumor-associated antigen expressed in a tumor of the test subject.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The system according to <claim-ref idref="CLM-00011">claim 11</claim-ref>, further comprising a step of selecting a T cell product expressing a CAR or an exogenous TCR that recognizes and binds to the identified antigen from a T cell product collection comprising two or more kinds of T cell products.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A method for producing a T cell product, comprising a process of constructing a master cell bank of T cell and/or a working cell bank of T cell.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell derived from an induced pluripotent stem cell.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein the master cell bank of T cell and/or working cell bank of T cell comprise(s) a T cell with suppressed expression of at least one kind of HLA gene.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00013">claim 13</claim-ref>, further comprising a process of introducing a nucleic acid comprising the exogenous gene into a T cell prepared from the master cell bank of T cell and/or working cell bank of T cell.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the exogenous gene is a CAR gene or an exogenous TCR gene.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00013">claim 13</claim-ref>, further comprising a process of expansion culturing a T cell.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The method for producing a T cell product according to <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein the process of expansion culturing the T cell comprises a process of stimulating the cell with a CD30 agonist.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. A master cell bank of T cell and/or a working cell bank of T cell.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The master cell bank of T cell and/or working cell bank of T cell according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, comprising a T cell derived from an induced pluripotent stem cell.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The master cell bank of T cell and/or working cell bank of T cell according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, comprising a T cell with suppressed expression of at least one kind of HLA gene.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A master cell bank collection of T cell and/or a working cell bank collection of T cell comprising two or more kinds of the master cell banks of T cell and/or working cell banks of T cell according to <claim-ref idref="CLM-00020">claim 20</claim-ref>.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A method for constructing a master cell bank of T cell and/or a working cell bank of T cell, comprising the following processes:<claim-text>(1) a process of differentiating an induced pluripotent stem cell free of a chimeric antigen receptor (CAR) gene into a T cell for CAR-T therapy,</claim-text><claim-text>(2) a process of stocking the differentiated T cell, and</claim-text><claim-text>(3) a process of characterization of the differentiated T cell.</claim-text></claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method for constructing a master cell bank of T cell and/or a working cell bank of T cell, comprising the following processes:<claim-text>(1) a process of differentiating an induced pluripotent stem cell free of an exogenous T cell receptor (TCR) gene into a T cell for TCR-T therapy,</claim-text><claim-text>(2) a process of stocking the differentiated T cell, and</claim-text><claim-text>(3) a process of characterization of the differentiated T cell.</claim-text></claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The method according to <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein the induced pluripotent stem cell has an exogenous T cell receptor (TCR) gene.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The method according to <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein at least one kind of HLA gene is deleted in the induced pluripotent stem cell.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The method according to <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein the T cell expresses CD8&#x3b1;&#x3b2;.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. A master cell bank of T cell and/or a working cell bank of T cell constructed by the method according to <claim-ref idref="CLM-00024">claim 24</claim-ref>.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. A method for producing a T cell product expressing a CAR or an exogenous TCR, comprising the following processes:<claim-text>(1) a process of preparing a T cell from the master cell bank of T cell and/or the working cell bank of T cell according to <claim-ref idref="CLM-00029">claim 29</claim-ref>,</claim-text><claim-text>(2) a process of introducing a CAR gene or an exogenous TCR gene into the prepared T cell, and</claim-text><claim-text>(3) a process of expansion culturing the T cell into which the CAR gene or exogenous TCR gene has been introduced.</claim-text></claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method according to <claim-ref idref="CLM-00030">claim 30</claim-ref>, wherein the CAR or exogenous TCR recognizes and binds to a tumor-specific antigen or a tumor-associated antigen.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method according to <claim-ref idref="CLM-00030">claim 30</claim-ref>, wherein the process (3) comprises a process of stimulating the T cell with a CD30 agonist.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. A T cell product produced by the method according to <claim-ref idref="CLM-00030">claim 30</claim-ref>.</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. A method for constructing a T cell product collection comprising two or more kinds of T cell products, comprising a process of collecting the T cell product according to <claim-ref idref="CLM-00033">claim 33</claim-ref>.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. A T cell product collection constructed by the method according to <claim-ref idref="CLM-00034">claim 34</claim-ref>.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. A method for providing a T cell product suitable for a test subject, comprising the following processes:<claim-text>(1) a process of identifying a tumor-specific antigen or a tumor-associated antigen expressed in the tumor of a test subject, and</claim-text><claim-text>(2) a process of selecting a T cell product that expresses a CAR or an exogenous TCR that recognizes and binds to the identified antigen from the T cell product collection according to <claim-ref idref="CLM-00035">claim 35</claim-ref>.</claim-text></claim-text></claim></claims></us-patent-application>